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1. EXECUTIVE SUMMARY
KEY PRIORITIES FOR IMPLEMENTATION
The following recommendations have been identified as recommendations for
implementation.
Providing information, advice and support
● Detoxification should be a readily available treatment option for people who are
opioid dependent and have expressed an informed choice to become abstinent. See
section 3.7.
● In order to obtain informed consent, staff should give detailed information to 
service users about detoxification and the associated risks, including:
– the physical and psychological aspects of opioid withdrawal, including the
duration and intensity of symptoms, and how these may be managed
– the use of non-pharmacological approaches to manage or cope with opioid
withdrawal symptoms
– the loss of opioid tolerance following detoxification, and the ensuing increased
risk of overdose and death from illicit drug use that may be potentiated by the
use of alcohol or benzodiazepines
– the importance of continued support, as well as psychosocial and appropriate phar-
macological interventions, to maintain abstinence, treat comorbid mental health
problems and reduce the risk of adverse outcomes (including death). See section 3.7.
The choice of medication for detoxification
● Methadone or buprenorphine should be offered as the first-line treatment in opioid
detoxification. When deciding between these medications, healthcare professionals
should take into account:
– whether the service user is receiving maintenance treatment with methadone or
buprenorphine; if so, opioid detoxification should normally be started with the
same medication
– the preference of the service user. See section 6.3.
Ultra-rapid detoxification
● Ultra-rapid detoxification under general anaesthesia or heavy sedation (where the
airway needs to be supported) must not be offered. This is because of the risk of
serious adverse events, including death. See section 6.5.8.
The choice of setting for detoxification
● Staff should routinely offer a community-based programme to all service users
considering opioid detoxification. Exceptions to this may include service users
who:
– have not benefited from previous formal community-based detoxification
– need medical and/or nursing care because of significant comorbid physical or
mental health problems
– require complex polydrug detoxification, for example concurrent detoxification
from alcohol or benzodiazepines
– are experiencing significant social problems that will limit the benefit of
community-based detoxification. See section 8.2.3.
1.1 GENERAL CONSIDERATIONS
1.1.1 Providing information, advice and support
1.1.1.1 Detoxification should be a readily available treatment option for people
who are opioid dependent and have expressed an informed choice to
become abstinent.
1.1.1.2 In order to obtain informed consent, staff should give detailed information
to service users about detoxification and the associated risks, including:
● the physical and psychological aspects of opioid withdrawal, including
the duration and intensity of symptoms, and how these may be managed
● the use of non-pharmacological approaches to manage or cope with
opioid withdrawal symptoms
● the loss of opioid tolerance following detoxification, and the ensuing
increased risk of overdose and death from illicit drug use that may be
potentiated by the use of alcohol or benzodiazepines
● the importance of continued support, as well as psychosocial and
appropriate pharmacological interventions, to maintain abstinence,
treat comorbid mental health problems and reduce the risk of adverse
outcomes (including death).
1.1.1.3 Service users should be offered advice on aspects of lifestyle that require
particular attention during opioid detoxification. These include:
● a balanced diet
● adequate hydration
● sleep hygiene
● regular physical exercise.
1.1.1.4 Staff who are responsible for the delivery and monitoring of a care plan
should:
● develop and agree the plan with the service user
Executive summary
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● establish and sustain a respectful and supportive relationship with the
service user
● help the service user to identify situations or states when he or she 
is vulnerable to drug misuse and to explore alternative coping strategies
● ensure that all service users have full access to a wide range of services
● ensure that maintaining the service user’s engagement with services
remains a major focus of the care plan
● review regularly the care plan of a service user receiving maintenance
treatment to ascertain whether detoxification should be considered
● maintain effective collaboration with other care providers.
1.1.1.5 People who are opioid dependent and considering self-detoxification
should be encouraged to seek detoxification in a structured treatment
programme or, at a minimum, to maintain contact with a drug service.
1.1.1.6 Service users considering opioid detoxification should be provided with
information about self-help groups (such as 12-step groups) and support
groups (such as the Alliance); staff should consider facilitating engagement
with such services.
1.1.1.7 Staff should discuss with people who present for detoxification whether to
involve their families and carers in their assessment and treatment plans.
However, staff should ensure that the service user’s right to confidentiality
is respected.
1.1.1.8 In order to reduce loss of contact when people who misuse drugs transfer
between services, staff should ensure that there are clear and agreed plans
to facilitate effective transfer.
1.1.1.9 All interventions for people who misuse drugs should be delivered by staff
who are competent in delivering the intervention and who receive appro-
priate supervision.
1.1.1.10 People who are opioid dependent should be given the same care, respect
and privacy as any other person.
1.1.2 Supporting families and carers
1.1.2.1 Staff should ask families and carers about, and discuss concerns regarding,
the impact of drug misuse on themselves and other family members,
including children. Staff should also:
● offer family members and carers an assessment of their personal, social
and mental health needs
● provide verbal and written information and advice on the impact of
drug misuse on service users, families and carers
● provide information about detoxification and the settings in which it may
take place
● provide information about self-help and support groups for families and
carers.
1.2 ASSESSMENT
1.2.1 Clinical assessment
1.2.1.1 People presenting for opioid detoxification should be assessed to establish
the presence and severity of opioid dependence, as well as misuse of and/or
dependence on other substances, including alcohol, benzodiazepines and
stimulants. As part of the assessment, healthcare professionals should:
● use urinalysis to aid identification of the use of opioids and other
substances; consideration may also be given to other near-patient testing
methods such as oral fluid and/or breath testing
● clinically assess signs of opioid withdrawal where present (the use of
formal rating scales may be considered as an adjunct to, but not a
substitute for, clinical assessment)
● take a history of drug and alcohol misuse and any treatment, including
previous attempts at detoxification, for these problems
● review current and previous physical and mental health problems, and
any treatment for these
● consider the risks of self-harm, loss of opioid tolerance and the misuse
of drugs or alcohol as a response to opioid withdrawal symptoms
● consider the person’s current social and personal circumstances, including
employment and financial status, living arrangements, social support
and criminal activity
● consider the impact of drug misuse on family members and any dependants
● develop strategies to reduce the risk of relapse, taking into account the
person’s support network.
1.2.1.2 If opioid dependence or tolerance is uncertain, healthcare professionals
should, in addition to near-patient testing, use confirmatory laboratory
tests. This is particularly important when:
● a young person first presents for opioid detoxification
● a near-patient test result is inconsistent with clinical assessment
● complex patterns of drug misuse are suspected.
1.2.1.3 Near-patient and confirmatory testing should be conducted by appropriately
trained healthcare professionals in accordance with established standard
operating and safety procedures.
1.2.2 Special considerations
1.2.2.1 Opioid detoxification should not be routinely offered to people:
● with a medical condition needing urgent treatment
● in police custody, or serving a short prison sentence or a short period of
remand; consideration should be given to treating opioid withdrawal
symptoms with opioid agonist medication
Executive summary
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● who have presented to an acute or emergency setting; the primary
emergency problem should be addressed and opioid withdrawal symp-
toms treated, with referral to further drug services as appropriate.
1.2.2.2 For women who are opioid dependent during pregnancy, detoxification
should only be undertaken with caution.
1.2.2.3 For people who are opioid dependent and have comorbid physical or
mental health problems, these problems should be treated alongside 
the opioid dependence, in line with relevant NICE guidance where 
available.
1.2.3 People who misuse benzodiazepines or alcohol in addition 
to opioids
1.2.3.1 If a person presenting for opioid detoxification also misuses alcohol,
healthcare professionals should consider the following.
● If the person is not alcohol dependent, attempts should be made to address
their alcohol misuse, because they may increase this as a response to
opioid withdrawal symptoms, or substitute alcohol for their previous
opioid misuse.
● If the person is alcohol dependent, alcohol detoxification should be
offered. This should be carried out before starting opioid detoxification
in a community or prison setting, but may be carried out concurrently
with opioid detoxification in an inpatient setting or with stabilisation in
a community setting.
1.2.3.2 If a person presenting for opioid detoxification is also benzodiazepine
dependent, healthcare professionals should consider benzodiazepine
detoxification. When deciding whether this should be carried out concur-
rently with, or separately from, opioid detoxification, healthcare profes-
sionals should take into account the person’s preference and the severity of
dependence for both substances.
1.3 PHARMACOLOGICAL INTERVENTIONS IN OPIOID
DETOXIFICATION
1.3.1 The choice of medication for detoxification
1.3.1.1 Methadone or buprenorphine should be offered as the first-line treatment
in opioid detoxification. When deciding between these medications,
healthcare professionals should take into account:
● whether the service user is receiving maintenance treatment with
methadone or buprenorphine; if so, opioid detoxification should
normally be started with the same medication
● the preference of the service user.
1.3.1.2 Lofexidine may be considered for people:
● who have made an informed and clinically appropriate decision not to
use methadone or buprenorphine for detoxification
● who have made an informed and clinically appropriate decision to
detoxify within a short time period
● with mild or uncertain dependence (including young people).
1.3.1.3 Clonidine should not be used routinely in opioid detoxification.
1.3.1.4 Dihydrocodeine should not be used routinely in opioid detoxification.
1.3.2 Dosage and duration of detoxification
1.3.2.1 When determining the starting dose, duration and regimen (for example,
linear or stepped) of opioid detoxification, healthcare professionals, in
discussion with the service user, should take into account the:
● severity of dependence (particular caution should be exercised where
there is uncertainty about dependence)
● stability of the service user (including polydrug and alcohol use, and
comorbid mental health problems)
● pharmacology of the chosen detoxification medication and any adjunc-
tive medication
● setting in which detoxification is conducted.
1.3.2.2 The duration of opioid detoxification should normally be up to 4 weeks 
in an inpatient/residential setting and up to 12 weeks in a community
setting.
1.3.3 Ultra-rapid, rapid and accelerated detoxification
1.3.3.1 Ultra-rapid and rapid detoxification using precipitated withdrawal should
not be routinely offered. This is because of the complex adjunctive medica-
tion and the high level of nursing and medical supervision required.
1.3.3.2 Ultra-rapid detoxification under general anaesthesia or heavy sedation
(where the airway needs to be supported) must not be offered. This is
because of the risk of serious adverse events, including death.
1.3.3.3 Rapid detoxification should only be considered for people who specifically
request it, clearly understand the associated risks and are able to manage
the adjunctive medication. In these circumstances, healthcare professionals
should ensure during detoxification that:
● the service user is able to respond to verbal stimulation and maintain a
patent airway
● adequate medical and nursing support is available to regularly monitor
the service user’s level of sedation and vital signs
● staff have the competence to support airways.
Executive summary
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1.3.3.4 Accelerated detoxification, using opioid antagonists at lower doses to
shorten detoxification, should not be routinely offered. This is because of
the increased severity of withdrawal symptoms and the risks associated
with the increased use of adjunctive medications.
1.3.4 Adjunctive medications
1.3.4.1 When prescribing adjunctive medications during opioid detoxification,
healthcare professionals should:
● only use them when clinically indicated, such as when agitation,
nausea, insomnia, pain and/or diarrhoea are present
● use the minimum effective dosage and number of drugs needed to manage
symptoms
● be alert to the risks of adjunctive medications, as well as interactions
between them and with the opioid agonist.
1.3.5 Monitoring of detoxification medication
1.3.5.1 Healthcare professionals should be aware that medications used in opioid
detoxification are open to risks of misuse and diversion in all settings
(including prisons), and should consider:
● monitoring of medication concordance
● methods of limiting the risk of diversion where necessary, including
supervised consumption.
1.4 OPIOID DETOXIFICATION IN COMMUNITY, RESIDENTIAL,
INPATIENT AND PRISON SETTINGS
1.4.1 The choice of setting
1.4.1.1 Staff should routinely offer a community-based programme to all service
users considering opioid detoxification. Exceptions to this may include
service users who:
● have not benefited from previous formal community-based detoxification
● need medical and/or nursing care because of significant comorbid
physical or mental health problems
● require complex polydrug detoxification, for example concurrent
detoxification from alcohol or benzodiazepines
● are experiencing significant social problems that will limit the benefit
of community-based detoxification.
1.4.1.2 Residential detoxification should normally only be considered for people
who have significant comorbid physical or mental health problems, or who
require concurrent detoxification from opioids and benzodiazepines or
sequential detoxification from opioids and alcohol.
1.4.1.3 Residential detoxification may also be considered for people who have 
less severe levels of opioid dependence, for example those early in their
drug-using career, or for people who would benefit significantly from a
residential rehabilitation programme during and after detoxification.
1.4.1.4 Inpatient, rather than residential, detoxification should normally only be
considered for people who need a high level of medical and/or nursing
support because of significant and severe comorbid physical or mental
health problems, or who need concurrent detoxification from alcohol or
other drugs that requires a high level of medical and nursing expertise.
1.4.2 Continued treatment and support after detoxification
1.4.2.1 Following successful opioid detoxification, and irrespective of the setting
in which it was delivered, all service users should be offered continued
treatment, support and monitoring designed to maintain abstinence. This
should normally be for a period of at least 6 months.
1.4.3 Delivering detoxification
1.4.3.1 Community detoxification should normally include:
● prior stabilisation of opioid use through pharmacological treatment
● effective coordination of care by specialist or competent primary 
practitioners
● the provision of psychosocial interventions, where appropriate, during
the stabilisation and maintenance phases (see section 1.5).
1.4.3.2 Inpatient and residential detoxification should be conducted with 24-hour
medical and nursing support commensurate with the complexity of the
service user’s drug misuse and comorbid physical and mental health
problems. Both pharmacological and psychosocial interventions should be
available to support treatment of the drug misuse as well as other significant
comorbid physical or mental health problems.
1.4.4 Detoxification in prison settings
1.4.4.1 People in prison should have the same treatment options for opioid 
detoxification as people in the community. Healthcare professionals should
take into account additional considerations specific to the prison setting,
including:
● practical difficulties in assessing dependence and the associated risk of
opioid toxicity early in treatment
Executive summary
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● length of sentence or remand period, and the possibility of unplanned
release
● risks of self-harm, death or post-release overdose.
1.5 SPECIFIC PSYCHOSOCIAL INTERVENTIONS
1.5.1 Contingency management to support opioid detoxification
1.5.1.1 Contingency management aimed at reducing illicit drug use should be
considered both during detoxification and for up to 3–6 months after
completion of detoxification.
1.5.1.2 Contingency management during and after detoxification should be based
on the following principles.
● The programme should offer incentives (usually vouchers that can be
exchanged for goods or services of the service user’s choice, or privileges
such as take-home methadone doses) contingent on each presentation of
a drug-negative test (for example, free from cocaine or non-prescribed
opioids).
● If vouchers are used, they should have monetary values that start in the
region of £2 and increase with each additional, continuous period of
abstinence
● The frequency of screening should be set at three tests per week for the
first 3 weeks, two tests per week for the next 3 weeks, and one per week
thereafter until stability is achieved.
● Urinalysis should be the preferred method of testing but oral fluid tests
may be considered as an alternative.
1.5.1.3 Staff delivering contingency management programmes should ensure that:
● the target is agreed in collaboration with the service user
● the incentives are provided in a timely and consistent manner
● the service user fully understands the relationship between the treatment
goal and the incentive schedule
● the incentive is perceived to be reinforcing and supports a healthy/
drug-free lifestyle.
1.5.2 Implementing contingency management
1.5.2.1 Drug services should ensure that as part of the introduction of contingency
management, staff are trained and competent in appropriate near-patient
testing methods and in the delivery of contingency management.
1.5.2.2 Contingency management should be introduced to drug services in the
phased implementation programme led by the National Treatment Agency
for Substance Misuse (NTA), in which staff training and the development
of service delivery systems are carefully evaluated. The outcome of this
evaluation should be used to inform the full-scale implementation of
contingency management.
1.6 RESEARCH RECOMMENDATIONS
1.6.1 Adjunctive medication during detoxification
If a person needs adjunctive medication during detoxification, in addition to their
opioid agonist reducing regimen or in addition to an adjunctive alpha-2 adrenergic
agonist (for example, lofexidine), what medications are associated with greater safety
and fewer withdrawal symptoms?
Why this is important
A large variety of adjunctive medications are used for the management of withdrawal
symptoms during detoxification, particularly when alpha-2 adrenergic agonists are
used. Research is needed to guide decisions on how best to manage withdrawal symp-
toms with minimal risk of harm to the service user.
1.6.2 Comparing inpatient or residential and community detoxification
Is inpatient or residential detoxification associated with greater probability of absti-
nence, better rates of completion of treatment, lower levels of relapse and increased
cost effectiveness than community detoxification?
Why this is important
There have been some studies comparing inpatient or residential detoxification with
community detoxification. However, these studies are often based on small sample
sizes, have considerable methodological problems and have produced inconsistent
results. Inpatient or residential detoxification requires significantly more resources
than community detoxification, so it is important to assess whether treatment in such
settings is more clinically and cost effective. If so, it is also important to understand
if there are particular subgroups that are more likely to benefit from treatment in these
settings.
Executive summary
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2. INTRODUCTION
This guideline has been developed to advise on opioid detoxification for drug misuse.
The guideline recommendations have been developed by a multidisciplinary team of
healthcare professionals, service users, a carer and guideline methodologists after
careful consideration of the best available evidence. It is intended that the guideline
will be useful to clinicians and service commissioners in providing and planning
high-quality care for people who misuse drugs while also emphasising the importance
of the experience of care for people who misuse drugs and their carers (see Appendix
1 for more details on the scope of the guideline).
Although the evidence base is rapidly expanding, there are a number of major
gaps, and future revisions of this guideline will incorporate new scientific evidence as
it develops. The guideline makes a number of research recommendations specifically
to address gaps in the evidence base. In the meantime, it is hoped that the guideline
will assist clinicians, people who misuse drugs and their carers by identifying the
merits of particular treatment approaches where the evidence from research and 
clinical experience exists.
2.1 NATIONAL GUIDELINES
2.1.1 What are clinical practice guidelines?
Clinical practice guidelines are ‘systematically developed statements that assist clini-
cians and patients in making decisions about appropriate treatment for specific condi-
tions’ (Mann, 1996). They are derived from the best available research evidence,
using predetermined and systematic methods to identify and evaluate the evidence
relating to the specific condition in question. Where evidence is lacking, the guidelines
incorporate statements and recommendations based upon the consensus statements
developed by the guideline development group (GDG).
Clinical guidelines are intended to improve the process and outcomes of health-
care in a number of different ways. Clinical guidelines can:
● provide up-to-date evidence-based recommendations for the management of
conditions and disorders by healthcare professionals
● be used as the basis to set standards to assess the practice of healthcare 
professionals
● form the basis for education and training of healthcare professionals
● assist patients and carers in making informed decisions about their treatment and
care
● improve communication between healthcare professionals, patients and carers
● help identify priority areas for further research.
2.1.2 Uses and limitations of clinical guidelines
Guidelines are not a substitute for professional knowledge and clinical judgement.
They can be limited in their usefulness and applicability by a number of different
factors: the availability of high-quality research evidence, the quality of the method-
ology used in the development of the guideline, the generalisability of research 
findings and the uniqueness of individuals who misuse drugs.
Although the quality of research in this field is variable, the methodology used
here reflects current international understanding on the appropriate practice for guide-
line development (AGREE: Appraisal of Guidelines for Research and Evaluation
Instrument; www.agreecollaboration.org), ensuring the collection and selection of the
best research evidence available, and the systematic generation of treatment recom-
mendations applicable to the majority of service users and situations. However, there
will always be some people for whom clinical guideline recommendations are not
appropriate and situations in which the recommendations are not readily applicable.
This guideline does not, therefore, override the individual responsibility of healthcare
professionals to make appropriate decisions in light of the service user’s circum-
stances, in consultation with the person who misuses drugs/or carer.
In addition to the clinical evidence, cost-effectiveness information, where avail-
able, is taken into account in the generation of statements and recommendations of
the clinical guidelines. While national guidelines are concerned with clinical and cost
effectiveness, issues of affordability and implementation costs are to be determined
by the National Health Service (NHS).
In using guidelines, it is important to remember that the absence of empirical
evidence for the effectiveness of a particular intervention is not the same as evidence
for ineffectiveness. In addition, of particular relevance in mental health, evidence-
based treatments are often delivered within the context of an overall treatment
programme including a range of activities, the purpose of which may be to help engage
the person and to provide an appropriate context for the delivery of specific interven-
tions. It is important to maintain and enhance the service context in which these inter-
ventions are delivered; otherwise the specific benefits of effective interventions will be
lost. Indeed, the importance of organising care in order to support and encourage a
good therapeutic relationship is at times as important as the specific treatments offered.
2.1.3 Why develop national guidelines?
The National Institute for Health and Clinical Excellence (NICE) was established as a
Special Health Authority for England and Wales in 1999, with a remit to provide a single
source of authoritative and reliable guidance for patients, professionals and the public.
NICE guidance aims to improve standards of care, to diminish unacceptable variations
in the provision and quality of care across the NHS and to ensure that the health service
is patient-centred. All guidance is developed in a transparent and collaborative manner
using the best available evidence and involving all relevant stakeholders.
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NICE generates guidance in a number of different ways, three of which are 
relevant here. First, national guidance is produced by the Technology Appraisal
Committee to give robust advice about a particular treatment, intervention, procedure
or other health technology. Second, NICE commissions public health intervention
guidance focused on types of activity (interventions) that help to reduce people’s 
risk of developing a disease or condition or help to promote or maintain a healthy
lifestyle. Third, NICE commissions the production of national clinical practice guide-
lines focused upon the overall treatment and management of a specific condition. 
To enable this latter development, NICE has established seven National Collaborating
Centres in conjunction with a range of professional organisations involved in 
healthcare.
2.1.4 The National Collaborating Centre for Mental Health
This guideline has been commissioned by NICE and developed within the National
Collaborating Centre for Mental Health (NCCMH). The NCCMH is a collaboration
of the professional organisations involved in the field of mental health, national
patient and carer organisations, a number of academic institutions and NICE. The
NCCMH is funded by NICE and is led by a partnership between the Royal College
of Psychiatrists’ Research and Training Unit and the British Psychological Society’s
equivalent unit (Centre for Outcomes Research and Effectiveness).
2.1.5 From national guidelines to local protocols
Once a national guideline has been published and disseminated, local healthcare
groups will be expected to produce a plan and identify resources for implementation,
along with appropriate timetables. Subsequently, a multidisciplinary group involving
commissioners of healthcare, primary care and specialist mental health professionals,
patients and carers should undertake the translation of the implementation plan into
local protocols taking into account both the recommendations set out in this guideline
and the priorities set in the National Service Framework (NSF) for Mental Health 
and related documentation. The nature and pace of the local plan will reflect local
healthcare needs and the nature of existing services; full implementation may take a
considerable time, especially where substantial training needs are identified.
2.1.6 Auditing the implementation of guidelines
This guideline identifies key areas of clinical practice and service delivery for local
and national audit. Although the generation of audit standards is an important and
necessary step in the implementation of this guidance, a more broadly based imple-
mentation strategy will be developed. Nevertheless, it should be noted that the
Healthcare Commission will monitor the extent to which Primary Care Trusts, trusts
responsible for mental health and social care and Health Authorities have imple-
mented these guidelines.
2.2 THE NATIONAL OPIOID DETOXIFICATION FOR DRUG
MISUSE GUIDELINE
2.2.1 Who has developed this guideline?
The GDG was convened by the NCCMH and supported by funding from NICE. The
GDG included two service users and a carer, and professionals from psychiatry, 
clinical psychology, pharmacy, toxicology, nursing, general practice, the prison serv-
ice, the National Treatment Agency for Substance Misuse (NTA) and the private and
voluntary sectors.
Staff from the NCCMH provided leadership and support throughout the process
of guideline development, undertaking systematic searches, information retrieval,
appraisal and systematic review of the evidence. Members of the GDG received train-
ing in the process of guideline development from NCCMH staff and the service users
and carer received training and support from the NICE Patient and Public
Involvement Programme. The NICE Guidelines Technical Advisor provided advice
and assistance regarding aspects of the guideline development process.
All GDG members made formal declarations of interest at the outset, which were
updated at every GDG meeting. The GDG met a total of nine times throughout the
process of guideline development. The GDG met as a whole, but key topics were led
by a national expert in the relevant topic. The GDG was supported by the NCCMH
technical team, with additional expert advice from special advisors where needed.
The group oversaw the production and synthesis of research evidence before presen-
tation. All statements and recommendations in this guideline have been generated and
agreed by the whole GDG.
2.2.2 For whom is this guideline intended?
This guideline will be relevant for adults and young people who misuse drugs.
The guideline covers the care provided by primary, community, secondary, 
tertiary, and other healthcare professionals who have direct contact with, and make
decisions concerning the care of adults and young people who misuse drugs.
The guideline will also be relevant to the work, but will not cover the practice, of
those in:
● occupational health services
● social services
● the independent sector.
The experience of drug misuse can affect the whole family and often the commu-
nity. The guideline recognises the role of both in the treatment and support of people
who misuse drugs.
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2.2.3 Specific aims of this guideline
The guideline makes recommendations for the opioid detoxification for drug misuse.
Specifically, it aims to:
● evaluate the role of opioid detoxification in the treatment of drug misuse
● evaluate the role of specific psychosocial interventions in combination with opioid
detoxification in the treatment of drug misuse
● integrate the above to provide best practice advice on the care of individuals
throughout the course of their drug misuse
● promote the implementation of best clinical practice through the development of
recommendations tailored to the requirements of the NHS in England and Wales.
2.2.4 The structure of this guideline
The guideline is divided into chapters, each covering a set of related topics. The first
three chapters provide a summary of the clinical practice and research recommenda-
tions, a general introduction to guidelines and an introduction to the drug misuse topic.
The fourth chapter provides a summary of the methods used to develop the recommen-
dations. Chapters 5 to 9 provide the evidence that underpins the recommendations.
Each evidence chapter begins with a general introduction to the topic that sets the
recommendations in context. Depending on the nature of the evidence, narrative
reviews or meta-analyses were conducted. Therefore, the structure of the chapters
varies accordingly. Where appropriate, details about current practice, the evidence
base and any research limitations are provided. Where meta-analyses were conducted,
information is given about both the interventions included and the studies considered
for review. Clinical summaries are then used to summarise the evidence presented.
Finally, recommendations related to each topic are presented at the end of each rele-
vant section of a chapter. On the CD-ROM, full details about the reviewed studies can
be found in Appendix 15. Where meta-analyses were conducted, the data are
presented using forest plots in Appendix 16 (see Text Box 1 for details) and evidence
profile tables in Appendix 17.
Text Box 1: Appendices on CD-ROM
Content Appendix
Reviewed studies Appendix 15
Forest plots Appendix 16
Evidence profile tables Appendix 17
3. INTRODUCTION TO DRUG MISUSE
3.1 DRUG MISUSE AND OPIOID DEPENDENCE
This guideline is concerned with detoxification from opioid dependence. Of the estimated
4 million people in the UK who use illicit drugs each year (cannabis being by far the
most commonly used), approximately 50,000 people misuse opioids, although this may
be an underestimate (Roe & Man, 2006). Opioid misuse is also associated with much
greater rates of harm than misuse of either cannabis or cocaine. Over 150,000 people are
in treatment for opioid misuse and are prescribed opioids such as methadone and
buprenorphine (NTA, 2005a; Hay et al., 2006).
The term ‘opioids’ refers to a class of psychoactive substances derived from the
poppy plant (including opium, morphine and codeine), as well as semi-synthetic forms
(including heroin) and synthetic compounds (including methadone and buprenor-
phine) with similar properties (WHO, 2006). Illicit use of opioids generally involves
injecting, or inhaling the fumes produced by heating the drug. The term ‘opiate’ refers
strictly to the subset of opioids that are naturally occurring or semi-synthetic, and
therefore includes heroin and morphine but excludes methadone and buprenorphine.
Drug misuse is defined as the use of a substance for a purpose not consistent with
legal or medical guidelines (WHO, 2006). It has a negative impact on health or func-
tioning and may take the form of drug dependence, or be part of a wider spectrum of
problematic or harmful behaviour (DH, 2006). In the UK, the Advisory Council on
the Misuse of Drugs (ACMD) characterises problem drug use as a condition that may
cause an individual to experience social, psychological, physical or legal problems
related to intoxication and/or regular excessive consumption, and/or dependence
(ACMD, 1998).
In this guideline, dependence is defined as a strong desire or compulsion to take
a substance, a difficulty in controlling its use, the presence of a physiological with-
drawal state, tolerance of the use of the drug, neglect of alternative pleasures and
interests and persistent use of the drug, despite harm to oneself and others (WHO,
2006). Dependence is diagnosed according to the Diagnostic and Statistical Manual
of Mental Disorders (DSM-IV) when three or more of the following criteria are pres-
ent in a 12-month period: tolerance; withdrawal; increasing use over time; persistent
or unsuccessful attempts to reduce use; preoccupation or excessive time spent on use
or recovery from use; negative impact on social, occupational or recreational activity;
and continued use despite evidence of its causing psychological or physical problems
(American Psychiatric Association [APA], 1994).
The diagnosis of dependence is clearest with opioids. The WHO states that:
‘opioid dependence develops after a period of regular use of opioids, with the
time required varying according to the quantity, frequency and route of adminis-
tration, as well as factors of individual vulnerability and the context in which
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drug use occurs. Opioid dependence is not just a heavy use of the drug but a
complex health connotation that has social, psychological and biological deter-
minants and consequences, including changes in the brain. It is not a weakness
of character or will’ (WHO, 2006).
Repeated use of a drug can lead to the development of tolerance in which
increased doses of the drug are required to produce the same effect. Cessation of use
leads to reduced tolerance and this may present significant risks for individuals who
return to drug doses at a level to which they had previously developed tolerance. This
can result in accidental overdoses and, in the case of opioid misuse, respiratory
depression and death.
Withdrawal syndromes have clearly been identified after cessation or reduction of
opioid use. DSM-IV criteria for a withdrawal disorder include the development of a
substance-specific syndrome due to cessation or reduction in use, the syndrome caus-
ing clinically significant distress, and symptoms not being due to a general medical
condition or better explained by another mental disorder (APA, 1994).
Opioids also produce intoxication, that is, disturbances in psychophysiological
functions and responses, including consciousness, cognition and behaviour, following
administration (WHO, 2006). These are described in greater detail in Section 3.5.
People who misuse drugs may present with a range of health and social problems
other than dependence, which may include (particularly with opioid users):
● physical health problems (for example, thrombosis, abscesses, overdose, hepatitis
B and C, human immunodeficiency virus [HIV], and respiratory and cardiac 
problems)
● mental health problems (for example, depression, anxiety, paranoia and suicidal
thoughts)
● social difficulties (for example, relationship problems, financial difficulties,
unemployment and homelessness)
● criminal justice problems.
Many people who misuse opioids also misuse a range of other substances concur-
rently and regularly (known as polydrug misuse). The use of opioids alongside
cocaine or crack cocaine is common, with the National Drug Treatment Monitoring
System (NDTMS), which collects, collates and analyses information from those
involved in the drug treatment system, reporting an increase in the use of both drugs
from 18% of those presenting for drug treatment in 1998 to 24% in 2001 (NTA,
2005b). Alcohol misuse is also common in people who misuse drugs; data from the
National Treatment Outcomes Research Study (NTORS) on drug misuse suggested
that 22% of participants also drank alcohol frequently, 17% drank extremely heavily
and 8% drank an excessive amount on a daily basis (Gossop et al., 2000a). People
who misuse opioids in particular may often take a cocktail of substances, including
alcohol, cannabis and prescribed drugs such as benzodiazepines, which can have
especially dangerous effects in comparison with one of the drugs taken individually.
Drug dependence is associated with a high incidence of criminal activity, with
associated costs to the criminal justice system in the UK estimated at £1 billion per
annum in 1996 (United Kingdom Anti-Drugs Coordinating Unit, 1998). For example,
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more than 17,000 offences were reported by an NTORS cohort of 753 participants in
a 90-day period before entering treatment (Gossop et al., 2000b). Notably, most of the
offences were committed by a small proportion of the cohort (10% of participants
accounted for 76% of the crimes). Illicit drug use is also much more common among
known offenders in the UK than among cohorts of comparable age drawn from the
general population. In a sample of 1,435 arrestees drug-tested and interviewed by
Bennett and colleagues (2001), 24% tested positive for opioids. The average weekly
expenditure on drugs (heroin and crack/cocaine) was £290, and the main sources of
illegal income were theft, burglary, robbery, handling stolen goods and fraud. The
NTORS also found 61% of a drug misuse treatment sample reported committing
crimes other than drug possession in the 3 months prior to starting treatment, with the
most commonly reported offence being shoplifting. In addition, there is a high preva-
lence of drug misuse among the incarcerated population: in a 1997 survey between
41 and 54% of remand and sentenced prisoners were reported to be opioid, stimulant
and/or cannabis dependent in the year prior to incarceration (Singleton et al., 1999).
Drug treatment can lead to significant reductions in offending levels (Gossop et al.,
2003) and, as a consequence, the prison and the broader criminal justice system is an
increasingly significant referral source and venue for providing drug treatment.
3.2 EPIDEMIOLOGY OF DRUG MISUSE
According to the national British Crime Survey 2005/6 (Roe & Man, 2006), 34.9%
of 16–59 year olds had used one or more illicit drugs in their lifetime, 10.5% in the
previous year and 6.3% in the previous month. These figures are much lower for
opioid use, with 0.1% of the population having used opioids (including heroin and
methadone) in the previous year. However, estimates based on data that also take into
account other indicators such as current service usage provide an illicit drug-use
figure of 9.35 per 1,000 of the population aged 15–64 years (360,811), of whom 3.2
per 1,000 (123,498) are injecting drug users (Chivite-Matthews et al., 2005). Analysis
of the 2004/5 data from the NDTMS suggests that there were an estimated 160,450
people in contact with treatment services in England during that period, the majority
for primary opioid misuse (NTA, 2005b). Males comprise over 70% of new presen-
tations, and the majority of those requiring treatment are opioid dependent (typically
using illicit heroin). Similar figures have emerged from Frischer and colleagues
(2001), who estimated 0.5% of the population of Britain (that is, 226,000 people) to
be problem drug users. More recent estimates indicate that there are around 327,000
problem drug users (of opioids and/or crack cocaine) in the UK, with 280,000 of
these opioid users (Hay et al., 2006).
Drug misuse is more common in certain vulnerable groups. For example, Ward
and colleagues (2003) found that among care leavers aged between 14 and 24 years,
drug misuse is much higher than in the general population, with three quarters of the
sample having at some time misused a drug and over half having misused a drug in
the previous month. Levels in the young homeless population are also much higher
than the general population, with one survey finding that almost all (95%) of the
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sample had at some time misused drugs, many (76%) having used cocaine, heroin,
and/or amphetamine in the previous month.
3.3 AETIOLOGY AND MAINTENANCE OF DRUG MISUSE
Drug misuse is increasingly portrayed in the field as a medical disorder, known as the
‘disease model’ of drug misuse, in part due to advances in our understanding of the
neurobiology underlying dependence (Volkow & Li, 2005). There is also no question
that numerous socioeconomic and psychological factors all play an important part in
the aetiology of drug misuse. These conceptualisations are not mutually exclusive;
rather they are facets of the multifactorial aetiology of drug misuse.
The most robust evidence highlights peer drug use, availability of drugs and also
elements of family interaction, including parental discipline and family cohesion, as
significant risk factors for drug misuse (Frischer et al., 2005). In particular, traumatic
family experiences such as childhood neglect, homelessness or abuse increase the
likelihood that the individual will develop problems with drugs later on in life
(Kumpfer & Bluth, 2004). Recent studies of twins, families and people who have
been adopted suggest that vulnerability to drug misuse may also have a genetic
component (Prescott et al., 2006), although it is unclear whether repeated use is
primarily determined by genetic predisposition, or socioeconomic and psychological
factors lead an individual to try and then later to use drugs compulsively. Risk factors
for heavy, dependent drug use are much more significant when they occur together
rather than individually.
A defining characteristic of drug dependence is that drug use begins as a volun-
tary action to seek a rewarding stimulus, but continued use results in loss of control
over the use, despite its negative consequences (Dackis & O’Brien, 2005). The effects
of many illicit drugs are mediated via various brain circuits, in particular the mesolim-
bic systems, which have evolved to respond to basic rewards (such as food and sex)
to ensure survival. A diverse range of substances, including opioids, stimulants and
cannabis, as well as alcohol and nicotine, all appear to produce euphoric effects via
increasing levels of dopamine (a neurotransmitter) in the nucleus accumbens (Dackis
& O’Brien, 2005). This has been well demonstrated in human brain-imaging studies
(Volkow et al., 1999). Euphoria resulting from use then potentiates further use, partic-
ularly for those with a genetic vulnerability (see below). Chronic drug use may
produce long-lasting changes in the reward circuits, including reductions in dopamine
receptor levels (Volkow et al., 1999), and these contribute to the clinical course of
drug dependence, including craving, tolerance and withdrawal (Lingford-Hughes &
Nutt, 2003). In addition, other types of neurotransmitter systems (for example,
opioids, glutamates and cannabinoids) are implicated in the misuse of specific drugs.
Although initiation into drug use does not lead inevitably to regular and problem-
atic use for many people (Anthony et al., 1994). It is clear that when use begins, it
often escalates to misuse and sometimes to dependence (tolerance, withdrawal symp-
toms and compulsive drug taking). Once dependence is established, particularly with
opioids, there may be repeated cycles of cessation and relapse extending over decades
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(National Consensus Development Panel on Effective Medical Treatment of Opiate
Addiction, 1998). Vulnerability to use is highest among young people, with most
problem heroin users being initiated before the age of 20. Individuals dependent on
drugs often become so in their early twenties and may remain intermittently depend-
ent for many years.
The neurobiological account of fundamental reward systems implicated in drug
misuse may parallel the sociocultural–behavioural–cognitive model presented by
Orford (2001). He conceptualised drug misuse as an ‘excessive appetite’, belonging to
the same class of disorders as gambling, eating disorders and sex addiction. All involve
activities that form strong attachment, and were once rewarding, but with excessive
consumption result in compulsion and negative consequences. Orford argued that the
emotional regulation of such appetitive behaviours in their respective social contexts
(for example, the excitement associated with gambling or the anticipation of the next
‘fix’ of heroin), well characterised within the principles of operant conditioning, is a
primary factor driving excessive use. Secondary factors such as internal conflict
(knowing that the behaviour is harmful yet being unable to disengage from it) poten-
tiate these emotions and thus excessive use, but an alternative result is that the individ-
ual alters behaviour in order to resolve such conflict. This crucially suggests that
recovery is not impossible, but also that successful treatment attempts are likely to
operate against a background of powerful natural processes (Orford, 2001).
3.4 THE COURSE OF DRUG MISUSE
Drug misuse is a relapsing and remitting condition often involving numerous treat-
ment episodes over several years (Marsden et al., 2004). While the initiation of drug
use does not lead inevitably to dependence over the long term (Anthony & Petronis,
1995), a number of factors can potentiate this developmental course. Earlier initiation
of drug use increases the likelihood of daily use, which in turn results in a greater like-
lihood of dependence (Kandel et al., 1986).
Among people who misuse opioids, who form the predominant in-treatment
population in the UK, most individuals develop dependence in their late teens or early
twenties, several years after first using heroin, and continue using over the next 10–30
years. In a long-term outcome study (up to 33 years) of 581 male opioid users in the
USA, 30% had positive (or refused) urine tests for opioids, 14% were in prison and
49% were dead (Hser et al., 2001). Longitudinal data from the US also showed that
the average time from first to last opioid use was 9.9 years, with 40% dependent for
over 12 years (Joe et al., 1990). Although it is the case that problem drug users can
cease drug use without any formal treatment (Biernacki, 1986), for many it is treat-
ment that alters the course of opioid dependence.
Although drug misuse can affect all socioeconomic groups, deprivation and social
exclusion are likely to make a significant contribution to the maintenance of drug
misuse (ACMD, 1998).
Factors that influence the cessation of drug use in adulthood are similar to those
associated with lack of drug use in adolescence. For example, transitions into social
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roles with greater conventionality, responsibility and/or contexts that are not favourable
to using drugs (such as employment, mortgage, marriage and pregnancy; for example,
Bachman et al., 1997), and good health are not associated with long-term use. Peer
pressure is a major influence on experimental use and is also likely to affect a move
towards regular use. The level of drug use is again a predictor of continued use.
Once an individual is dependent, drug use is generally a chronic condition, 
interspersed with periods of relapse and remission (Marsden et al., 2004). Repeated
interaction with the criminal justice system, long-term unemployment and increasing
social isolation serve to further entrench drug use.
3.5 THE PHARMACOLOGY OF OPIOIDS
Opioids have many effects on the brain, mediated through specific receptors (, , or
). The key opioid receptor subtype is , which mediates euphoria, as well as respi-
ratory depression, and is the main target for opioids (Lingford-Hughes & Nutt, 2003),
while the  receptor is involved in mood regulation. Drugs such as heroin and
methadone are agonists, which stimulate the receptor. Buprenorphine is a partial
agonist; that is, it occupies the receptor in the same way but only partially activates
it. In addition, it is an antagonist at the  receptor and therefore is less likely to lower
mood compared with  agonists.
Soon after injection (or inhalation), heroin metabolises into morphine and binds to
opioid receptors. This is subjectively experienced as a euphoric rush, normally accom-
panied by a warm flush, dry mouth, and sometimes nausea, vomiting and severe itch-
ing. As the rush wears off, drowsiness, and slowing of cardiac function and breathing
(sometimes to the point of death in an overdose), persist for several hours (National
Institute on Drug Abuse [NIDA], 2005a). The effects of methadone are similar but
more drawn out and therefore less intense (lasting up to 24 hours when taken orally as
prescribed); however, this may be circumvented by illicit users who inject the drug.
3.6 THE PUBLIC HEALTH IMPACT OF DRUG MISUSE
The most obvious consequence of long-term illicit opioid use is the development of
opioid dependence itself, and the associated harms. These include: increased mortal-
ity from overdose and from other directly or indirectly associated harms such as
increased risk of infection with blood-borne viruses (HIV, hepatitis B and hepatitis
C); high levels of depression and anxiety disorders; social problems such as disrupted
parenting, employment and accommodation; and increased participation in income-
generating crime.
Mortality, particularly in heroin-dependent users, is high, with estimates of
between 12 (Oppenheimer et al., 1994) and 22 times (Frischer et al., 1997) that of the
general population. In England and Wales, there were 1,382 drug-related deaths in
2005 (National Programme on Substance Abuse Deaths, 2005). The majority (59%)
were cases of accidental poisoning, although a sizeable proportion (16%) was a result
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of intentional self-poisoning. Opioids (alone or in combination with other drugs)
accounted for some 70% of the deaths, and cocaine 13%. Many of the deaths appear
to be due to multiple drug toxicity, especially the presence of central nervous system
depressants (for example, alcohol and benzodiazepines), rather than simply an ‘over-
dose’ of an opioid. This is supported by research that shows those whose deaths were
attributed to overdose have opioid levels no higher than those who survive, or than
heroin users who die from other causes (Darke & Zador, 1996). Recent cohort stud-
ies have shown that mortality rates from methadone-related death are decreasing
(Brugal et al., 2005).
Repeated injection will have medical consequences, such as scarring, infection of
blood vessels, abscesses, and compromised functioning of the kidney, liver and lungs
(with increased vulnerability to infections). HIV infection is a major problem for
injecting drug users, with the number of new diagnoses of HIV in the UK holding at
around a hundred for the last few years, and 5.6% of all UK diagnoses attributed to
injecting drug use by the end of 2005 (Health Protection Agency et al., 2006). There
are differences in geographical distribution of HIV in the UK, with rates higher in
some centres such as London. Approximately 50% of injecting drug users have been
infected with hepatitis C, but this rate, like the HIV prevalence rate, is lower than in
many other countries (Health Protection Agency et al., 2006). Transmission of both
hepatitis A and B continues, even though there are effective vaccines. Needle and
syringe sharing increased in the late 1990s and since then has been stable, with
around one in three injecting drug users reporting this activity in the last month
(Health Protection Agency et al., 2005).
Psychiatric comorbidity is common in drug misuse populations, with anxiety and
depression generally common, and antisocial and other personality disorders in opioid-
using populations (Regier et al., 1990, 1998). The national US Epidemiological
Catchment Area study of the prevalence of mental health disorders reported a 47% life-
time prevalence rate of substance misuse (drugs and alcohol) among people with schiz-
ophrenia compared with 16% in the general population, and found that more than 60%
of people with a diagnosis of bipolar I disorder had a lifetime diagnosis of substance
misuse disorder. Around one in five of the people in the NTORS sample had previously
received treatment for a psychiatric health problem other than substance misuse
(Marsden et al., 2000). Drug misuse disorders complicated by other comorbid mental
disorders have been recognised as having a poorer prognosis and being more difficult
to treat than those without comorbid disorders; comorbid disorders are more likely to
be chronic and disabling, and result in greater service utilisation.
Lost productivity and unemployment increase with the severity and duration of
drug misuse, and personal relationships are placed under considerable strain by
dependent drug use. Problems with accommodation are also common in such groups.
For example, prior to intake in the NTORS, 7% of the study group were homeless and
living on the street, 5% were living in squats and 8% were living in temporary hostel
accommodation (Gossop et al., 1998).
Drug misuse may also have a negative impact on children and families 
(see section 3.12). In the UK it is estimated that 2–3% of all children under the age
of 16 years have parents with drug problems (ACMD, 2003). While use of opioids
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does not necessarily impact on parenting capacity, registration on UK child protection
registers for neglect has been correlated strongly with parental heroin use, and
parental problem drug use has been shown to be one of the commonest reasons for
children being received into the care system (Barnard & McKeganey, 2004).
3.7 IDENTIFICATION AND ASSESSMENT OF DRUG MISUSE
So prevalent is drug use that all healthcare professionals, wherever they practice,
should be able to identify and carry out a basic assessment of people who use drugs.
Many people who misuse drugs do not present to drug treatment services, with
perhaps 50% not seeking treatment; however this represents a significant improve-
ment on the position in the UK in the early 1990s, when perhaps only 20% of people
who misused drugs sought treatment. Of those who do not seek treatment for their
drug misuse, a proportion may nevertheless present to other medical services, the
criminal justice system and social care agencies. Many will not be seeking help for
their drug problems and many, for example some of those primarily misusing cocaine
or cannabis, may not be aware of the potentially harmful effects of their drug use. It
is probable that those who present to services for drug treatment have the greatest
number of problems (Best et al., 2006b).
Routine screening for drug misuse is largely restricted in the UK to criminal
justice settings, including police custody and prisons (Matrix Research and
Consultancy & National Association for the Care and Rehabilitation of Offenders
[NACRO], 2004); it is sparsely applied in health and social care settings. For exam-
ple, a recent study of psychiatric inpatients in London found that only 1 in 50 people
admitted to hospital had undergone screening for drug misuse (Barnaby et al., 2003).
The NTA’s updated Models of Care service framework emphasises the importance of
non-specialist (tier 1) services in the identification of drug misuse as a precursor to
referral for treatment (NTA, 2006). Opportunistic methods for the effective identifi-
cation of drug misuse should therefore be considered in a variety of healthcare
settings. These are described in more detail in the NICE clinical guideline Drug
Misuse: Psychosocial Interventions (NICE, 2007).
For those identified and considering treatment, a good assessment is essential to
continuing care. Assessment skills are important across all health and social care
professionals who may come into contact with drug misuse. Assessment includes
information about past and current drug use (amount, type, duration, periods of absti-
nence and effect of abstinence), history of injecting, risk of HIV and other blood-
borne viruses, medical history, forensics and previous contact with treatment services.
Assessment is a continuous process carried out at every contact with the individual
and his or her healthcare professional, counsellor or social worker and can take place
over many years. Urine testing for the absence or presence of drugs is an important
part of assessment and monitoring. Formal rating scales may be helpful in assessing
outcomes and in certain areas of monitoring, for example of withdrawal symptoms.
The aims of assessment are: to confirm drug use (history, examination and urinal-
ysis); assess the degree of dependence; identify complications of drug misuse and
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assess risk behaviour; identify other medical, social and mental health problems;
determine the expectations of treatment and the degree of motivation to change;
assess the most appropriate level of expertise required; determine the need for substi-
tute medication; and refer to/liaise appropriately with shared care, specialist or
specialised generalist care, or other forms of psychosocial care where appropriate. In
addition, immediate advice on harm minimisation, including, if appropriate, access to
sterile needles and syringes, as well as testing for hepatitis and HIV, and immunisa-
tion against hepatitis, should take place.
3.7.1 Clinical practice recommendations
3.7.1.1 Detoxification should be a readily available treatment option for people
who are opioid dependent and have expressed an informed choice to
become abstinent.
3.7.1.2 People who are opioid dependent should be given the same care, respect
and privacy as any other person.
3.7.1.3 In order to obtain informed consent, staff should give detailed information
to service users about detoxification and the associated risks, including:
● the physical and psychological aspects of opioid withdrawal, including
the duration and intensity of symptoms, and how these may be
managed
● the use of non-pharmacological approaches to manage or cope with
opioid withdrawal symptoms
● the loss of opioid tolerance following detoxification, and the ensuing
increased risk of overdose and death from illicit drug use that may be
potentiated by the use of alcohol or benzodiazepines
● the importance of continued support, as well as psychosocial and
appropriate pharmacological interventions, to maintain abstinence,
treat comorbid mental health problems and reduce the risk of adverse
outcomes (including death).
3.7.1.4 All interventions for people who misuse drugs should be delivered by staff
who are competent in delivering the intervention and who receive appro-
priate supervision.
3.8 THE AIMS OF THE TREATMENT AND MANAGEMENT 
OF DRUG MISUSE
The clinical management of drug misuse may be categorised into three broad
approaches: harm reduction, maintenance-oriented treatments and abstinence-
oriented treatments. Detoxification is often seen as the first stage in the process of
achieving abstinence. All treatments aim to prevent or reduce the harms resulting
from use of drugs. Care planning and keyworking should form a core part of 
subsequent treatment and care.
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Harm reduction aims to prevent or reduce negative health or other consequences
associated with drug misuse, whether to the drug-using individual or, more widely, to
society. With such approaches, it is not essential for there to be a reduction in the drug
use itself (although, of course, this may be one of the methods of reducing harm). For
instance, needle and syringe exchange services aim to reduce transmission of blood-
borne viruses through the promotion of safer drug injecting behaviour.
Maintenance-oriented treatments in the UK context primarily refer to the phar-
macological maintenance of people who are opioid dependent, through the prescrip-
tion of opioid substitutes (methadone or buprenorphine). This therapy aims to reduce
or end their illicit drug use and the consequential harms.
Abstinence-oriented treatments aim to reduce an individual’s level of drug use,
with the ultimate goal of abstinence. The NTORS found that approximately one third
of those entering treatment services were abstinent 5 years later (Gossop et al., 2003).
However, these treatments may be associated with an increased risk of death from
overdose in the event of relapse after a period of abstinence, during which time drug
tolerance is lost (Verger et al., 2003). Consequently, it is particularly important for
abstinence-oriented treatment to include education on post-detoxification vulnerability
to relapse (Gossop et al., 1989) and to overdose, and for wider psychosocial rehabil-
itation support to be provided.
Detoxification refers to the process by which the effects of opioid drugs are elim-
inated from dependent opioid users in a safe and effective manner, such that with-
drawal symptoms are minimised (WHO, 2006). With opioids, this process may be
carried out by using the same drug or another opioid in decreasing doses, and can be
assisted by the prescription of adjunct medications to reduce withdrawal symptoms
(DH, 1999). The pharmacological process of detoxification is the first stage of achiev-
ing abstinence, with the primary aim to provide symptomatic relief from withdrawal
while physical dependence on the drugs is being eliminated (Anglin & Hser, 1990);
this should be an active process carried out following the joint decision of the service
user and clinician, with adequate planning for or provision of aftercare. Opioid detox-
ification takes place in a variety of settings, including the community, inpatient units,
residential units and prisons, and at different rates.
Care planning should consider the following when any treatment or management
plan is developed:
● type and pattern of use
● level of dependence
● comorbid mental and physical health problems
● setting
● age and gender
● service users’ aspirations and expectations.
The general principles of treatment are that no single treatment is appropriate for
all individuals, treatments should be readily available and begin when the service user
presents, and there should be the capacity to address multiple needs. It is also
accepted that treatments will change over time. It appears that treatment does not
need to be voluntary to be successful – comparisons of voluntary and legally coerced
drug treatment have been reviewed recently elsewhere (NCCMH, 2008). For most
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people in long-term treatment, that is those with opioid dependence, substitute
medications, such as methadone and buprenorphine, are important elements of care.
However, services also need to address coexisting problems, such as mental health
and physical health problems, alongside the drug misuse.
Keyworking forms the core part of treatment for most service users with long-
term drug misuse problems (NTA, 2006). Typically, this involves the following:
● conducting an assessment of need (and a risk assessment)
● establishing and sustaining a therapeutic relationship
● clarification of the service user’s goals in relation to his/her drug use
● discussion, implementation, evaluation and revision of a treatment plan to address
the client’s goals and needs
● liaison and collaboration with other care providers
● integration of a range of interventions based on a biopsychosocial model of drug
use (for example, prescribing, addressing needs such as housing and improving
personal relationships)
● use of one or more techniques derived from one or more therapeutic models to
engage and retain the service user in treatment and to support the treatment plan
(for example, drug diaries and motivational skills) in the absence of delivering a
complete course of formal psychological therapy.
3.8.1 Clinical practice recommendations
3.8.1.1 Service users should be offered advice on aspects of lifestyle that require
particular attention during opioid detoxification. These include:
● a balanced diet
● adequate hydration
● sleep hygiene
● regular physical exercise.
3.8.1.2 Staff who are responsible for the delivery and monitoring of a care plan
should:
● develop and agree the plan with the service user
● establish and sustain a respectful and supportive relationship with the
service user
● help the service user to identify situations or states when he or she is
vulnerable to drug misuse and to explore alternative coping strategies
● ensure that all service users have full access to a wide range of services
● ensure that maintaining the service user’s engagement with services
remains a major focus of the care plan
● review regularly the care plan of a service user receiving maintenance
treatment to ascertain whether detoxification should be considered
● maintain effective collaboration with other care providers.
3.8.1.3 In order to reduce loss of contact when people who misuse drugs transfer
between services, staff should ensure that there are clear and agreed plans
to facilitate effective transfer.
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3.9 THE DEVELOPMENT OF DETOXIFICATION SERVICES
As stated above, opioid detoxification is the first stage in the process of achieving
abstinence, with the primary aim of providing symptomatic relief from withdrawal
while physical dependence on the drugs is being eliminated (Anglin & Hser, 1990).
Opioid withdrawal includes a variety of symptoms: anxiety, tremors, nightmares,
insomnia, weight loss, nausea, vomiting, seizures and delirium (for example, Bradley
et al., 1987). The process of detoxification alone is not perceived as a solution for
long-term abstinence (Lipton & Maranda, 1983). Indeed psychosocial interventions
should be delivered concordantly in order to maximise benefits derived from detoxi-
fication and to address wider issues surrounding drug use. If these are not delivered,
benefits from detoxification may only be temporary, and the intervention could be
ultimately unsuccessful (Hanson et al., 2006). Detoxification from opioids takes
place in a variety of settings, including the community, inpatient units, residential
units and prisons. The context in which it is delivered will depend on the nature of the
drug itself and the severity of dependence.
Methadone, the most widely used opioid agonist in assisted detoxification (Jaffe,
1989), was developed in Germany during the second world war, when morphine was
unavailable. During the post-war period, methadone was primarily used in hospital
settings to detoxify dependent opioid users (Gerstein & Harwood, 1990). The aim of
using methadone to detoxify heroin users is to suppress withdrawal symptoms
through the provision of an opioid-based substitute medication. Service users are
initially provided with a dose of methadone equivalent to their illicit opioid (heroin)
use, and doses are gradually lowered until they are opioid free. The most rapid
regimes take 7–21 days, while ‘slow tapering’ regimes may take up to 6 months or
longer (DH, 1999), depending on what is judged to be most appropriate by the prac-
titioner and service user. Methadone does not deliver the intense euphoric ‘high’ asso-
ciated with heroin, and also has a longer half-life, meaning that it remains in the body
for longer than heroin; while the effects of heroin wear off in 2–3 hours, the effects
of oral methadone continue for 12–24 hours. Therefore, methadone dose reductions
are relatively easy to achieve in the initial phase of a detoxification programme, but
during the latter stages withdrawal symptoms may become more prominent and
harder to manage. These concerns have led to the use of alternative detoxification
agents such as clonidine, lofexidine, buprenorphine and dihydrocodeine.
Like methadone, buprenorphine is a synthetic opioid that acts as a substitute for
heroin. It was licensed for use for opioid dependence treatment in the UK in 1999,
and thus it is not as well established as other detoxification treatments (Lintzeris
et al., 2002). Buprenorphine is a partial opioid  agonist, which occupies receptors
without fully activating the system, and is therefore associated with a less severe
withdrawal syndrome (Ford et al., 2004). In comparison with methadone, buprenor-
phine also has a longer duration of action, and an increased safety profile in overdose
due to its lesser effects (Walsh et al., 1994).
Alpha2 adrenergic agonists, which include clonidine and lofexidine, are known to
ameliorate a cluster of opioid withdrawal symptoms (those associated with the nora-
drenaline system, including sweating, shivering, and runny nose and eyes). Clonidine,
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originally developed as an anti-hypertensive drug, had received widespread use as one
of the first non-opioid-based options for managing opioid withdrawal (Gossop, 1988),
but its hypotensive effects are problematic in the context of detoxification. Lofexidine
was therefore developed as an alternative to clonidine with reduced hypotensive
effects, and is currently licensed and used widely in the UK for opioid detoxification.
Whilst alpha2 adrenergic agonists allow for detoxification to be attained over a shorter
length of time (typically ranging from 5–7 days) compared with buprenorphine, they
do not address other (non-noradrenergic) withdrawal symptoms, and therefore must
be supplemented by additional medications.
Problems commonly associated with detoxification are low completion rates and
high levels of relapse post treatment (Mattick & Hall, 1996). In an attempt to address
this issue, ultra-rapid detoxification techniques using naltrexone administered under
anaesthesia or deep sedation within a medically monitored setting have been estab-
lished in recent years (Loimer et al., 1991). Naltrexone is a long-acting opioid antag-
onist, first approved for use in 1984 as a maintenance treatment to block the effects
of opioids after detoxification (Tai & Blaine, 1997). When used in the context of
opioid detoxification, it displaces any opioids that are already present in the drug
user’s system, thereby precipitating withdrawal.
Service users undergoing ultra-rapid detoxification are typically admitted to the
intensive care unit of a hospital or a high dependency unit for 24 hours, during which
time naltrexone and/or naloxone is administered to precipitate withdrawal. On pres-
entation of withdrawal symptoms, the service user is anaesthetised or heavily sedated,
such that (in theory) he or she does not consciously experience any of the ensuing
acute withdrawal symptoms. A significant number of adjunct medications, such as
antidiarrhoeals, antiemetics, alpha2 adrenergic agonists and benzodiazepines, are also
administered to manage withdrawal symptoms. There is no uniformity in methods
employed to carry out ultra-rapid detoxification, and there has been much controversy
surrounding their safety, cost and effectiveness due to the limited long-term outcome
data (Strang et al., 1997a). Ultra-rapid detoxification is currently not used in the NHS.
3.10 CURRENT CARE AND TREATMENT IN THE NHS
The British response to drug problems dates back to the report of the Rolleston
Committee of 1926. The committee accepted dependence as a disease and established
a medical approach to drug problems in Britain rather than the predominantly puni-
tive one pursued in other countries such as the US. Rolleston gave doctors a large
degree of clinical freedom in their response to people who were dependent, including
the use of maintenance treatment. To this day, maintenance is considered an essential
aspect of drug treatment.
A large increase in the number of people with heroin dependence in Britain in the
mid-1960s prompted the establishment of a network of drug dependence clinics set in
psychiatric hospitals and run directly by the NHS. The second epidemic of heroin use
in the early 1980s led to a further re-shaping of the British treatment response. A
multidisciplinary approach was encouraged through the establishment of community
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drug teams and attempts to increase general practitioner (GP) involvement in drug
treatment, with the first in a series of clinical guidelines setting out the responsibili-
ties of the prescribing doctor (DH, 1999). The guidelines also sought to encourage
shared care of the person who misuses drugs by different professional groups. While
the drug dependence clinics remained the cornerstone of this reshaped approach, the
vast majority of treatment prescriptions, namely oral methadone, were now dispensed
by community pharmacists and consumed at home. This was further supported by the
2004 General Medical Services contract provision for enhanced maintenance
prescribing services (British Medical Association, 2004).
The emergence of HIV/autoimmune deficiency syndrome (AIDS) in the 1980s led
to the introduction of needle and syringe exchange schemes as an addition to the treat-
ment services available. These schemes provided needles and syringes to the depend-
ent and non-dependent injector. Harm reduction also became an important aspect of
treatment responses to drug misuse. Another refocusing of drug treatment came in the
1990s, with increased concern over the link between criminal activity and drug
misuse. Criminal justice settings were seen as an important conduit for getting people
who misuse drugs into treatment and a number of interventions such as Drug
Treatment and Testing Orders (DTTOs) were established. In 2003, the Home Office,
with the DH and the NTA as its key partners, introduced the Drug Interventions
Programme (DIP), which seeks to bring treatment and criminal justice services
together in responding to drug misuse (Witton et al., 2004).
Most drug treatment is initiated as a result of drug users themselves seeking treat-
ment. However, there has recently been a rapid expansion in forms of legally coerced
treatment, whereby the person who misuses drugs is coerced into treatment as an
alternative or adjunct to criminal sanctions (Wild et al., 2002). Such treatment may
be legally ordered by the court or through referral away from the judicial process,
usually following arrest and charge for drug-related and other offences. Despite
recent policy shifts of referral away from the courts, however, many people who
misuse drugs still serve prison sentences. A recent estimate suggests that around
39,000 prisoners with a serious drug problem are in custody at any one time (All-
Parliamentary Group on Prison Health, 2006). Within the prison setting, drug misuse
treatment is increasingly being offered following a number of recent developments,
including the phased transfer of responsibilities for commissioning healthcare in
publicly funded prisons from the Home Office to the NHS (DH, 2006). While the
mainstay of treatment in prison has traditionally been one of detoxification upon
admission, there has been a recent policy shift allowing increased access to opioid
maintenance therapy and psychosocial interventions.
Current practice in detoxification
Much of the current treatment of drug misuse in services directly provided or
purchased by the NHS focuses on the treatment of opioid misuse. In large part this is
reactive to the drug problems with which service users present, who may themselves
be informed by awareness of relevant treatments as well as their own perceptions of
whether their drug use is problematic. In the last decade there has been a significant
increase in the numbers of service users being treated in primary care settings, with a
Introduction to drug misuse
36
national survey showing that in 2001 almost three times as many GPs were seeing
people who misused opioids compared with in 1989 (Strang et al., 2005). GPs are
now a large part of the substance misuse workforce. Much of the change in the
response from primary care has been through initiatives from the Royal College of
General Practitioners, for example the development of a national drugs training
programme and the creation of a national primary care network.
Around 30,000 detoxifications are currently carried out each year, and the major-
ity are in the community; among individuals who have received any form of treatment
for drug misuse, 19% had previously undergone community detoxification while 13%
had received residential treatment (Best et al., 2006a). Approximately one third enter-
ing treatment services generally are abstinent 5 years later (at least for a period of time)
(Gossop et al., 1998).
Service users consulting either a GP or a community drug team are assessed
initially and their plans for treatment elicited. One of the dilemmas of drug treatment
is that the majority of heroin users – as high as 81% according to the NTA Annual
User Satisfaction Survey – wish to become drug free (Best et al., 2006a), hence they
may frequently ask for detoxification. This is often unrealistic as there may be many
factors that make abstinence unlikely to be possible for the individual at that time.
These would include drug-related risk factors such as polysubstance use and social
risk factors such as homelessness. The availability of treatment options for detoxifi-
cation may also be limited by external factors, in particular for inpatient detoxifica-
tion. Thus the process of treatment planning is often one of negotiation and education,
with the treatment provider having to give the service user realistic information about
outcomes and the possible range of treatment options.
In practice, this means that most service users only commence formal detoxifica-
tion following a period of stabilisation on a substitute opioid (either methadone or
buprenorphine). The stabilisation results in the cessation of illicit drug use, with the
individual feeling comfortable on the dose of substitute opioids he or she is taking.
This process can take months or even years to achieve and for many only happens
after years of maintenance treatment.
Once a prescriber and a service user have planned a detoxification, the rate and
nature of the dose reductions are agreed in advance, although they can be revised. The
service provider should provide a package of psychosocial support, which is usually
delivered via a keyworking relationship which may or may not be with the prescriber.
The prescriber and service user also need to agree on a package of aftercare to support
the service user after the pharmacological phase of treatment is finished.
For a service user in the community who is seriously committed to detoxification
treatment, dose reduction can take place over anything from a few days to several
months, with a higher initial stabilisation dose taking longer to taper. In practice, up
to 3 months is typical for methadone reduction, while buprenorphine reductions are
typically carried out over 14 days to a few weeks. Detoxification using lofexidine is
much faster than using either methadone or buprenorphine, typically lasting 5–7 days,
and up to a maximum of 10 days.
Although a substantial number of service users benefit from detoxification in the
community, many who start these programmes may fail because they start to use
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illicit drugs when their substitute opioid dose is reduced. The programme can then be
changed to maintenance by increasing the dose again and changing the treatment plan
to address other issues. Unfortunately this can result in service providers having treat-
ment plans with unclear treatment goals.
Service users on maintenance programmes often also reduce their doses over time.
If they are otherwise stable, this can be successful but it may be very slow; indeed,
dose reductions may be planned over many years. These gradual dose reductions are
not really detoxifications; clinical experience would indicate that this approach may
be successful but there is little research evidence to support it. In practice, a gradual
dose reduction may prepare a service user for detoxification.
Detoxification in an inpatient setting can take place over a shorter time than in the
community as the supportive environment helps a service user to tolerate emerging
withdrawal symptoms. However, a similar process occurs as in the community: that
of stabilisation on the dose of a substitute opioid and then gradual dose reduction. In
an inpatient environment, reduction typically takes place over a shorter time: 14–21 days
for methadone and 7–14 days for buprenorphine.
Various rapid detoxification programmes involve the use of naltrexone and other
adjuncts (see above) to accelerate the pharmacological process of detoxification to as
short as 24 hours, but these are not currently available in the NHS.
Service users who are incarcerated are often detoxified in prison. Historically this
has been done involuntarily, although increasingly maintenance is available to serv-
ice users who are eligible. Also, historically, service users have had no choice about
the drugs used for their detoxification but again this is beginning to change. It is also
important to remember that, despite the involuntary nature of prison detoxification,
many inmates regard a detoxification in prison as welcome and a chance to reduce
their drug use either temporarily or indeed permanently.
3.11 THE EXPERIENCE OF DRUG MISUSE – PERSONAL
PERSPECTIVES
3.11.1 Testimony A
My first experience of taking drugs was at senior school. One of my school friends
had started smoking cannabis and tried to assure me that it was harmless. After build-
ing up the courage, I half pretended to take a few puffs to test the ground. After this
experience, I discovered that one of my teachers smoked cannabis too. Sometimes I
would go to the pub at lunchtime, have a pint (in the same pub as the teachers) and a
joint, then maybe go back to school if I didn’t get too wrecked. For the last year of
school, I experimented with so many drugs that I never attended and, when it came to
leaving, the teachers didn’t know who I was.
Along with alcohol and cannabis, I discovered that pills seemed to take me away
from my boredom and depression. My mother had a stock of them in the cupboard
and I soon discovered which pills were which and that diazepam and chlordiazepox-
ide seemed to do the trick. Not long after this, I met lots of people who mainly smoked
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dope but were also buying different drugs. In those early days, there were all kinds of
uppers and downers, either acquired from people’s families or stolen from chemists,
such as ‘reds’ and ‘browns’, ‘clears’, ‘black bombers’, ‘purple hearts’, dextroamphet-
amine, and so on. I experimented with just about everything I could get my hands on,
from speed, LSD [lysergic acid diethylamide] and mushrooms, to dextromoramide,
secobarbital, diazepam, dipipanone and methaqualone.
I was about 16 when I first realised I had a problem: I wanted to stay permanently
stoned from whatever drugs I could get my hands on. I usually always had cannabis
to enhance the feeling of other substances.
I was 16 or 17 when I was introduced to heroin. I would go to a friend’s house on
a regular basis and smoke dope until I changed colour; one day I went and was offered
heroin. I remember my friend saying: ‘Look, all of us have had it and we are fine’.
Even though I had fears about becoming addicted on the first go, I tried it and loved it.
All of my true friends warned me against it and what would happen, but I just had to
see for myself. Little did I know that it was going to cost me 23 years of my life, and
that I would have no friends left. Even though I knew lots of other people who took
drugs, I felt very isolated; I didn’t even feel equal to someone who had a different
addiction to me. I felt the lowest of the low for many years and felt so tightly trapped
in my heroin addiction that I truly believed I would only ever come out of it dead.
Some people accept that lifestyle and others hate it. I was one of those who hated it but
could never see an end to it no matter how hard I tried. I was depressed as a child,
which became more severe and hard to handle as my addictive years went by. I twice
came to the point of taking my own life and at the last second couldn’t do it. I also
thought about it more times than I can remember, just wishing I could have been dead.
My mother feared she would be getting a phone call any time to tell her that her
son was dead. I believe my drug use affected my mother’s health because she was
always worrying about me. My sister thought I was a waste of time and at one point
my father disowned me. I moved away from my home town to London in 1982 in an
attempt to give up heroin. Since then, I have never moved back home; I wanted to try
to hide as much of my addiction as I could from my family.
Any relationships I had while using heroin inevitably didn’t last very long. Being
an addict, I lied a lot about where I was going and what I was doing. Methadone made
things a little more stable, but needless to say, sex wasn’t as regular as it should have
been. One or two ex-partners actually thought I had a mistress; they were right: ‘Lady
Heroin’.
I was first treated for drug addiction in the psychiatric unit of my local hospital in
1980. I entered a detox programme and was prescribed methadone but I was not
offered any counselling. When I came out, I started using again. After this, I was in
and out of prison for drug-related offences, but I was offered no treatment inside;
when it looked like I was going to prison for a third time, I decided I needed help.
Instead of receiving a third prison sentence, I asked the judge if I could go into resi-
dential rehab in London. I felt safe in rehab and didn’t realise how little I had to look
forward to once completing and leaving rehab. I eventually went back on heroin
again. For a time, I was prescribed physeptone and pure heroin ampoules but without
much in the way of counselling.
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It wasn’t until 1985 that I saw a counsellor (in order to get methadone from a
community treatment programme you had to see a counsellor twice or three times a
week). My relationships with professionals were not particularly good. I resented the
fact that I had to do what my keyworker said or be thrown off my course. Once I had
finished one course of 6-week reduction, I went back on the waiting list for another
one. You were deemed to have failed if you wanted to go on another course. It took
years before I began to trust any of the workers. For over 2 and a half months I was
refused a place for community treatment due to false positive urine tests; the tests said
that I had diazepam in my system when I really hadn’t taken anything.
I was also offered treatment, from a little help at home with a dihydrocodeine
from a sympathetic doctor, to a detox at home with lofexidine after being monitored
for blood pressure for a couple of hours.
During this period of my life I was on heroin for most of the time with brief peri-
ods of taking methadone. I had no life at all, except the routine of waking up, look-
ing for money to buy heroin, and then buying heroin.
But in 2003 I decided that I wanted to stop using for good; I felt like it was ‘wake-
up or die’ time. One of the main reasons I wanted to stop was because heroin
suppressed just about all of my emotions and I desperately wanted to feel something
again. Without emotions I had no incentive to drive a car, love a woman, get a house,
fly a kite; without emotions I was a zombie. I was living with someone at the time
who used to go out every day and do all the scheming for money for drugs. But I
wasn’t going to put my neck on the line any longer by risking going to prison, so 
the day he left I knew was the day I was going to give up for good. Without support
from a drug worker, I stopped using heroin and 2 days later started taking buprenor-
phine, which to my mind is a godsend; on the third day, I was up and about, helping
deliver 7 tonnes of food aid and feeling great. Since that day I have not wanted to take
heroin at all.
After 23 years, I had stopped using drugs. It had been a relatively simple process
and I wondered why it could not have happened before. But it hadn’t happened, prob-
ably because I had not been able to break the cycle before. I realised that this was the
time that one big window of opportunity was opening; but, without doing something
to keep me occupied, I knew there was every chance of slipping backwards.
I found a crumbling self-help group with one person attending and one part-time
staff member; we managed to bring that group back to life. I spent the next 2 and a
half years volunteering support to others who wanted to use self-help. I’ve also had
lots of input into my local addiction organisations as well as national input; this in
turn helped me to help myself.
Since this time, I’ve never looked back. I’ve had so much energy and time to start
enjoying it all. Life is radically different: buprenorphine, which I take daily, has
helped me gain stability and self-respect. I no longer have the worry of being in and
out of prison because I don’t need to go out on the streets looking for money for
heroin. And, thanks to buprenorphine, I really don’t have any craving for heroin. I am
now thinking about stopping taking buprenorphine.
Since stopping using drugs, I still get depression but it’s much easier to handle and
much less frequent. I can sometimes feel depressed for days on end, but usually all I
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need to do is think about the desperation I felt from 23 years of using; I then just make
a simple comparison.
The drug use has taken its toll on my physical health. I had a blood test after I
stopped taking heroin and found out that I have hepatitis C. The doctor didn’t give me
any sympathy and told me that I can expect to be dead within 30 years after my liver
becomes cancerous. I still have the virus, which hasn’t got any worse over the years,
but I am giving some thought to having it treated soon.
I didn’t learn lessons I should or could have while using, but now with clarity of
mind, one of the many lessons I’ve learned is that it will pass, but if any window of
opportunity opens before it does pass, I take it.
Since I first started using, I think that overall the whole of the field of care has
changed for the better. I believe that listening to addicts’ and ex-addicts’ views on
treatment has reformed drug treatment services nationwide. Many more doctors have
become involved with community treatment and, from my experience, really do care.
3.11.2 Testimony B
I witnessed drug and alcohol misuse very early on in my life, either through relatives
who openly smoked cannabis in front of me, or simply by being present at drinking
parties in my home, but my own first-hand experience of illicit drugs began when I
was 11 years old. I had just started senior school and I knew that drugs were available
there, due to the fact that I had cousins at the school who used drugs. Soon after start-
ing senior school, I was associating with older pupils; after school at a friend’s house,
we inhaled some poppers (amyl nitrate) that my friend had stolen from his aunt, but
I didn’t really like the experience. Shortly after that, we used our dinner money to buy
a small amount of hash from one of my cousins. We smoked a spliff during the lunch
break, and I was so smashed that I couldn’t go back to school.
After this experience, I smoked cannabis as often as I could afford, but I used to read
up on all the different drugs and their effects, and what I really wanted to try out was
LSD, which during that time was in plentiful supply, and also at a relatively low price.
Before long, I had found someone prepared to sell me acid on a regular basis. Following
this experience, I then moved on to just about all of the other drugs available at that
time, and by the age of 14, I was selling drugs in and outside school. Eventually, I was
expelled from school for selling drugs, non-attendance and disruption. No charges were
brought, but I acquired a label as someone who could be approached for drugs.
I realised very early on during my substance misuse that I had a problem. At the
time, I couldn’t admit, or in some cases fully comprehend, some of the reasons why
I used drugs and drank alcohol, although now that I look back, I am able to identify
the reasons. It would be difficult to provide a summary-like version of the antecedents
to my drug use and criminality, except to say that I felt the need to opt out of reality.
I definitely knew I had a problem because I could see that my habits were different
from other people’s. Most people with whom I took drugs would all gather round at
one of our houses; then, at a particular time, they would have to go home, as they were
expected to, because they had to be at school. However, I didn’t, so I would then go
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on to an older person’s house, where I would take more amphetamine, smoke
cannabis all night and drink. Very quickly, my circle of ‘friends’ was reduced to
people who were similar to me. I used to stay awake for days at a time, and the major-
ity of people who I came into contact with were just buying drugs from me. During
this time, despite the fact that I was still enjoying taking certain drugs, I led a lonely,
maladjusted life. I used to take such large amounts of drugs (several types at once)
that I’d experience many unpleasant effects; my health began to suffer at an early age,
and I later contracted hepatitis C. I had become addicted, was surrounded by drugs,
had become accustomed to a particular lifestyle and, above all, didn’t feel able or
ready to even contemplate a life without drugs.
My drug use devastated my family, and my family’s drug use devastated me. (My
mother didn’t use drugs, although she is an alcoholic, and her steady, almost
controlled use of alcohol was very different  from my chaotic use of many different
kinds of drugs.) I had a very bad attitude, and made my mother’s home unsafe to live
in. Police would bust the house at least twice a year for about 10 years. People would
come to the house demanding money; one time, I was even kidnapped, and my
mother had to bail me out. I had my life threatened several times during my drug use,
and I used to keep guns, knives, CS gas and a whole range of weapons in my mother’s
house. My younger brothers suffered as a result of this behaviour, and the only time
they ever felt safe was when I was in prison. My mother found me when I almost died
from an overdose, and watched me waste away to nothing over years of drug abuse.
I first accessed treatment services when I was 18. I obtained a methadone script,
which was eventually three times a week, but I had absolutely no interest in coming
off drugs. I used to sell my script most of the time in those days, and viewed my drugs
worker as an inconvenience. I didn’t need him at that stage, as I wasn’t destitute, and
was just taking the piss. One month, when I wasn’t even dependent on opioids, I had
to buy some methadone, because I had a routine urine test coming up, and knew that
I had to have some meth in my system. I didn’t even take the methadone that I scored;
I gave it to someone else, and submitted their urine, which I heated up with a lighter
in the toilets of the service. In those days, as far as I was concerned, they either didn’t
give a shit, or just didn’t know the score.
Over the years, I got more tired of using and in real need of help. I went through
many different services, prescribers, GPs and counsellors, until I eventually arrived at
the stage where I was truly ready to give up drugs. It was around this time, at the age
of 25, after 16 years of substance misuse, that I had enough. When I got to this stage,
I began to be truthful with the workers with whom I came into contact, with reason-
able results, although none of the community-based staff could deliver what I needed.
Some of them didn’t have the skills, personally or professionally, and just couldn’t
imagine what it was like for me at that point in my life. I had become so immersed in
the lifestyle, and had ingrained habitual behaviour, that any work they attempted to do
with me was generally ineffective, because the one important aspect of my addiction
which they had no control over was my personal circumstances and my immediate
environment.
I decided to enter a detox programme while inside prison in November 2003. To
gain entry into the programme, I had to agree to go onto the drug-free wing within
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the prison, which was a standard prison wing, exactly the same as the rest of the
prison. Also, I had to agree to a regime of regular urine testing. The unit wasn’t actu-
ally drug free in reality, although there were definitely more prisoners who were not
using heroin and other drugs, and perhaps a few more positive attitudes. At the time
of making the decision, I was absolutely desperate to be detoxified.
Drugs for the detoxification were administered by the prison healthcare team; the
programme consisted of a 3-week buprenorphine reduction programme, with one-to-
one support on a regular basis, although not by anyone who was a trained drugs
worker or counsellor. The unit itself was run by prison officers, managed by two offi-
cers in particular who showed the most interest in drug treatment, although they were
by no means specialists. It was as close as one could be to a detox centre within that
setting, given that the majority of those accessing it had absolutely no intention of
trying to become or remain drug free. In spite of this, I was determined to get some-
thing out of it, and took advantage of everything that was on offer, such as comple-
mentary therapies like auricular acupuncture, relaxation sessions and one-to-one
sessions, which I enjoyed. It was respite for me, in the sense that it was a different
atmosphere from the prison wing.
I didn’t complete the detox in prison, as I was bailed onto a DTTO. On release from
prison, I was offered no follow-up support. I went back to my home town and accessed
my local drug services, who seeing the effort I had made not to use upon release, got a
script sorted out for me on the day that I saw them. I’d been a client at this place for a
number of years, but I had never received treatment as efficient as this, and I made full
use of it in a positive way. If I had to pinpoint one aspect of the care that was good, it
would be the way that the service, at that particular point in my treatment journey, made
an effort to provide me with seamless care. From there, I was taken up by my local
DTTO team who took my script over. The prescribing nurse and my keyworker in
probation agreed that I should be maintained on buprenorphine for the duration of the
12-month order, to try and maximise my chances of addressing my needs at that time.
I didn’t complete the DTTO, because I got sick and tired of it. I had a discussion with
my personal probation officer about the possibility of entering residential treatment, as I
felt unable to cope with the situation I was in at that time. I went into a residential reha-
bilitation centre in 2004 in order to address my addiction, as I needed a holistic package
of care, which thankfully I received during a 12-month programme. I managed to secure
a place at a residential rehab, just 6 months after being bailed from prison. The rehab was
a therapeutic community with 36 beds and used cognitive behavioural therapy (CBT)
techniques. I went through opioid withdrawal without the assistance of any substitutes,
or adjunctive medicine. In the end, it was other people that helped me to get through my
withdrawals, not chemicals. My relationship with my keyworker in rehab was one of
complete honesty, trust and mutual respect. This person was the catalyst that enabled me
to explore the underlying issues that underpinned my substance misuse. They helped me
achieve this by being empathic, determined and creative in their practice, as well as effec-
tively coordinating my care with other agencies.
I now lead a very happy and fulfilling life. I have chosen not to drink alcohol or
use any illicit substances, nor do I commit crime. I have a family of my own now 
who have never known me under the influence of drugs or alcohol. I work in the drug
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treatment field, as a support worker at a residential rehab. I also teach at a pupil 
referral unit, and I’m half way through a sociology degree with the Open University.
In the next academic year, I’m going to take a place at my local university to embark
on a degree in social work. I plan to specialise in working with families with
substance misuse problems. I currently sit on an advisory group that informs social
work students about transferring their academic skills into good practice.
Although my drug use led to a few physical ailments, I feel relatively healthy now,
as I’ve been drug free for nearly 4 years. When I entered residential rehab, a GP
referred me to a liver specialist, who treated the hepatitis, and I’ve been clear of the
virus for nearly 2 years.
I have many tools that aid me in my recovery at present, all of which I’ve accu-
mulated over time. I believe that every individual has their own unique set of circum-
stances, thus their own set of precursors or reasons that lead to problematic drug use
in the first place. Based on this, I would say that each person needs to find what is
right for them, not just in terms of treatment, but also after treatment. Personally, 
I keep myself extremely busy, not just with my social-care-related work, but in every-
thing I do. I make sensible choices when it comes to who I associate with, where 
I live (I’ve subsequently relocated) and how I behave towards others.
3.12 IMPACT OF DRUG MISUSE ON FAMILIES AND CARERS
There is an increasing recognition that drug misuse affects the entire family and the
communities in which these families live. The NTA user satisfaction survey found
that 25% of respondents felt that staff did not offer families and carers enough support
(Best et al., 2006a). The Home Office’s updated Drug Strategy (2002) includes
targets on increasing access to help, advice and counselling for parents, carers and
families of people who misuse drugs. Staff should be particularly aware of the needs
of children (ACMD, 2003 & 2007) and consider their own responsibility under the
Children Act (1989).
There has also been a growth in carer organisations, most notably Adfam and
Families Anonymous, for carers of people who misuse drugs, and over 100 peer-
support family groups in the UK founded on parents’ own experience of drug use in
their families. Families Anonymous is a self-help service based on the 12-steps and is
aimed at helping families affected by drug use and behavioural problems (for further
details on evidence for the effectiveness of 12-steps and similar approaches, see
NCCMH, 2008). Families attend meetings on a regular basis and share their experi-
ences with other families. However, despite the recognition of carers’ needs and the
growth of carer organisations, there is a rather limited evidence base assessing the
impact on carers/families of drug misuse, on interventions intended to support them,
and even less attention given to the needs of the family/carer in their own right. Most
interventions have targeted carers/families primarily to improve outcomes of the
person who misuses drugs and only secondarily to address the needs of the family.
Adfam’s report (Sims, 2002) identified a number of needs of families of people
who misuse drugs and alcohol. One of the major needs reported by families was
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coping with stigma. It was argued that stigma was a major barrier in preventing carers
or family members from accessing services, both in terms of actual exclusion from
primary care services as well as self-exclusion through fear of being judged. A further
need was to access services. Provision of services for families of people who misuse
drugs was found to be rather limited (see also Bancroft et al., 2002), but even where
these services were available, many families were either not aware of them or did not
know how to access them. Many families also perceived themselves to be excluded
from participation in the treatment provided for their family member. Some families
felt that workers were hiding behind confidentiality when they could have provided
general information about treatment. Families may also have different treatment goals
from the person misusing drugs and staff involved in his or her care.
The involvement of families and carers remains problematic, but many families
express a clear desire for the person with a drug problem to become abstinent and
detoxification has a clear role to play in this. Appropriate involvement of family
members in the assessment and engagement process may both support the family
member and facilitate a more successful outcome. Some psychosocial interventions
also explicitly involve family members with the aim of maintaining abstinence
following detoxification (see Chapter 7).
3.12.1 Clinical practice recommendations
3.12.1.1 Staff should discuss with people who present for detoxification whether to
involve their families and carers in their assessment and treatment plans.
However, staff should ensure that the service user’s right to confidentiality
is respected.
3.12.1.2 Staff should ask families and carers about, and discuss concerns regarding,
the impact of drug misuse on themselves and other family members,
including children. Staff should also:
● offer family members and carers an assessment of their personal, social
and mental health needs
● provide verbal and written information and advice on the impact of
drug misuse on service users, families and carers
● provide information about detoxification and the settings in which it
may take place
● provide information about self-help and support groups for families and
carers.
3.13 ECONOMIC IMPACT OF DRUG MISUSE
Drug misuse is a growing public health concern that carries a substantial economic
burden. It is associated with high healthcare and social costs, mainly as a result of trans-
mission of infectious disease, crime and violence (Petry et al., 2004). It has been esti-
mated that problematic drug use accounts for annual social costs in England and Wales
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of approximately £11,961 million, or £35,455 per user, per year (Godfrey et al., 2002).
Chronic health problems comprise a significant element of the health and social care
costs of drug misuse. It has been estimated that the prevalence of HIV among new
injecting drug users in London reaches 4.2% (Judd et al., 2005). Godfrey and
colleagues (2002) estimated the median number of HIV-positive injectors in England
and Wales in 2002 to comprise 931 asymptomatic individuals, 1,756 symptomatic 
and 1,007 with AIDS. The same authors estimated the median per person annual cost
of combination therapy at £13,381 for asymptomatic, £14,222 for symptomatic and
£24,314 for people with AIDS. These estimates yielded median annual costs to the NHS
of £12.5 million, £25 million and £24 million, respectively, totalling over £60 million.
In 1999, the reported prevalence of hepatitis B in injecting drug users was esti-
mated at 25% among those attending agencies in London and 17% outside London,
with a combined estimate for England and Wales of 21% (Godfrey et al., 2002).
Based on these estimates, the same study calculated that the number of injecting drug
users who were infected with hepatitis B in 2002 was roughly 54,000. An annual cost
of £143 per year assumes a lifetime cost of £4,300 to treat people with hepatitis over
their average life expectancy of 30 additional years (Godfrey et al., 2002). The annual
NHS treatment cost of hepatitis B for injecting drug users was therefore calculated at
approximately £7.8 million (Godfrey et al., 2002). Similar estimates for hepatitis C
(based on a median 2002 estimate of 81,782 injecting drug users with the virus)
yielded an annual NHS treatment cost of £11.7 million (Godfrey et al., 2002). Beyond
the healthcare costs incurred directly by the users, the NHS costs relating to treatment
of neonates affected by mothers’ drug misuse were calculated at £4.3 million per year
(Godfrey et al., 2002), with the annual cost of social services in caring for these chil-
dren amounting to £63 million.
Including primary care, emergency departments, inpatient care, community
mental health, and inpatient mental healthcare, problem drug users are estimated to
cost the health service between £283 million and £509 million per year (Godfrey
et al., 2002). This estimate was in addition to psychosocial interventions, which at
present cost £1,000 per user, per year (Godfrey et al., 2002). Furthermore, drug
misuse substantially increases crime-ralated costs. Godfrey and colleagues (2002)
estimated that the criminal justice system and crime victim costs were £2,366 million
and £10,556 million respectively, based on the medium estimates of the number of
problematic drug users. Criminal justice costs include costs associated with drug
arrests for acquisitive crimes, stays in police custody, appearances in court, and stays
in prison; crime victim costs refer to material or physical damage, crime victims’ loss
and expenditures taken in anticipation of crime.
The above estimates did not consider the impact of current drug use on future
healthcare demands, the lost output of the victim or perpetrator of crime, nor the
intangible effects on the community at large, such as security expenditure, property
depreciation or increased reliance on private transportation. It is therefore evident that
drug misuse places a considerable economic burden to the health service and society
as a whole.
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4. METHODS USED TO DEVELOP 
THIS GUIDELINE
4.1 OVERVIEW
The development of this guideline drew upon methods outlined by NICE (The
Guidelines Manual1 [NICE, 2006a]). A team of healthcare professionals, lay repre-
sentatives and technical experts known as the Guideline Development Group (GDG),
with support from the NCCMH staff, undertook the development of a patient-centred,
evidence-based guideline. There are six basic steps in the process of developing a
guideline:
● Define the scope, which sets the parameters of the guideline and provides a focus
and steer for the development work
● Define clinical questions considered important for practitioners and service users
● Develop criteria for evidence searching and search for evidence
● Design validated protocols for systematic review and apply to evidence recovered
by search
● Synthesise and (meta-) analyse data retrieved, guided by the clinical questions,
and produce evidence profiles
● Answer clinical questions with evidence-based recommendations for clinical
practice.
The clinical practice recommendations made by the GDG are therefore derived
from the most up-to-date and robust evidence base for the clinical and cost effective-
ness of opioid detoxification for people who misuse drugs. In addition, to ensure a
service user and carer focus, the concerns of service users and carers regarding health
and social care have been highlighted and addressed by good practice points and
recommendations agreed by the whole GDG.
4.2 THE SCOPE
Guideline topics are selected by the Department of Health (DH) and the Welsh Assembly
Government, which identify the main areas to be covered by the guideline in a specific
remit (see The Guideline Development Process – An Overview for Stakeholders, the
Public and the NHS (second edition)2 [NICE, 2006b]). The remit for this guideline was
translated into a scope document by staff at the NCCMH (see Appendix 1).
The purpose of the scope was to:
● provide an overview of what the guideline would include and exclude
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● identify the key aspects of care that must be included
● set the boundaries of the development work and provide a clear framework to
enable work to stay within the priorities agreed by NICE and the National
Collaborating Centre and the remit from the DH/Welsh Assembly Government
● inform the development of the clinical questions and search strategy
● inform professionals and the public about the expected content of the guideline
● keep the guideline to a reasonable size to ensure that its development could be
carried out within a 12-month period.
The draft scope was subject to consultation with stakeholders over a 4-week
period. During the consultation period, the scope was posted on the NICE website
(www.nice.org.uk). Comments were invited from stakeholder organisations and the
Guideline Review Panel (GRP). Further information about the GRP can also be found
on the NICE website. The NCCMH and NICE reviewed the scope in light of
comments received, and the revised scope was signed off by the GRP.
4.3 THE GUIDELINE DEVELOPMENT GROUP
The GDG consisted of: two service users and a carer, and professionals from
psychiatry, clinical psychology, pharmacology, toxicology, nursing, general practice,
the prison service and the private and voluntary sectors. The guideline development
process was supported by staff from the NCCMH, who undertook the clinical litera-
ture searches, reviewed and presented the evidence to the GDG, managed the process,
and contributed to drafting the guideline.
4.3.1 Guideline Development Group meetings
Nine GDG meetings were held between January 2006 and April 2007. During each
day-long GDG meeting, in a plenary session, clinical questions and clinical and
economic evidence were reviewed and assessed, and recommendations formulated.
At each meeting, all GDG members declared any potential conflict of interests, and
service user and carer concerns were routinely discussed as part of a standing agenda.
4.3.2 Topic groups
The GDG divided its workload along clinically relevant lines to simplify the guide-
line development process, and GDG members formed smaller topic groups to under-
take guideline work in that area of clinical practice. Topic group 1 covered questions
relating to pharmacology and physical treatments; topic group 2 covered psychoso-
cial treatments; topic group 3 covered inpatient and prison settings; and topic 
group 4 covered testing methods. These groups were designed to efficiently manage
the large volume of evidence appraisal prior to presenting it to the GDG as a whole.
Each topic group was chaired by a GDG member with expert knowledge of the topic
area (one of the healthcare professionals). Topic groups refined the clinical questions
and the clinical definitions of treatment interventions, reviewed and prepared the
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evidence with the systematic reviewer before presenting it to the GDG as a whole,
and helped the GDG to identify further expertise in the topic. Topic group leaders
reported the status of the group’s work as part of the standing agenda. They also intro-
duced and led the GDG discussion of the evidence review for that topic and assisted
the GDG Chair in drafting that section of the guideline relevant to the work of each
topic group.
4.3.3 Service users and carers
Individuals with direct experience of services gave an integral service-user focus to 
the GDG and the guideline. The GDG included two service users and a carer. They
contributed as full GDG members to writing the clinical questions, helping to ensure that
the evidence addressed their views and preferences, highlighting sensitive issues and
terminology relevant to the guideline, and bringing service-user research to the attention
of the GDG. In drafting the guideline, they contributed to writing the guideline’s intro-
duction and identified recommendations from the service user and carer perspective.
4.3.4 Special advisors
Special advisors, who had specific expertise in one or more aspects of treatment and
management relevant to the guideline, assisted the GDG, commenting on specific
aspects of the developing guideline and making presentations to the GDG. Appendix
3 lists those who agreed to act as special advisors.
4.3.5 National and international experts
National and international experts in the area under review were identified through
the literature search and through the experience of the GDG members. These experts
were contacted to recommend unpublished or soon-to-be published studies in order
to ensure up-to-date evidence was included in the development of the guideline. They
informed the group about completed trials at the pre-publication stage, systematic
reviews in the process of being published, studies relating to the cost effectiveness of
treatment, and trial data if the GDG could be provided with full access to the
complete trial report. Appendix 6 lists researchers who were contacted.
4.4 CLINICAL QUESTIONS
Clinical questions were used to guide the identification and interrogation of the
evidence base relevant to the topic of the guideline. Before the first GDG meeting,
draft questions were prepared by NCCMH staff based on the scope and an overview
of existing guidelines. They were then discussed by the GDG at their first two 
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meetings and amended as necessary. Where appropriate, the questions were refined
once the evidence had been searched and, where needed, sub-questions were gener-
ated. The final list of clinical questions can be found in Appendix 7.
For questions about interventions, the PICO (patient, intervention, comparison and
outcome) framework was used. This structured approach divides each question into
four components: the patients (the population under study), the interventions (what is
being done), the comparisons (other main treatment options) and the outcomes (the
measures of how effective the interventions have been) (see Text Box 2).
Methods used to develop this guideline
50
Patients/population Which patients or population of patients are we interested
in? How can they be best described? Are there subgroups
that need to be considered?
Intervention Which intervention, treatment or approach should be
used?
Comparison What is/are the main alternative/s to compare with the 
intervention?
Outcome What is really important for the patient? Which outcomes
should be considered: intermediate or short-term meas-
ures; mortality; morbidity and treatment complications;
rates of relapse; late morbidity and readmission; return to
work, physical and social functioning and other measures
such as quality of life; general health status; costs?
Text Box 2: Features of a well-formulated question on effectiveness
intervention – the PICO guide
For questions relating to diagnosis, the PICO framework was not used, since such
questions do not involve an intervention designed to treat a particular condition. Rather,
the questions were designed to pick up key issues specifically relevant to diagnostic
tests, for example their accuracy, reliability, safety and acceptability to the patient.
In some situations the prognosis of a particular condition is of fundamental impor-
tance, over and above its general significance in relation to specific interventions.
Areas where this is particularly likely to occur relate to assessment of risk, for exam-
ple in terms of behaviour modification or screening and early intervention. In
addition, questions related to issues of service delivery are occasionally specified in
the remit from the DH/Welsh Assembly Government. In these cases, appropriate clin-
ical questions were developed to be clear and concise.
To help facilitate the literature review, a note was made of the best study design
type to answer each question. There are four main types of clinical questions 
of relevance to NICE guidelines. These are listed in Text Box 3. For each type of
question the best primary study design varies, where ‘best’ is interpreted as ‘least
likely to give misleading answers to the question’.
However, in all cases, a well-conducted systematic review of the appropriate type
of study is likely to always yield a better answer than a single study.
Deciding on the best design type to answer a specific clinical or public health
question does not mean that studies of different design types addressing the same
question were discarded.
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Type of question Best primary study design
Effectiveness or other impact Randomised controlled trial (RCT); other
of an intervention studies that may be considered in the absence
of an RCT are the following: 
internally/ externally controlled before and
after trial, interrupted time-series
Accuracy of information Comparing the information against
(for example, risk factor, test, a valid gold standard in a randomised
prediction rule) trial or inception cohort study
Rates (of disease, patient Cohort, registry, cross-sectional study
experience, rare side effects)
Costs Naturalistic prospective cost study
Text Box 3: Best study design to answer each type of question
4.5 SYSTEMATIC CLINICAL LITERATURE REVIEW
The aim of the clinical literature review was to systematically identify and synthesise
relevant evidence from the literature in order to answer the specific clinical questions
developed by the GDG. Thus, clinical practice recommendations are evidence-based,
where possible, and if evidence is not available, consensus methods were used (see
Section 4.5.6) and the need for future research was specified.
4.5.1 Methodology
A step-wise, hierarchical approach was taken to locating and presenting evidence to
the GDG. The NCCMH developed this process based on methods set out in the The
Guidelines Manual3 (NICE, 2006a) and after considering recommendations from a
range of other sources. These included:
● Centre for Clinical Policy and Practice of the New South Wales Health Department
● Clinical Evidence Online
● The Cochrane Collaboration
3Available from: www.nice.org.uk
● Grading of Recommendations: Assessment, Development, and Evaluation
(GRADE) Working Group
● New Zealand Guideline Group
● NHS Centre for Reviews and Dissemination
● Oxford Centre for Evidence-Based Medicine
● Oxford Systematic Review Development Programme
● Scottish Intercollegiate Guidelines Network (SIGN)
● United States Agency for Health Research and Quality.
4.5.2 The review process
After the scope was finalised, a more extensive search for systematic reviews and
published guidelines was undertaken. Existing NICE guidelines were updated where
necessary. Other relevant guidelines were assessed for quality using the AGREE
instrument (AGREE Collaboration, 2003). The evidence base underlying high-
quality existing guidelines was utilised and updated as appropriate.
At this point, the review team, in conjunction with the GDG, developed a review
protocol that detailed all comparisons necessary to answer the clinical questions. The
initial approach taken to locating primary-level studies depended on the type of clin-
ical question and availability of evidence.
The GDG decided which questions were best addressed by good practice based on
expert opinion, which questions were likely to have a good evidence base and which
questions were likely to have little or no directly relevant evidence. Recommendations
based on good practice were developed by informal consensus of the GDG. For
questions with a good evidence base, the review process depended on the type of key
question (see below). For questions that were unlikely to have a good evidence base, a
brief descriptive review was initially undertaken by a member of the GDG.
Searches for evidence were updated 6–8 weeks before the stakeholder consulta-
tion. After this point, studies were included only if they were judged by the GDG to
be exceptional (for example, the evidence was likely to change a recommendation).
The search process for questions concerning interventions
For questions related to interventions, the initial evidence base was formed from well-
conducted RCTs that addressed at least one of the clinical questions. Although there
are a number of difficulties with the use of RCTs in the evaluation of interventions in
mental health, the RCT remains the most important method for establishing treatment
efficacy (this is discussed in more detail in appropriate clinical evidence chapters).
For other clinical questions, searches were for the appropriate study design.
All searches were based on the standard mental health related bibliographic data-
bases (EMBASE, MEDLINE, PsycINFO, Cochrane Library, CINAHL) for all trials
potentially relevant to the guideline. The search was not restricted to English language
publications but included papers from other languages where native speakers were
available to translate.
Where the evidence base was large, recent high-quality English-language systematic
reviews were used primarily as a source of RCTs (see Appendix 10 for quality criteria
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used to assess systematic reviews). However, in some circumstances existing datasets
were utilised. Where this was the case, data were cross-checked for accuracy before
use. New RCTs meeting inclusion criteria set by the GDG were incorporated into the
existing reviews and fresh analyses performed.
After the initial search results were scanned liberally to exclude irrelevant papers,
the review team used a purpose-built ‘study information’ database to manage both the
included and the excluded studies (eligibility criteria were developed after consulta-
tion with the GDG). For questions without good-quality evidence (after the initial
search), a decision was made by the GDG about whether to (a) repeat the search using
subject-specific databases (for example, AMED, SIGLE or PILOTS), (b) conduct a
new search for lower levels of evidence, or (c) adopt a consensus process (see Section
4.5.6). Future guidelines will be able to update and extend the usable evidence base
starting from the evidence collected, synthesised and analysed for this guideline.
In addition, searches were made of the reference lists of all eligible systematic
reviews and included studies, as well as the list of evidence submitted by stakeholders.
Known experts in the field (see Appendix 6), based both on the references identified
in early steps and on advice from GDG members, were sent letters requesting relevant
studies that were in the process of being published4. In addition, the tables of contents
of appropriate journals were periodically checked for relevant studies.
The search process for questions of diagnosis and prognosis
For questions related to diagnosis and prognosis, the search process was the same as
described above, except that the initial evidence base was formed from studies with
the most appropriate and reliable design to answer the particular question. That is, for
questions about diagnosis, the initial search was for cross-sectional studies and for
questions about prognosis, it was for cohort studies of representative patients. In situ-
ations where it was not possible to identify a substantial body of appropriately
designed studies that directly addressed each clinical question, a consensus process
was adopted (see Section 4.5.6).
Search filters
Search filters developed by the review team consisted of a combination of subject
heading and free-text phrases. Specific filters were developed for the guideline topic,
and where necessary, for each clinical question. In addition, the review team used
filters developed for systematic reviews, RCTs and other appropriate research designs
(see Appendix 8).
Study selection
All primary-level studies included after the first scan of citations were acquired in full
and re-evaluated for eligibility at the time they were being entered into the study
information database. Eligibility criteria were developed for each clinical question
and are described in the relevant clinical evidence chapters. Eligible systematic
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4Unpublished full trial reports were also accepted where sufficient information was available to judge 
eligibility and quality (see section on unpublished evidence overleaf).
reviews and primary-level studies were critically appraised for methodological
quality (see Appendix 10 and Appendix 15 [the characteristics of reviewed studies
tables]). The eligibility of each study was confirmed by at least one member of the
appropriate topic group.
For some clinical questions, it was necessary to prioritise the evidence with
respect to the UK context (that is, external validity). To make this process explicit, the
topic groups took into account the following factors when assessing the evidence:
● participant factors (for example, gender, age and ethnicity)
● provider factors (for example, model fidelity, the conditions under which the inter-
vention was performed and the availability of experienced staff to undertake the
procedure)
● cultural factors (for example, differences in standard care and differences in the
welfare system).
It was the responsibility of each topic group to decide which prioritisation factors
were relevant to each clinical question in light of the UK context and then decide how
it should modify its recommendations.
Unpublished evidence
The GDG used a number of criteria when deciding whether or not to accept unpub-
lished data. First, the evidence must have been accompanied by a trial report contain-
ing sufficient detail to properly assess the quality of the data. Second, the evidence
must have been submitted with the understanding that data from the study and a
summary of the study’s characteristics would be published in the full guideline (there-
fore, the GDG did not accept evidence submitted as commercial in confidence).
However, the GDG recognised that unpublished evidence submitted by investigators
might later be retracted by those investigators if the inclusion of such data would
jeopardise publication of their research.
4.5.3 Data extraction and synthesising the evidence
Outcome data were extracted from all eligible studies that met the quality criteria.
Where possible, meta-analysis was used to synthesise the evidence using Review
Manager 4.2.8 (Cochrane Collaboration, 2005). If necessary, reanalyses of the data or
sub-analyses were used to answer clinical questions not addressed in the original
studies or reviews.
Where possible, dichotomous efficacy outcomes were calculated on an intention-
to-treat basis (that is, a ‘once-randomised-always-analyse’ basis). This assumes that
those participants who ceased to engage in the study – from whatever group – had an
unfavourable outcome. Adverse effects were entered into Review Manager as
reported by the study authors because it was usually not possible to determine
whether early withdrawals had an unfavourable outcome. For the outcome ‘leaving
the study early for any reason’, the denominator was the number randomised.
Included/excluded studies tables, generated automatically from the study informa-
tion database, were used to summarise general information about each study (see
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Appendix 15). Where meta-analysis was not appropriate and/or possible, the reported
results from each primary-level study were also presented in the included studies
table (and included, where appropriate, in a narrative review).
Consultation was used to overcome difficulties with coding. Data from studies
included in existing systematic reviews were extracted independently by one reviewer
and cross-checked with the existing dataset. Where possible, two independent review-
ers extracted data from new studies. Where double data extraction was not possible,
data extracted by one reviewer was checked by the second reviewer. Disagreements
were resolved with discussion. Where consensus could not be reached, a third
reviewer resolved the disagreement. Masked assessment (that is, blind to the journal
from which the article comes, the authors, the institution and the magnitude of the
effect) was not used since it is unclear that doing so reduces bias (Jadad et al., 1996;
Berlin, 1997).
4.5.4 Presenting the data to the GDG
Summary characteristics tables and, where appropriate, forest plots generated with
Review Manager, were presented to the GDG, in order to prepare an evidence profile
for each review and to develop recommendations.
Evidence profile tables
An evidence profile table was used to summarise both the quality of the evidence and
the results of the evidence synthesis (see Table 1 for an example of an evidence profile
table). Each table included details about the quality assessment of each outcome:
number of studies, the study design, limitations (based on the quality of individual stud-
ies; see Appendix 10 for the quality checklists and Appendix 15 for details about each
study), information about the consistency of the evidence (see below for how consis-
tency was measured), directness of the evidence (that is, how closely the outcome meas-
ures, interventions and participants match those of interest) and any other
considerations (for example, effect sizes with wide confidence intervals [CIs] would be
described as imprecise data). Each evidence profile also included a summary of the
findings: number of patients included in each group, an estimate of the magnitude of the
effect, and quality of the evidence. The quality of the evidence was based on the qual-
ity assessment components (study design, limitations to study quality, consistency,
directness and any other considerations) and graded using the following definitions:
● High  Further research is very unlikely to change our confidence in the estimate
of the effect.
● Moderate  Further research is likely to have an important impact on our confi-
dence in the estimate of the effect and may change the estimate.
● Low  Further research is very likely to have an important impact on our confi-
dence in the estimate of the effect and is likely to change the estimate.
● Very low  Any estimate of effect is very uncertain.
For further information about the process and the rationale of producing an
evidence profile table, see GRADE (2004).
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Forest plots
Forest plots were used to present the results of the meta-analyses to the GDG (see
Appendix 16). Each forest plot displayed the effect size and CI for each study, as well
as the overall summary statistic.
For dichotomous data, the graphs were generally organised so that the display of
data in the area to the right of the ‘line of no effect’ indicated a favourable outcome
for the treatment in question. Dichotomous outcomes were presented as relative risks
(RRs) with the associated 95% CI (for an example, see Figure 1). A relative risk (or
risk ratio) is the ratio of the treatment event rate to the control event rate. An RR of 1
indicates no difference between treatment and control.
The CI shows with 95% certainty the range within which the true treatment effect
should lie and can be used to determine statistical significance. If the CI does not
cross the ‘line of no effect’, the effect is statistically significant.
For continuous data, the graphs were generally organised so that the display of
data in the area to the left of the ‘line of no effect’ indicated a favourable outcome for
the treatment in question. Continuous outcomes were analysed as weighted mean
differences (WMD), or as standardised mean differences (SMD) when different
measures were used in different studies to estimate the same underlying effect (for an
example, see Figure 2). If provided, intention-to-treat data, using a method such as
‘last observation carried forward’, were preferred over data from completers.
To check for consistency between studies, both the I2 test of heterogeneity and a
visual inspection of the forest plots were used. The I2 statistic describes the propor-
tion of total variation in study estimates that is due to heterogeneity (Higgins &
Thompson, 2002). The I2 statistic was interpreted in the following way:
● 50%: notable heterogeneity (an attempt was made to explain the variation, for
example outliers were removed from the analysis or sub-analyses were conducted
to examine the possibility of moderators. If studies with heterogeneous results
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Figure 1: Example of a forest plot displaying dichotomous data
Review: DMP: Contingency Management (CM)
Comparison: 01 CM vs Control                                                                                              
Outcome: 10 Abstinence from cannabis (during treatment)                                                                
Study  CM  Control  RR (fixed)  Weight  RR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Minimum of 9 weeks continuous abstinence
 Kadden2006       12/54               7/62  47.84     1.97 [0.83, 4.64]       
Subtotal (95% CI) 54                 62  47.84     1.97 [0.83, 4.64]
Total events: 12 (CM), 7 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
02 Minimum of 2 weeks continuous abstinence
 Carroll 2006       15/34               7/33  52.16     2.08 [0.97, 4.44]       
Subtotal (95% CI) 34                 33  52.16     2.08 [0.97, 4.44]
Total events: 15 (CM), 7 (Control)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.06)
Total (95% CI) 88                 95 100.00     2.03 [1.15, 3.58]
Total events: 27 (CM), 14 (Control)
Test for heterogeneity: Chi² = 0.01, df = 1 (P = 0.92), I² = 0%
Test for overall effect: Z = 2.43 (P = 0.02)
 0.1  0.2  0.5  1  2  5  10
 Favours control  Favours CM
were found to be comparable, a random-effects model was used to summarise the
results (DerSimonian & Laird, 1986). In the random-effects analysis, heterogene-
ity is accounted for both in the width of CIs and in the estimate of the treatment
effect. With decreasing heterogeneity, the random-effects approach moves asymp-
totically towards a fixed-effects model).
● 30–50%: moderate heterogeneity (both the chi-squared test of heterogeneity and
a visual inspection of the forest plot were used to decide between a fixed- and
random-effects model).
● 	30%: mild heterogeneity (a fixed-effects model was used to synthesise the results).
4.5.5 Forming the clinical summaries and recommendations
The included study tables, forest plots and evidence profiles formed the basis for
developing the evidence summaries and recommendations.
For intervention studies, quality assessment was conducted using SIGN method-
ology (SIGN, 2002) and classified according to a hierarchy (see Text Box 4).
Once the evidence profile tables and evidence summaries were finalised and
agreed by the GDG, recommendations were developed, taking into account factors
from the evidence, including trade-offs between the benefits and risks of treatment.
Other important factors that were considered in developing recommendations
included economic considerations, values of the GDG and society, and the group’s
awareness of practical issues (Eccles et al., 1998).
4.5.6 Consensus method used to answer a key question in the absence 
of appropriately designed, high-quality research
In the absence of level-1 evidence (or a level that is appropriate to the question), 
or where the GDG were of the opinion (on the basis of previous searches or their
knowledge of the literature) that there was unlikely to be such evidence, a consensus
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Figure 2: Example of a forest plot displaying continuous data
Review: NCCMH clinical guideline review (Example)
Comparison:  01 Intervention A compared with a control group
Outcome: 03 Mean frequency (endpoint)
Study Intervention A Control  SMD (fixed)  Weight  SMD (fixed)
or sub-category N Mean (SD) N Mean (SD)  95% CI %  95% CI
01 Intervention A vs. control
Freeman1988     32      1.30(3.40)          20      3.70(3.60)  25.91    -0.68 [-1.25, -0.10] 
Griffiths1994     20      1.25(1.45)          22      4.14(2.21)  17.83    -1.50 [-2.20, -0.81] 
Lee1986     14      3.70(4.00)          14     10.10(17.50)  15.08    -0.49 [-1.24, 0.26]
Treasure1994     28     44.23(27.04)         24     61.40(24.97)  27.28    -0.65 [-1.21, -0.09] 
Wolf1992     15      5.30(5.10)          11      7.10(4.60)  13.90    -0.36 [-1.14, 0.43]
Subtotal (95% CI)    109                          91 100.00    -0.74 [-1.04, -0.45]
Test for heterogeneity: Chi² = 6.13, df = 4 (P = 0.19), I² = 34.8%
Test for overall effect: Z = 4.98 (P < 0.00001)
 -4  -2  0  2  4
 Favours intervention  Favours control
process was adopted. This process focused on those questions that the GDG 
considered a priority.
The starting point for the process of consensus was that a member of the topic
group identified, with help from the systematic reviewer, a narrative review that most
directly addressed the key question. Where this was not possible, a brief review of the
recent literature was initiated.
This existing narrative review or new review was used as a basis for beginning an
iterative process to identify lower levels of evidence relevant to the clinical question and
to lead to written statements for the guideline. The process involved a number of steps:
1. A description of what is known about the issues concerning the clinical question
was written by one of the topic group members.
2. Evidence from the existing review or new review was then presented in narrative
form to the GDG and further comments were sought about the evidence and its
perceived relevance to the clinical question.
3. Based on the feedback from the GDG, additional information was sought and
added to the information collected. This may include studies that did not directly
address the clinical question but were thought to contain relevant data.
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Level Type of evidence
1 High-quality meta-analyses, systematic reviews of RCTs or RCTs with
a very low risk of bias
1 Well-conducted meta-analyses, systematic reviews of RCTs or RCTs
with a low risk of bias
1 Meta-analyses, systematic reviews of RCTs or RCTs with a high risk of
bias*
2 High-quality case–control or cohort studies with a very low risk 
of confounding, bias or chance and a high probability that the 
relationship is causal
2 Well-conducted case–control or cohort studies with a low risk of
confounding, bias or chance and a moderate probability that the 
relationship is causal
2 Case–control or cohort studies with a high risk of confounding bias or
chance and a significant risk that the relationship is not causal*
3 Non-analytic studies (for example, case reports and case series)
4 Expert opinion, consensus methods
Text Box 4: Levels of evidence for intervention studies
*Studies with a level of evidence ‘–’ should not be used as a basis for making a recommendation.
Reproduced with permission from SIGN.
4. If, during the course of preparing the report, a significant body of primary-level
studies (of appropriate design to answer the question) were identified, a full
systematic review was conducted.
5. At this time, subject possibly to further reviews of the evidence, a series of state-
ments that directly addressed the clinical question was developed.
6. Following this, on occasions and as deemed appropriate by the GDG, the report
was then sent to appointed experts outside of the GDG for peer review and
comment. The information from this process was then fed back to the GDG for
further discussion of the statements.
7. Recommendations were then developed and could also be sent for further exter-
nal peer review.
8. After this final stage of comment, the statements and recommendations were
again reviewed and agreed upon by the GDG.
4.6 SYSTEMATIC ECONOMIC LITERATURE REVIEW
The aim of the economic literature review was to contribute to the guideline’s devel-
opment by providing evidence on the relative cost effectiveness of different treatment
options covered in the guideline. This process had two stages:
● identification of the areas with likely major cost impacts within the scope of the
guideline
● systematic review of existing evidence on the cost effectiveness of different detox-
ification treatment options for problem drug misuse.
In areas with likely major resource implications where economic evidence did not
already exist, economic modelling was undertaken alongside the guideline development
process, in order to provide cost-effectiveness evidence and assist decision making.
4.6.1 Key economic issues
The following areas relating to the management of drug misuse were identified by the
GDG in collaboration with the health economist as the key issues that should be
considered in the guideline:
● cost effectiveness of contingency management in opioid detoxification
● cost effectiveness of various settings for detoxification.
4.6.2 Search strategy
For the systematic review of economic evidence on detoxification for drug misuse the
standard mental health related bibliographic databases (EMBASE, MEDLINE,
CINAHL and PsycINFO) were searched. For these databases, a health economics
search filter adapted from the Centre for Reviews and Dissemination (CRD) at the
University of York was used in combination with a general filter for drug misuse. The
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subject filter employed a combination of free-text terms and medical subject headings,
with subject headings having been exploded. Additional searches were performed in
specific health economics databases (NHS EED, OHE HEED), as well as in the HTA
database. For the HTA and NHS EED databases, the general filter for drug misuse was
used. OHE HEED was searched using a shorter, database-specific strategy. Initial
searches were performed in April 2006. The searches were updated regularly, with the
final search undertaken between 4 and 6 weeks before the final submission to NICE.
In parallel with searches of electronic databases, reference lists of eligible studies
and relevant reviews were searched by hand. Studies included in the clinical evidence
review were also screened for economic evidence.
The systematic search for economic evidence on detoxification resulted in 12
potentially relevant studies. Full texts of all potentially eligible studies (including
those for which relevance/eligibility was not clear from the abstract) were obtained.
These publications were then assessed against a set of standard inclusion criteria by
the health economists, and papers eligible for inclusion were subsequently assessed
for internal validity. The quality assessment was based on the checklists used by the
British Medical Journal to assist referees in appraising full and partial economic
analyses (Drummond & Jefferson, 1996) (see Appendix 12).
4.6.3 Selection criteria
The following inclusion criteria were applied to select studies identified by the
economic searches for further analysis:
● No restriction was placed on language or publication status of the papers.
● Studies published from 1990 onwards were included. This date restriction was
imposed in order to obtain data relevant to current healthcare settings and costs.
● Only studies from Organisation for Economic Co-operation and Development
countries were included, as the aim of the review was to identify economic infor-
mation transferable to the UK context.
● Selection criteria based on types of clinical conditions and patients were identical
to the clinical literature review.
● Studies were included provided that sufficient details regarding methods and
results were available to enable the methodological quality of the study to be
assessed, and provided that the study’s data and results were extractable.
● Full economic evaluations that compared two or more options and considered
both costs and consequences (that is, cost-minimisation analysis [CMA], cost–
consequences analysis [CCA], cost-effectiveness analysis [CEA], cost–utility
analysis [CUA] or cost–benefit analysis [CBA]), were included in the review.
4.6.4 Data extraction
Data were extracted by the health economist using a standard economic data extrac-
tion form (see Appendix 13).
Methods used to develop this guideline
62
4.6.5 Presentation of the results
The economic evidence identified by the health economics systematic review is
summarised in the respective chapters of the guideline, following presentation of the
clinical evidence. The characteristics and results of all economic studies included in
the review are provided in the form of evidence tables in Appendix 14. Results of
additional economic modelling undertaken alongside the guideline development
process are also presented in the relevant chapters.
4.7 STAKEHOLDER CONTRIBUTIONS
Professionals, service users and companies have contributed to and commented on
the guideline at key stages in its development. Stakeholders for this guideline include:
● Service user/carer stakeholders: the national service user and carer organisations
that represent people whose care is described in this guideline
● Professional stakeholders: the national organisations that represent healthcare
professionals who are providing services to service users
● Commercial stakeholders: the companies that manufacture medicines used in the
treatment of drug misuse
● Primary Care Trusts
● DH and Welsh Assembly Government.
Stakeholders have been involved in the guideline’s development at the following
points:
● Commenting on the initial scope of the guideline and attending a briefing meet-
ing held by NICE
● Contributing possible clinical questions and lists of evidence to the GDG
● Commenting on the draft of the guideline.
4.8 VALIDATION OF THIS GUIDELINE
Registered stakeholders had an opportunity to comment on the draft guideline, which
was posted on the NICE website during the consultation period. The GRP also
reviewed the guideline and checked that stakeholders’ comments had been addressed.
Following the consultation period, the GDG finalised the recommendations and
the NCCMH produced the final documents. These were then submitted to NICE.
NICE then formally approved the guideline and issued its guidance to the NHS in
England and Wales.
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5. ASSESSMENT AND TESTING
5.1 INTRODUCTION
Testing and assessment are important aspects in the management of detoxification.
Clinical assessment is important in deciding if detoxification is appropriate for the
service user (that is, if he or she is opioid dependent) and, if so, how most effectively
to manage the detoxification. Assessment is also important during detoxification,
including the careful monitoring of the service user’s progress and the level of his or
her withdrawal symptoms.
This chapter will discuss the process of conducting a clinical assessment before
and during detoxification. Additionally, the use of testing of body fluids and the use
of formal psychometric measurement as aids to clinical assessment and
treatment/monitoring will be considered.
5.2 CLINICAL ASSESSMENT IN THE MANAGEMENT 
OF DETOXIFICATION
5.2.1 Clinical assessment of dependence
Most service users presenting for detoxification will show a clear history of opioid
dependence, whether by being on prescribed methadone or buprenorphine, or by the
clinical presentation of signs of illicit heroin use (for example, abundance of needle
marks). Some may have been misusing other opioids additional to any prescribed
medication. Often service users may also misuse and be dependent on benzodi-
azepines and/or alcohol, or stimulants such as cocaine or amphetamines.
It is important that any opioid detoxification regimen should be appropriate to the
service user’s degree of dependence and the extent of the withdrawal symptoms he or
she experiences. Errors have occurred where service users have persuaded the health-
care professional conducting a clinical assessment that their degree of opioid use and/or
dependence is significantly greater than it is in reality; in some such cases they have had
no dependence on or even use of opioid drugs at all. This can lead to the prescription of
dangerously high doses of opioids. Adequate assessment of a service user’s opioid
dependence status is therefore crucial prior to undertaking opioid detoxification.
Opioid dependence is normally diagnosed primarily through a clinical assessment
but can be assisted by testing for drugs in biological fluids and by the use of psycho-
metric measures. The clinical assessment of opioid dependence involves asking the
service user about the pattern and nature of his or her drug use, the extent of use and
treatment episodes in the past, to ascertain the degree of dependence (DH, 1999). 
A formal psychometric measure may sometimes be employed as an aid to the 
assessment of dependence. For example, dependence is diagnosed according to the
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) when three or more
of the following criteria are present in a 12-month period: tolerance; withdrawal;
increasing use over time; persistent or unsuccessful attempts to reduce use; preoccu-
pation or excessive time spent on use or recovery from use; negative impact on 
social, occupational or recreational activity; and continued use despite evidence of its
causing psychological or physical problems (APA, 1994).
The use of biological testing is important to confirm the reported use of specific
drugs, including prescribed and illicit opioids and other non-opioid drugs. In addition,
an examination of physical and psychiatric health is important to assist diagnosis of
dependence and to assess any further complication to the process, such as comorbid
physical or mental health problems or pregnancy (DH, 1999).
The clinical assessment of opioid dependence aids the clinician in determining the
level of caution required during detoxification. In particular, if the service user has a
low level of dependence or uncertain tolerance, it is vital that detoxification is
conducted in a setting that allows the clinician to observe withdrawal symptoms and
titrate medication accordingly. In general, detoxification is not required for people
who misuse drugs but are not dependent. In addition, caution is also required where
polysubstance use or possible polysubstance dependence (commonly alcohol and
benzodiazepines) is detected. Polysubstance dependence can complicate the detoxifi-
cation process and settings for titration therefore need to be appropriate for the level
of observation required.
Where a clinical assessment determines that the service user is misusing alcohol,
in addition to being opioid dependent, attempts should be made to address this. 
The possibility should also be noted that a service user may substitute alcohol for 
his or her previous opioid misuse during or after the detoxification process. Where
alcohol dependence is present, detoxification of alcohol should also be considered
either before (in community-based settings) or, if there is adequate medical 
supervision (for example, inpatient settings), concurrently with opioid detoxification.
If a service user is dependent on benzodiazepines, the severity of dependence and
the preference of the service user should be taken into account when deciding whether
to detoxify from benzodiazepines concurrently or separately from opioids.
5.2.2 Clinical assessment and monitoring of withdrawal
It is important to assess both objective and subjective withdrawal symptoms, at the
start of treatment and during the induction and withdrawal stages. This is necessary
in order to titrate the medication to alleviate withdrawal symptoms (DH, 1999). The
objective signs of withdrawal can be assessed through careful monitoring of the 
service user’s pulse, blood pressure, agitation and sedation. In addition, asking 
the service user about the subjective signs of distress should also form part of the
assessment. Formal psychometric tools may be useful in that they aid standardisation,
but they are not a substitute for appropriate clinical assessment. Regular review is
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crucial because an overdose of methadone during detoxification may initially present
as sedation and/or sleepiness, with under dosing presenting as agitation and anxiety.
5.2.3 Clinical practice recommendations
Clinical assessment of dependence
5.2.3.1 People presenting for opioid detoxification should be assessed to establish
the presence and severity of opioid dependence, as well as misuse of and/or
dependence on other substances, including alcohol, benzodiazepines and
stimulants. As part of the assessment, healthcare professionals should:
● use urinalysis to aid identification of the use of opioids and other
substances; consideration may also be given to other near-patient test-
ing methods such as oral fluid and/or breath testing
● clinically assess signs of opioid withdrawal where present (the use of
formal rating scales may be considered as an adjunct to, but not a
substitute for, clinical assessment)
● take a history of drug and alcohol misuse and any treatment, including
previous attempts at detoxification, for these problems
● review current and previous physical and mental health problems, and
any treatment for these
● consider the risks of self-harm, loss of opioid tolerance and the misuse
of drugs or alcohol as a response to opioid withdrawal symptoms
● consider the person’s current social and personal circumstances, includ-
ing employment and financial status, living arrangements, social
support and criminal activity
● consider the impact of drug misuse on family members and any 
dependants
● develop strategies to reduce the risk of relapse, taking into account the
person’s support network.
5.2.3.2 For women who are opioid dependent during pregnancy, detoxification
should only be undertaken with caution.
5.2.3.3 For people who are opioid dependent and have comorbid physical or
mental health problems, these problems should be treated alongside 
the opioid dependence, in line with relevant NICE guidance where 
available.
Care for people who misuse other medicines and/or substances in addition to opioids
5.2.3.4 If a person presenting for opioid detoxification also misuses alcohol,
healthcare professionals should consider the following.
● If the person is not alcohol dependent, attempts should be made to
address their alcohol misuse, because they may increase this as a
response to opioid withdrawal symptoms, or substitute alcohol for their
previous opioid misuse.
● If the person is alcohol dependent, alcohol detoxification should be
offered. This should be carried out before starting opioid detoxification
in a community or prison setting, but may be carried out concurrently
with opioid detoxification in an inpatient setting or with stabilisation in
a community setting.
5.2.3.5 If a person presenting for opioid detoxification is also benzodiazepine
dependent, healthcare professionals should consider benzodiazepine
detoxification. When deciding whether this should be carried out concur-
rently with, or separately from, opioid detoxification, healthcare profes-
sionals should take into account the person’s preference and the severity of
dependence for both substances.
5.3 DRUG TESTING
5.3.1 Introduction
The analysis of human body fluids can yield important information in support of
healthcare professionals’ caring for service users who are about to undertake, or who
are undertaking, opioid detoxification. Such analyses are only an adjunct to an appro-
priate clinical investigation of the service user. Currently, no single test is available
that is able to establish or confirm a diagnosis of drug dependence.
In drug misuse services, oral fluid or urine testing are commonly employed, while
hair and blood testing are utilised to a lesser extent (NACB, 2006). The numerous test-
ing procedures available can provide evidence of drug consumption, trend of use over
time when repeated, and compliance with prescribed drugs.
Moreover, testing may also be useful during a longer-term detoxification, to assess
compliance with prescribed medication and to ascertain possible use of illicit drugs.
Random intermittent interval testing is probably the most clinically and cost-effective
regime. It will help the clinician in confirming the clinical picture and aid assessment
of the success of detoxification and possible need to review dosage.
Testing occurs in a variety of settings, including specialist drug services, primary
care, residential units, prisons and some hospital settings. The rationale for testing is to
help confirm opioid use and to assess other complicating factors, as well as monitoring
of care. Testing can be conducted at point of care (that is, near-patient testing) or can be
confirmed in a laboratory. Both forms of testing are important tools in clinical practice
and will be considered in the sections below.
5.3.2 Near-patient testing
Near-patient testing refers to the process of obtaining a biological sample from a 
service user and using a drug-testing kit to detect immediately the presence of any of
a variety of substances (for example, opioids, amphetamines, cocaine metabolite,
benzodiazepines, methadone and cannabis) on site. This process eliminates the need
for external laboratory support and provides rapid results.
Assessment and testing
67
Assessment and testing
68
In current practice, oral swabs or urine screening kits are most commonly used for
near-patient testing. These forms of testing are used for a variety of reasons, including
monitoring within a criminal justice order, arrest referral schemes, prison systems and
medicolegal situations.
Current rapid screening of biological samples for misused drugs depends on
immunochemical techniques. Essentially, antibodies with a specific and high affinity
for a particular drug, and/or its metabolites, react with the drug present in the sample.
The extent to which the antibodies have become bound to drugs present in the sample
is then detected by one of several different techniques. All immunochemical methods
have problems in relation to specificity, whereby the antibody employed may react
with compounds in the sample other than those that the test is intended to measure
(DH, in press). There are also potential issues with matrix effects, whereby problems
with the sample may destroy the drug/metabolite or the antibody, or interfere with the
reaction between the two.
While new technologies based on techniques such as Fourier transform infrared
spectroscopy and nanotechnology are under active development and techniques using
liquid chromatography in combination with tandem mass spectroscopy are starting to
come into use in the laboratory, for the next 2–3 years immunochemical techniques
are likely to be the basis of most rapid screening inside the laboratory or at the point
of service-user contact.
The analytical, quality and safety issues involved with near-patient testing are well
known to clinical laboratories (George & Braithwaite, 2002). For example, false posi-
tives may result where the identification of a specific substance may be due to the pres-
ence of artefacts or compounds in the biological matrix that are similar to the drug of
interest (NACB, 2006). False positive results may also occur due to misinterpretation
of a test result. The presence of morphine in urine is often assumed to be indicative of
heroin use but may also reflect the consumption of analgesic preparations or poppy
seeds (Mule & Casella, 1988).
The problems involved with ensuring results obtained with tests undertaken
outside of the laboratory, such as pregnancy or blood glucose testing, are fit for
purpose have been well described (George & Braithwaite, 2002). For example, when
urine dipsticks are used, colour change must be detected to indicate the presence 
of an illicit substance; however, this can be difficult for the inexperienced eye 
(George & Braithwaite, 2002) and such processes are highly subjective. Samples
must also be kept in adequate conditions, as they are susceptible to contamination.
Some testing kits are only able to determine whether a drug is present but not the type
or quantity.
Training and meticulous attention to the manufacturer’s instructions are essential
for test results to match the levels of performance (for example, sensitivity and speci-
ficity) found in validation studies. Further, experience with other analytes measured
outside the laboratory suggests the necessity for continued training of staff and the
need for the use of quality assurance techniques. Where service users are being
assessed in a clinic within a district general hospital, it is arguable that there is no
need for near-patient testing of urine samples.
Urinalysis
Urinalysis remains the most reliable tool for identifying drug use in a drug using
population (DH, in press). A further advantage of this testing method is that it can
detect drug use during the previous few days. Most opioids can be detected between
2 and 3 days after use, methadone up to 9 days and cannabis up to 27 days after use
(DH, 1999). However, caution must be exercised when interpreting results of urinal-
ysis as there are a number of products commercially available specifically designed
to produce false negative urinalysis results by seeking to remove illicit drugs from 
the body (NACB, 2006). These substances have the ability to either dilute 
urine samples or partially eliminate drugs, thereby making detection of illicit drugs
difficult.
A recent targeted screening study by Tomaszewski and colleagues (2005) in a US
emergency department found promising sensitivity and specificity for near-patient
urine testing for opioids (sensitivity  100%, specificity  98.7%) and cocaine use
(sensitivity  96.8%, specificity  100%), but lower sensitivity for cannabis use
(sensitivity  87.5%, specificity  99.3%) when a comparison was made with
confirmatory laboratory tests.
However, lower levels of sensitivity and specificity have been reported elsewhere.
This is illustrated by the experience of the prison service, where urine samples for
mandatory drug testing are collected under a high degree of supervision. On average,
of all samples submitted where a screening test had produced a positive result, the
confirmation test, using definitive analytical procedures such as gas chromatography/
mass spectroscopy, or liquid chromatography/mass spectroscopy, did not confirm the
positive screening test on 11% of occasions (HM Prison Service, 2005). In the case of
opioids, only 90% of positive tests on screening were confirmed to be positive by
definitive testing; for benzodiazepines this was 70%, for methadone 80% and for
amphetamines 50% (HM Prison Service, 2005). It should be noted that screening tests
on samples submitted for mandatory testing in prison are carried out in the laboratory
using sophisticated analytical equipment rather than with kits at the point of contact.
Oral fluid testing
The major advantages of oral fluid drug testing are that it can potentially be relatively
easily obtained and is less intrusive than urinalysis. It is also less open to adulteration.
These properties enable oral fluid testing to be conducted by personnel with relatively
little training, while maintaining an acceptable balance between service-user dignity and
sample integrity (DH, in press). On the other hand, many opioid users will have a dry
mouth on presentation for detoxification and may have genuine difficulty in providing a
suitable sample. A further problem of oral fluid testing is that the detection time of drug
use is considerably shorter than for urinalysis, generally providing information on use
within the last 24 hours (DH, in press; Verstraete, 2004). Drug concentration can also
differ depending on the collection method. Stimulation of saliva flow is often used. This
can be problematic because the pH for stimulated flow is approximately 8, compared
with the basal saliva pH of 6.5. Therefore any drug with a pKa around these values will
be substantially affected and may lead to decreased drug concentration (NACB, 2006).
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Thirdly, there is a lack of evidence on interferences, oral drug residues, and other issues
of manipulation that may affect the validity of this matrix (NACB, 2006).
There is limited evidence for the sensitivity and specificity of oral fluid testing
products (DH, in press). In a small study (N 15), results obtained by law enforce-
ment officers correlated well with laboratory results for cocaine and amphetamines
but were unsatisfactory for detecting heroin and cannabis use (Samyn & van Haeren,
2000). Gronholm and Lillsunde (2001) also found poor sensitivity for detecting
benzodiazepines and cannabinoids for oral fluid testing.
5.3.3 Confirmation of screening tests
Confirmatory tests are often needed to reduce false positive results; this may relate to
adulteration of the sample or a false interpretation when medications that are chemi-
cally similar to the drug of interest are taken legitimately. Conversely, a negative test
may not rule out dependence. This may be due to a number of factors, such as the
sample being taken some time after drug ingestion, adulteration of the sample or
threshold of sensitivity of the analytical procedure in the laboratory.
Confirmation of screening test results is a sophisticated laboratory exercise that
requires a considerable investment in skilled staff and dedicated equipment. In
general, it is not a service that can be set up or completed rapidly with non-specialised
staff or equipment.
The majority of the cases presenting for detoxification will involve opioids
detectable by near-patient testing. However, some opioids, including buprenorphine,
fentanyl, oxycodone, pethidine and others, are not detectable under standard immuno-
chemical tests and would produce a false negative near-patient test result. If there is
uncertainty after a clinical assessment about the drug use or dependence of a service
user, confirmatory laboratory testing should be considered.
Confirmatory laboratory testing should be capable of detecting service users who
deliberately contaminate their urine with heroin or methadone in order to produce a
false positive result. Heroin use may be ascertained in the laboratory by the demon-
stration of compounds such as 6-monoacetylmorphine, codeine, acetylcodeine,
meconin and possible others in urine. There is also a need to confirm the presence of
both methadone and its principal metabolite in urine.
The standard of testing in a laboratory providing screening and/or confirmatory
services should be high, with appropriately trained staff who all participate in
programmes of continuing professional education. There should be appropriate estab-
lished standard operating and safety procedures in place, and participation in quality
assurance schemes that assess not just the analytical capabilities of the laboratory but
also the ability of the laboratory staff to interpret results.
In order for a laboratory to react appropriately to an analytical request, the sample
must be unequivocally identified and appropriate clinical information must be
provided. The format of the report should be clear and should be accompanied by
sufficient information to enable the report to be interpreted by the person responsible
for the management of the service user’s care. For example, if a report indicates the
presence of 6-monoacetylmorphine, then the significance of this should be explained
in text below the analytical result; that is, that this metabolite is unique to heroin and
can distinguish between the use of codeine prescriptions or poppy seed consumption
(which may result in a morphine positive urine sample) and heroin use (Mule &
Casella, 1988). The nature of the substance identified should be described accurately
and unambiguously; for instance, it would be inappropriate for a near-patient testing
instrument that identifies the presence of opioids to report a sample as being positive
for heroin.
Where the laboratory is remote from the treatment facility, arrangements must be
in place for the rapid and secure electronic reporting of results. Both the laboratory and
the care providers should have protocols in place to ensure that results are reported
rapidly by the laboratory and reviewed quickly and efficiently by the care providers.
5.3.4 Summary
Testing of biological fluids for misused drugs is an important tool to ensure safety in
the care of service users undergoing opioid detoxification. At present, most data on
testing is for urinalysis and this remains the most reliable tool for clinical practice.
Screening of biological fluids for the presence of opioid drugs should be carried out
by techniques that are fit for purpose by adequately trained staff who continue to
maintain their skills. Ease of collection, training implications and the equipment
required also need to be taken into consideration.
However, the interpretation of tests for the presence of drugs and their metabolites
cannot be divorced from knowledge of the clinical circumstances and the donation of
the sample. The clinician must also have knowledge of the characteristics of the tests,
their limitations and the interpretation of a variety of tests in different settings. If there
is uncertainty about the service user’s drug dependence, the clinician may wish to
defer initiation of detoxification until confirmatory tests are available. If initiating
with only screening tests, the clinician must be certain of clinical dependence or
organise detoxification in a setting with adequate observation and dose titration.
Training is important for all clinicians, who should have the support of appropriate
and trained laboratory staff. Protocols should be available regarding the practical aspects
of taking tests, their refrigeration if appropriate, the need for supervised samples, the
extent to which service users should be supervised while providing a sample (that is,
the frequency and intrusiveness of the supervision), the need for confirmatory testing
and ensuring clinical governance and quality assurance of this aspect of care.
Urinalysis is the most reliable tool for identifying drug use and has higher 
sensitivity and specificity than oral fluid testing for a number of substances (DH, in
press). In addition, urinalysis is substantially less costly than oral fluid testing.
Therefore, the routine use of urinalysis is more cost effective, since it represents a
more efficient use of limited NHS resources. Healthcare professionals should
normally consider using urinalysis for drug testing as the first choice, and consider
oral fluid testing only in circumstances were urinalysis is impractical or unacceptable
to the service user.
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5.3.5 Clinical practice recommendations
5.3.5.1 If opioid dependence or tolerance is uncertain, healthcare professionals
should, in addition to near-patient testing, use confirmatory laboratory
tests. This is particularly important when:
● a young person first presents for opioid detoxification
● a near-patient test result is inconsistent with clinical assessment
● complex patterns of drug misuse are suspected.
5.3.5.2 Near-patient and confirmatory testing should be conducted by appropriately
trained healthcare professionals in accordance with established standard
operating and safety procedures.
5.3.5.3 Healthcare professionals should be aware that medications used in opioid
detoxification are open to risks of misuse and diversion in all settings
(including prisons), and should consider:
● monitoring of medication concordance
● methods of limiting the risk of diversion where necessary, including
supervised consumption.
5.4 PSYCHOMETRIC ASSESSMENT TOOLS
5.4.1 Introduction
The importance of a clinical assessment of opioid (and other drug or alcohol) 
dependence and monitoring withdrawal before and during detoxification has been
discussed above (see Section 5.2). This section is concerned with the use of psycho-
metric instruments as adjuncts to clinical assessment and monitoring.
Crome and colleagues (2006) argue that there are a number of advantages for the
use of assessment tools. Recording is standardised, and a checklist of domains
ensures that important issues are covered and that multidisciplinary professionals
have a common understanding of what has been assessed. Furthermore, the imple-
mentation of tools over time can be utilised to demonstrate progress to the service
user and to measure outcome. Finally, the use of assessment tools is empirically
testable and therefore it is possible to evaluate the reliability and validity of these
tools. The reliability and validity of the psychometric tools used to assess dependence
and monitor withdrawal are discussed below.
5.4.2 Assessment of dependence
Identification (simple assessment) tools have most recently been reviewed by NICE
(2007; National Collaborating Centre for Mental Health, 2008). The present review
will focus on assessment of dependence.
There have been a number of recent reviews evaluating assessment tools for 
drug misuse (Crome et al., 2006; Scottish Executive, 2003; Sperling et al., 2003).
Crome and colleagues (2006) and the Scottish Executive (2003) briefly evaluated the
assessment tools. Sperling and colleagues (2003) conducted a more detailed 
consensus-based evaluation of these measures on training/costs, administration, UK
relevance, psychometric properties and content, providing an overall summary
percentage score of the extent to which these criteria were judged to be fulfilled.
Self-report questionnaires
The Leeds Dependence Questionnaire (LDQ; Raistrick et al., 1994) is a ten-item 
self-report scale designed to measure dependence on a variety of substances, to be
sensitive to change over time (although follow-up data in validation was not long
enough to assess this) and to account for the range of mild to severe dependence.
Concurrent validity was assessed by comparing the LDQ with the Severity of Opiate
Dependence Questionnaire (SODQ) for opioid users and a moderate association was
found (r  0.30). Additionally, there was a high level of internal consistency
(Cronbach 
  0.94). Sperling and colleagues’ (2003) consensus-based evaluation of
this measure rated it very highly (97%).
The Severity of Dependence Scale (SDS; Gossop et al., 1995) is a short (five-item)
self-report scale designed to measure the degree of dependence on a variety of drugs.
The SDS is related to behavioural patterns of drug taking such as heroin dose
(r  0.24), frequency of heroin use (r  0.43) and duration of use (r  0.27). In addi-
tion, it has good concurrent validity, with treatment-seeking participants reporting
higher mean scores (t  10.00, p 	 0.001) than non-treatment seeking controls
(Gossop et al., 1995). The scale was also found to have a high level of internal consis-
tency (Cronbach 
 ranging from 0.84 to 0.90 in heroin-user samples). There are mixed
reviews of the utility of this measure for clinical practice. Sperling and colleagues
(2003), on the same criteria listed above (training/costs, administration, UK relevance,
psychometric properties and content), rated this measure the most highly (99%) of all
the assessment scales they reviewed. However, another reviewer expressed major
concerns about the use of this scale as a measure of dependence due to the lack of
items on tolerance and withdrawal (Scottish Executive, 2003).
Clinician-administered questionnaires
The Addiction Severity Index (ASI; McLellan et al., 1980) is a clinician-administered
multi-dimensional 200-item measure with seven main areas: medical, employment/
support, alcohol, drug, legal, family/social and psychiatric. This assessment tool has
been investigated extensively. Makela (2004), in a review of 37 studies on the psycho-
metric properties of the ASI, concluded that there were inconsistent findings on inter-
rater reliability, test-retest reliability, and internal consistency for this scale.
Furthermore, this scale was not rated very highly (69%) in a review of assessment
scales, mainly due to difficulties administering such a large measure in clinical prac-
tice, training costs and relevance to the UK (Sperling et al., 2003).
The Opiate Treatment Index (OTI; Darke et al., 1992) is a clinician-administered
multi-dimensional measure with sub-scales on drug use, HIV risk behaviour, social
functioning, criminality, health and psychological adjustment. Test–retest reliability
correlations were large and ranged from 0.88 to 0.96. Associations between the OTI
and the ASI generally ranged from r  0.43 to r  0.70; however, the correlation
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between the criminality subscale and the legal subscale of the ASI was very low
(r  0.02). Additionally, agreement between self-report and collateral report (partner
or family member) was relatively high. Sperling and colleagues (2003) did not rate
this measure particularly highly (73%), citing problems with relevance to the UK and
difficulties with administration in clinical practice.
The Maudsley Addiction Profile (MAP; Marsden et al., 1998) is a clinician-
administered 60-item scale covering the following domains: substance use, health risk,
physical/psychological health and personal/social functioning. Concurrent validity
was acceptable, with high correlations (r  0.72) between the physical and psycho-
logical health measure and items adapted from the ASI. Similarly, for the relationship
conflict measures of the MAP there were high correlations (r  0.74) with subscales
from the Life Stress and Social Resources Inventory (LISRES). In addition, there was
high test–retest reliability averaging 0.94 overall and 0.88 for reported substance use.
This measure was also rated highly (96%) by Sperling and colleagues (2003).
However, the reviews of both Sperling and colleagues (2003) and the Scottish
Executive (2003) advised caution concerning the length of the scale and therefore the
ease of administration in clinical practice. As a response to such criticisms, the MAP
has recently been adapted into a shorter (20-item) self-completion version (Luty
et al., 2006). There were relatively large correlations (r  0.70) between the adapted
self-completion and the original interviewer-completion version of the MAP.
The Christo Inventory for Substance-Misuse Services (CISS; Christo et al., 2000)
is a ten-item clinician-administered measure including social functioning, general
health, sexual/injecting risk behaviour, psychological functioning, occupation, crimi-
nal involvement, drug/alcohol use, ongoing support, compliance and working rela-
tionships. Relatively large correlations were found with the OTI (generally ranging
from r  0.70 to 0.91). There was also good inter-rater reliability with Pearson’s
correlations of r  0.84 and an intraclass correlation of 0.82 (Christo et al., 2000).
The reviews of both Sperling and colleagues (2003) and the Scottish Executive (2003)
suggested problems with the content of this measure, suggesting it may be too
simplistic.
5.4.3 Monitoring of withdrawal
The most important aspects of monitoring objective and subjective withdrawal symp-
toms in clinical practice are to determine that over- or under-prescribing is not occur-
ring and that the service user is comfortable on his or her dose. This is primarily
monitored by clinical assessment, but the use of psychometric measures can aid this
process.
Scales measuring withdrawal are commonly categorised as objective (clinician-
rated) or subjective (self-report). There are several scales that have been developed to
monitor the withdrawal process; these include: the Clinical Opiate Withdrawal Scale
(COWS; Wesson & Ling, 2003), Opiate Withdrawal Scale (OWS; Bradley et al.,
1987), Short Opiate Withdrawal Scale (Gossop, 1990) and the Subjective and
Objective Withdrawal Scales (Handelsman et al., 1987).
The self-reported OWS was assessed during a 20-day detoxification trial of 
84 participants (Bradley et al., 1987). The pattern of withdrawal as measured by the
scale was as expected. As methadone dose was reduced, a rise in distress was reported
that faded by the end of the third week to a total withdrawal score in the normal range
(derived from a non-dependent control group). There was a relatively small correla-
tion (r  0.25) between the self-report OWS and nurse observation of withdrawal,
although correlations between nurse observation and the OWS were much higher
when the nurse-observed rating was high (r  0.71). Gossop (1990) compared the
Short Opiate Withdrawal Scale (10 items) with the OWS (32 items). A very high
correlation (r  0.97) was found between these measures, suggesting the usefulness
of the shorter version.
The Subjective and Objective Opiate Withdrawal Scales were assessed for 32 partic-
ipants admitted for inpatient detoxification (Handelsman et al., 1987). Significant
changes were found for both scales at the stabilisation stage of the trial and after a
naloxone challenge.
The COWS is a clinician-rated measure. There appears to be little validation of this
measure, with the exception that all items have been validated in previous measures
(Wesson & Ling, 2003).
5.4.4 Summary
The development of psychometric tools to assess dependence and monitor withdrawal
is still at an early stage. Although data were relatively sparse for most measures, some
had reasonable reliability and validity. The use of reliable and valid assessment tools
may aid the process of conducting a clinical assessment and monitoring withdrawal
during the process of detoxification.
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6. PHARMACOLOGICAL AND PHYSICAL
INTERVENTIONS IN OPIOID 
DETOXIFICATION
6.1 INTRODUCTION
The aim of detoxification for a dependent opioid user is to eliminate the effects of
opioid drugs in a safe and effective manner (WHO, 2006). Appropriate administration
of pharmacological agents plays a crucial role in increasing the likelihood of a success-
ful detoxification, while minimising the discomfort of withdrawal experienced by the
service user.
6.1.1 The psychopharmacology of opioid dependence
This section sets out the key aspects of the pharmacology of the opioids and other
drugs used in detoxification, including the use of opioid agonists, partial agonists and
opioid antagonists. In addition, the pharmacology of tolerance and withdrawal will 
be briefly discussed within the context of detoxification and the use of opioid and
non-opioid drugs (for example, alpha2 adrenergic agonists) to manage withdrawal
symptoms.
Opioid agonists
All opioids, including heroin and methadone, are agonists that stimulate opioid recep-
tors. Many opioid agonists are also prescribed for their analgesic properties in pain
management, including morphine, codeine, dihydrocodeine, oxycodone, hydrocodone
and fentanyl.
Partial agonists
Buprenorphine is a partial agonist at the  opioid receptor subtype, which means that
the system is not fully stimulated even when all the receptors are occupied. This lesser
effect is the main contributory mechanism underlying buprenorphine’s better safety
profile when taken alone, since the threshold for respiratory depression is not reached
even when all the receptors are occupied (Walsh et al., 1994).
As a partial agonist, buprenorphine can also appear to act as an antagonist (and as
such may have been described in older literature as a mixed agonist-antagonist). If
buprenorphine is given to a person who has taken a full agonist (for example, heroin
or methadone), it displaces the full agonist, due to buprenorphine’s higher affinity at
the  opioid receptor, but only partially stimulates these receptors. The difference in
activation results in the individual experiencing withdrawal. This can be seen when
people convert from their street drug or high-dose methadone to buprenorphine.
Therefore a partial agonist behaves like an agonist in the presence of no other agonist;
in the presence of high levels of an opioid agonist, it behaves like an antagonist.
Buprenorphine is also an antagonist at the  receptor and therefore may be less
likely to lower mood compared with an agonist.
Tramadol is a more complex drug; its pharmacology is currently not well under-
stood, but it could either be a low-potency  agonist or a partial agonist. It is more
commonly used in the context of pain relief.
Antagonists
An antagonist, such as naltrexone or naloxone, binds to the receptor but does not
stimulate it. Naltrexone and naloxone have a high affinity with opioid receptors, such
that they will displace existing agonists and prevent further agonists from binding to
the receptors. Therefore if an agonist is present stimulating the receptor, for example
heroin or methadone, taking naltrexone or naloxone will stop this stimulation, result-
ing in precipitated (abrupt) withdrawal. For these reasons, naloxone is commonly
used in emergency medicine to reverse opioid overdose, while the longer acting
naltrexone is prescribed as a maintenance treatment to prevent detoxified service
users from relapsing to opioid use.
Tolerance
If opioids are taken repeatedly, their effects are diminished due to the development of
tolerance. This means that, in order to achieve the same effect, more of the drug has to
be taken. Depending on the effect, tolerance can occur at different rates; for instance,
tolerance to euphoria occurs much faster than tolerance to respiratory depression.
Such pharmacological tolerance to opioids is not clearly defined in the literature, but
it is likely that it involves changes in opioid receptor availability and function through
changes within the cell or effects on other neurotransmitter systems, for example nora-
drenaline (Maldonado, 1997). In a dependent opioid user, changes in the brain’s circuitry
(involving reward, learning and impulse control) also occur. The brain’s opioid system is
thought to play a significant role in mediating reward to other drugs of misuse including
alcohol and cocaine (Herz, 1997; Van Ree et al., 2000). Tolerance can also vary depend-
ing on the context or environment in which the opioid is being taken and can lead to a
dose of opioids producing more or less of an effect than expected (Siegel et al., 1982).
Withdrawal
When a person who has become tolerant to the effects of a drug stops taking it, with-
drawal symptoms ensue. These may vary in their intensity depending on the level of
opioid use as well as other factors such as context and environment. Minimising these
symptoms, which emerge within 6–12 hours from short-acting opioids such as heroin
and about 24–36 hours after the last dose of methadone or buprenorphine, depending
on the dose, is the main aim in any opioid detoxification programme. Although previ-
ously divided into psychological and physical symptoms, such a distinction has
limited clinical utility given that physical withdrawal can have a large psychological
component. Withdrawal can also ensue when an opioid antagonist, such as naloxone
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or naltrexone is taken; this is called precipitated or abrupt withdrawal. While the with-
drawal syndrome for opioids is rarely life-threatening (unlike that for alcohol, due to
the potential for seizures and delirium tremens), the discomfort for some people
makes it hard to withstand.
Opioid withdrawal consists of a constellation of symptoms, such as pupil dilation,
diarrhoea, low mood, irritability, anxiety, insomnia, muscular and abdominal pains,
restlessness and ‘craving’. In addition, tachycardia, sweating, runny nose, hair stand-
ing on end, shivering, goosebumps (hence the term ‘going cold turkey’) are generally
experienced. The latter symptoms are known to be associated with hyperactivity of
the noradrenaline system (called a ‘noradrenergic storm’) that occurs to compensate
for tolerance at the opioid receptor. This provides the rationale and clinical efficacy for
using medication that reduces noradrenergic activity, such as lofexidine or clonidine
(alpha2 adrenergic agonists).
The contribution of changes in the opioid system directly producing withdrawal
symptoms is less clear, although increased receptor availability has been shown
(Williams, 2007). Gradual reductions of opioid medication should result in the
complete absence of, or minimal, withdrawal symptoms. However, medication acting
on the noradrenergic system will only ameliorate particular symptoms (see above),
necessitating use of other medications to manage all withdrawal symptoms.
The role of the GABA-benzodiazepine receptor is also not certain, but opioids
taken over long periods can alter this system (Sivam et al., 1982; Rocha et al., 1993),
which may be the basis on which benzodiazepines (such as diazepam and
temazepam) are often prescribed during detoxification or used by dependent opioid
users when they cannot obtain heroin.
6.2 PHARMACOLOGICAL INTERVENTIONS IN DETOXIFICATION
6.2.1 Introduction
This section reviews the evidence for pharmacological interventions in detoxification
for opioid dependent adults and young people. For the purposes of this guideline, a
young person is defined as an individual aged 16–18, and studies have been included
for review only if they were judged to include a significant proportion of participants
aged 16 or above (that is in each given study, at least 50% of participants are aged 
16 years or over; where such information is not provided, mean age is greater than or
equal to 15.5 years).
Opioid agonists and partial agonists
The most straightforward pharmacological approach to detoxify a dependent opioid user
is by reducing over a period the dose of an opioid substitute medication, for example
methadone or buprenorphine. As described above, this should cover all the symptoms of
withdrawal. Depending on the substitute medication and starting dose, detoxification can
take days to months. For methadone, the most rapid regimes last 7–21 days, while ‘slow
tapering’ regimens can last up to 6 months or longer (DH, 1999). Detoxification with
buprenorphine is usually faster than with methadone, and can in theory be completed
within less than a week, though 14 days to several weeks appears to be typical.
Although it is pharmacologically possible to detoxify directly via tapered doses of
heroin (indeed any opioid agonist), this is rarely recommended clinically because the
short elimination half-life of heroin results in a particularly acute and intense withdrawal
syndrome. Illicit heroin users are normally first stabilised on an opioid substitute prior to
starting detoxification.
Opioid antagonists
Opioid antagonists such as naltrexone and naloxone may be used to speed up the
process of detoxification. The aim is to flood the brain with an opioid antagonist to
remove all agonists and fully occupy the opioid receptors. If given at the start of detox-
ification, this will lead to abrupt withdrawal for a dependent user with opioids in his or
her system, which can be subjectively extremely unpleasant, depending on the amount
of agonist present. Sedation or general anaesthesia are likely to be used here, alongside
a variety of adjunctive medications, to minimise discomfort. The service user is then
generally maintained on naltrexone to prevent relapse. Use of opioid antagonists in this
way is often referred to as ultra-rapid or rapid detoxification and is covered in detail in
Section 6.5.
Alternatively, to minimise discomfort, naloxone or naltrexone is started after a
few days of detoxification and not at full dose, thus shortening and speeding up detox-
ification while avoiding the requirement for sedation or general anaesthesia. This
approach is covered in greater detail also in Section 6.5.
Adjunctive medications
Adjunctive medications are used to ameliorate symptoms of opioid withdrawal, and
the term covers a wide number of medications and uses. Those that target the nora-
drenaline system, including clonidine and lofexidine, alter a brain system known to
be involved in mediating a cluster of opioid withdrawal symptoms and signs. Other
forms of adjunctive medications are directed at a specific symptom, such as an anti-
spasmodic for gut cramps, or a collection of symptoms, for instance benzodiazepines
for anxiolysis and sedation or antipsychotics for agitation or sedation.
Adjunctive medications are often used during detoxification. Their use is particu-
larly important when conducting a detoxification with non-opioid drugs, such as
clonidine or lofexidine, since they are not able to cover all withdrawal symptoms.
However, the use of adjunctive medications for symptoms, such as for sedation, is
also not uncommon during a detoxification using opioid medications (for example,
methadone or buprenorphine).
Therefore it is critical when comparing detoxification regimens in the trials
reviewed below that the use of adjunctive medication is taken into consideration. This
is especially important when comparing opioids (methadone or buprenorphine) with
alpha2 adrenergic agonists (clonidine or lofexidine).
The use of opioid antagonists in addition to other medications is not considered
here as a form of adjunctive medication since they do not ameliorate symptoms of
withdrawal, although their use can shorten or accelerate detoxification (see above).
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Current practice
In the UK, only methadone and buprenorphine are licensed as substitute opioids for
the management of opioid dependence. In addition, lofexidine is licensed for symp-
tomatic relief during opioid detoxification. These medications are currently used in
the vast majority of opioid detoxifications in the UK. A minority of detoxifications
within specialist drug services have involved medications unlicensed for detoxifica-
tion, including clonidine, naltrexone and dihydrocodeine (Day et al., 2005).
Dihydrocodeine has also been used in some primary care and criminal justice settings
for opioid detoxification (Wright et al., 2007a).
There appears to be widespread administration of adjunctive medications, most
notably benzodiazepines, alongside a ‘core’ medication for the management of opioid
withdrawal symptoms, but a review of UK practice has not been conducted to assess
how such adjunctive medication is being prescribed.
In addition, there are a number of service users who have attempted unassisted
detoxification (Gossop et al., 1991; Noble et al., 2002; Scherbaum et al., 2005; Ison
et al., 2006). This is discussed in more detail in Chapter 8.
6.2.2 Treatment outcomes
Abstinence
This refers to evidence for the absence of opioid use at a particular time point (for exam-
ple, at the end of treatment or at 3-month follow-up). Measures based on urinalysis or
other forms of chemical testing were preferred, but self-report measures were not
excluded. However, outcomes relating to abstinence, in particular at follow-up, were not
widely reported in the trials identified by the evidence search. Although in the majority
of studies abstinence was clearly the important long-term goal of detoxification, in
some detoxification resulted in the participant being re-established on substitute
medication.
Completion of treatment
This is regarded as an important proxy measure of detoxification success. Completion
has typically been defined as being retained in treatment up to the final day of its
planned duration, ingestion of the final dose of study medication, or reaching the
point of zero dose of study medication.
6.2.3 Side effects and adverse events
During detoxification or withdrawal from opioids, many signs and symptoms can
become evident. These can be categorised broadly as due to opioid withdrawal itself
or to side effects of the medication given for the detoxification regimen. During the
latter stages of detoxification and in early abstinence, some signs and symptoms such
as anxiety or insomnia might be the emergence of the person’s ‘natural state’. For
example, a service user’s opioid use may have reduced his or her levels of anxiety or
insomnia, but such symptoms may re-emerge during detoxification. In addition to
these, adverse events can also occur as a consequence of the medication prescribed
and include events predictable from a drug’s pharmacology; these can be undesirable
and dangerous. It is possible that any symptom or sign could be due to any one or
more of these reasons. The considerable heterogeneity among the studies in how
withdrawal symptoms, side effects or adverse events were described and attributed
makes this difficult to comment on.
Adverse events
Adverse events are a potentially serious consequence of detoxification and may result
in significant negative impact on the individual’s well-being or in the individual being
removed from a study (with some requiring medical attention). Significant concerns
have been raised over serious adverse events, including death, especially in relation
to rapid and ultra-rapid detoxification, and the sedation and anaesthesia procedures
involved (Strang et al., 1997a).
Respiratory depression
The following applies to whenever methadone and buprenorphine are being
prescribed rather than particularly referring to the process of detoxification.
As a full  opioid agonist, methadone can result in respiratory depression.
Therefore initiation should be undertaken with care (NICE, 2006c). However, some
degree of tolerance to its respiratory depressive effects occurs after a period of
methadone use. By contrast, buprenorphine, as a partial agonist at the  opioid recep-
tor, is not associated with significant respiratory depression when taken at therapeu-
tic doses. During detoxification and in early abstinence, it is presumed that any
tolerance to respiratory depression is lost, leading to the warning about potential for
‘overdose’ and death from respiratory depression.
However, it is important to remember that for both methadone and buprenorphine,
interactions with other respiratory depressants such as alcohol, benzodiazepines and
the newer non-benzodiazepine hypnotics (Z-drugs), other sedatives or tricyclic 
antidepressants may also induce serious respiratory depression (NICE, 2006c). The
additive or synergistic effects of such depressant drugs, particularly alcohol or benzo-
diazepines, may play a contributory role in deaths involving either methadone,
buprenorphine or other opioid agonists (White & Irvine, 1999; Corkery et al., 2004;
Pirnay et al., 2004). Warning individuals about ‘potential for overdose’ should extend
to include concurrent use of respiratory depressant drugs.
Severity of withdrawal
This was generally not reported comprehensively; that is, data were rarely presented
for each day over the entire duration of detoxification. The most frequently used
scales were the Subjective Opiate Withdrawal Scale and Short Opiate Withdrawal
Scale. There was sparse reporting of more protracted withdrawal symptoms that may
persist after completion of detoxification. In this analysis, withdrawal scores are
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presented as: peak (mean maximum score), lowest (mean minimum score), overall
(total or mean score over the duration of detoxification) and mean change from 
baseline (the difference between mean overall score and mean score at baseline).
Subjective rather than objective measures of withdrawal were used, as the former
were judged by the GDG as more representative of service-user acceptability. In addi-
tion, while it is clearly important to use such validated withdrawal scales in trials, the
GDG felt that in routine clinical practice these scales should not replace good clini-
cal skills or knowledge, but that consideration could be given to using them to
complement good clinical assessment.
6.2.4 Databases searched and inclusion/exclusion criteria
Information about the databases searched and the inclusion/exclusion criteria used for
this section of the guideline can be found in Table 2.
Electronic MEDLINE, EMBASE, PsycINFO, Cochrane Library, HMIC
databases
Date searched Database inception to November 2006; table of contents
November 2005 to January 2007
Study design RCT
Patient population Adults and young people who are opioid dependent
Interventions Methadone, buprenorphine, other opioid agonists, alpha2
adrenergic agonists, opioid antagonists, sedatives (including
benzodiazepines and Z-drugs)
Outcomes Abstinence, treatment completion, safety/adverse events,
severity of withdrawal
Table 2: Databases searched and inclusion/exclusion criteria for clinical
effectiveness of pharmacological interventions
5Here, and elsewhere in the guideline, each study considered for review is referred to by a study ID in capi-
tal letters (primary author and date of study publication, except where a study is in press or only submit-
ted for publication, then a date is not used).
6.2.5 Studies considered5
The review team conducted a new systematic search for RCTs that assessed the 
efficacy and safety of pharmacological detoxification. In addition, a further search 
for observational studies was undertaken to assess the safety of pharmacological
detoxification.
The following treatments were included in the review:
● methadone
● buprenorphine
● dihydrocodeine
● clonidine
● lofexidine
● naltrexone
● naloxone
● benzodiazepines
● carbamazepine.
In contrast to other sections of the guideline there are not specific clinical summaries
for each drug as most trials compare active treatments with one another rather than
placebo or minimal control groups. Therefore an overall summary (see section 6.3) 
is provided instead that discusses the evidence for effectiveness of the main classes 
of drugs in comparison with each other, which reflects how these trials were
conducted.
6.2.6 Opioid agonists
Methadone
For comparisons of methadone against other opioid agonists, clonidine or lofexidine,
12 RCTs (BEARN1996; GERRA2000; HOWELLS2002; JIANG1993;
KLEBER1985; SALEHI2006; SAN1990; SORENSEN1982; TENNANT1975;
TENNANT1978; UMBRICHT2003; WASHTON1980) met the eligibility criteria,
providing data on 712 participants. All studies were published in peer-reviewed 
journals (see Table 3 and Table 4 for further details on study information, critical
outcomes and overall quality of evidence). The forest plots and full evidence profiles
can be found in Appendix 16 and Appendix 17, respectively.
Comparisons of methadone against buprenorphine are reviewed separately in the
section on buprenorphine below.
Table 4 and Table 5 show studies comparing methadone with an alpha2 adrener-
gic agonist. It was found that methadone had a better adverse–event profile, especially
in relation to hypotension (versus clonidine), and that it was associated with better
completion of detoxification (versus lofexidine). Where described in these trials,
additional adjunct medications were typically not used in either treatment arm 
(clonidine/lofexidine or methadone).
Methadone did not differ in efficacy compared with other opioid agonists
(propoxyphene napsylate, levo-alpha acetylmethadol [LAAM], tramadol). These 
are neither licensed nor routinely used in the UK for the treatment of opioid 
dependence.
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Pharmacological and physical interventions in opioid detoxification
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Buprenorphine
For comparisons of buprenorphine with methadone, clonidine or lofexidine, 12 RCTs
(CHESKIN1994; JANIRI1994; JOHNSON1992; LING2005; LINTZERIS2002;
MARSCH2005; NIGAM1993; O’CONNOR1997; PETITJEAN2002; RAISTRICK2005;
SEIFERT2002; UMBRICHT2003) met the eligibility criteria, providing data on 
653 participants. While the sublingual preparation of buprenorphine was most
commonly used, one study (LING2005) used the buprenorphine-naloxone prepara-
tion, and in one study all participants received carbamazepine in both the buprenor-
phine and methadone groups (SEIFERT2002). Most of the included studies were of
adults but one study was of adolescents (MARSCH2005). In addition, one cluster-
randomised trial (PONIZOVSKY2006) compared buprenorphine with methadone;
this study was not included in the meta-analysis. All were published in peer-reviewed
journals, with additional unpublished data for one trial provided by the authors
(RAISTRICK2005). For further details on study information, critical outcomes and
overall quality of evidence see Table 6, Table 7 and Table 8. The forest plots and full
evidence profiles can be found in Appendix 16 and Appendix 17, respectively.
Comparisons of buprenorphine with dihydrocodeine are reviewed separately in
the section on dihydrocodeine below.
All individual RCTs were included in the meta-analyses (see Table 7). People who
underwent buprenorphine detoxification achieved clearly better outcomes on most
measures, including completion, abstinence and withdrawal severity, compared with
those who used clonidine or lofexidine. Buprenorphine did not differ significantly
from methadone on completion rate for detoxification; however, no extractable data
were available for abstinence outcomes.
Ponizovsky and colleagues’ (2006) cluster-randomised trial was not included in
the meta-analysis and is thus summarised here. Opioid-dependent participants were
randomised to receive a 10-day inpatient detoxification using either buprenorphine
(n  100) or clonidine (n  100) depending on which hospital they attended. The
clonidine protocol also included the use of adjunctive medications as indicated
(promethazine, dipyrone, trazodone, phenobarbital and antiemetics). Some 90% 
of the buprenorphine group completed detoxification, compared with only 50% in 
the clonidine group, a significant difference (RR  1.80, 95% CI: 1.46 to 2.21).
Abstinence outcomes were not reported. This result was consistent with the other
buprenorphine trials meta-analysed above.
Dihydrocodeine
Dihydrocodeine is an opioid agonist licensed in the UK for pain relief. It has also been used
in a range of UK settings as a substitute medication for opioid dependence both in mainte-
nance and detoxification (Day et al., 2005; Strang et al., 2005; Wright et al., 2007a, b).
Two RCTs (WRIGHT2007A; SHEARD2007B) comparing dihydrocodeine with
buprenorphine met the eligibility criteria, providing data on 150 participants. Protocols
for both studies were published in peer-reviewed journals, with unpublished data for
both trials provided by the authors (see Table 9 and Table 10 for further details on study
information, critical outcomes and overall quality of evidence). The forest plots and
full evidence profiles can be found in Appendix 16 and Appendix 17, respectively.
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Buprenorphine versus dihydrocodeine
Total no. of trials 2 RCTs 
(total no. of (N  150)
participants)
Study ID WRIGHT2007A 
SHEARD2007
Diagnosis Opioid dependence
Mean years of 7.8 (WRIGHT2007A), 9.3 (SHEARD2007)
opioid use
Mean daily opioid use Illicit opioids: £15.60–£23.20 (WRIGHT2007A),
£41.05– £45.56 (SHEARD2007)
Treatment length 12 days (dihydrocodeine) versus 9 days (buprenor-
phine)
Length of follow-up 6 months
Mean age 29–31 years
Evidence profile table Table A17-7
number (Appendix 17)
Overall quality of Moderate
evidence
Benefits
Abstinence Endpoint: 43% versus 23%, RR 1.90 (1.21 to 3.01)
K  2, N  150
1-month follow-up: 38% versus 35%, 
RR 1.08 (0.63 to 1.85) 
K  1, N  90
3-month follow-up: 33% versus 20%, RR 1.64 (0.94
to 2.86) 
K  2, N  150
6-month follow-up: 17% versus 10%, RR 1.71 (0.74
to 3.96) 
K  2, N  150
Completion of treatment 59% versus 46%, RR 1.27 (0.97 to 1.66)
K  2, N  150
Table 9: Study information and summary evidence table for trials of
dihydrocodeine for opioid detoxification
RR  1 favours buprenorphine.
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Study ID Primary detoxification Adjunct Symptoms of withdrawal,
or regimen medications medication side effects
reference and adverse events
Buprenorphine versus dihydrocodeine (RCTs)
WRIGHT Buprenorphine versus None No serious adverse events
2007A dihydrocodeine reported. were reported.
Dosages at the discretion
of prescribing doctor but
within standard regimens
SHEARD Buprenorphine versus None No serious adverse events
2007 dihydrocodeine reported. were reported.
Dosages at the discretion
of prescribing doctor but
within standard regimens
Table 10: Adjunct medications, symptoms and adverse 
events for dihydrocodeine detoxification
People undergoing dihydrocodeine detoxification were less likely to be abstinent
at the end of treatment, and appeared to be no more likely to complete detoxification,
than those receiving buprenorphine. There is little justification to recommend the
routine use of dihydrocodeine in detoxification.
6.2.7 Alpha2 adrenergic agonists
Alpha2 adrenergic agonists (such as clonidine and lofexidine) act to reduce the nora-
drenergic hyperactivity seen in opioid withdrawal. They are therefore a type of
adjunctive medication. They can be either used alone or alongside a rapid reduction
in opioid dose; however, this generally requires use of other adjunctive medications
to ameliorate those symptoms not associated with noradrenergic hyperactivity. This
should be considered and taken into account when comparing regimens.
For comparisons of lofexidine versus clonidine, four RCTs (CARNWATH1998;
GERRA2001; KAHN1997; LIN1997) met the eligibility criteria, providing data on
198 participants. Two RCTs (GHODSE1994; SAN1994) compared clonidine or guan-
facine versus placebo as an adjunct to tapered methadone detoxification, providing
data on 230 participants. All were published in peer-reviewed journals (see Table 11
and Table 12 for further details on study information, critical outcomes and overall
quality of evidence). The forest plots and full evidence profiles can be found in
Appendix 16 and Appendix 17, respectively.
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No difference in efficacy was found between clonidine and lofexidine. Although
the meta-analysis also found no significant difference in adverse event profiles (possi-
bly due to a lack of statistical power), there was a strong trend associated with
increased hypotension for participants receiving clonidine. It was also apparent that 
a wide range of adjunct medications were being used with alpha2 adrenergic agonists
in a majority of studies to ameliorate remaining withdrawal symptoms. However,
generally there was not a full description of which medication was used, and there-
fore it was not possible to take this fully into account in the comparison.
Adding clonidine or guanfacine to a methadone taper did not improve efficacy of
detoxification, but in one study clonidine significantly increased the occurrence of
hypotension.
6.2.8 Adjunctive and other medications
The term ‘adjunctive medication’ covers a wide range of medications used to ameliorate
symptoms of opioid withdrawal when used in addition to or instead of an opioid agonist
(see 6.2.1). Adjunctive medication can target specific symptoms (such as diarrhoea), a
collection of symptoms (such as insomnia and agitation), or, as with clonidine and lofex-
idine, hyperactivity in the noradrenaline system, which mediates a cluster of symptoms.
Alpha2 adrenergic agonists
The evidence for alpha2 adrenergic agonists is described in 6.2.7.
Benzodiazepines
Although benzodiazepines are often prescribed as an adjunct during detoxification to
treat a range of symptoms such as insomnia, anxiety or agitation, the efficacy of two
benzodiazepines compared with an opioid agonist for opioid detoxification has been
studied. One study (DRUMMOND1989) compared chlordiazepoxide with
methadone and another oxazepam with buprenorphine (SCHNEIDER2000). In the
latter study, both groups also received carbamazepine. Both studies had small sample
sizes providing data on 51 participants in total.
Evidence from critical outcomes and overall quality of evidence are presented in
Table 13. The forest plots and full evidence profiles can be found in Appendix 16 and
Appendix 17, respectively. The meta-analysis failed to find a difference between the
use of benzodiazepines and opioid agonists for completion of detoxification treatment
(see Table 13).
Alternatively, two studies have investigated the use of a benzodiazepine as an
adjunct to a reducing methadone regimen. One placebo-controlled crossover study
compared diazepam with doxepin, a tricyclic antidepressant, as an adjunct in outpa-
tient methadone detoxification (McCaul et al., 1984). Participants were randomised
to receive diazepam (n  10) or doxepin (n  13) over the 10-week methadone taper
period, and initially received their assigned medication in a range of doses, in a
random order. In the final 4 weeks of detoxification, participants could self-administer
the assigned medication in an intermediate dose, which could then be titrated. A greater
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proportion (RR  6.50; 95% CI 0.90 to 47.19) of the diazepam group (five of ten)
completed detoxification in comparison with the doxepin group (1 of 13), who also
presented a greater proportion of opioid-positive urines throughout detoxification.
However, given the wide scope for within-group variability in dosing schedules, it is
not possible to draw any firm conclusions from the above findings.
Preston and colleagues (1984) also conducted a placebo-controlled crossover
study, comparing oxazepam and clonidine as adjuncts to methadone detoxification.
Six participants were assigned to each group on the basis of baseline characteristics.
During each 5-day period for 30 days, participants received their assigned medication
(oxazepam 20 mg/day, or clonidine 0.2 mg/day) and placebo capsules, in a random
order. Participants then received either capsule of their choice. All participants were
tapered from 50 mg methadone to zero over the first 15 days of the study. The authors
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Opioid agonists versus benzodiazepines
Total no. of trials (total 2 RCTs 
no. of participants) (N 51)
Study ID Chlordiazepoxide versus methadone: 
DRUMMOND1989 
Oxazepam versus buprenorphine: SCHNEIDER2000
Diagnosis Opioid dependence
Mean years of opioid use 4.7 (DRUMMOND1989), 
10.1 (SCHNEIDER2000)
Mean daily opioid use Heroin: 0.8 g (DRUMMOND1989)
Treatment length 13 days: DRUMMOND1989 
21 days: SCHNEIDER2000
Length of follow-up None
Age 24–31 years
Evidence profile table Table A17-10
number (Appendix 17)
Overall quality of Low
evidence
Benefits
Completion of treatment 57% versus 48%, RR 1.19 (0.71 to 1.98)
K2, N50
Table 13: Study information and summary evidence table for trials of
benzodiazepines for opioid detoxification
RR  1 favours opioid agonists.
found that neither clonidine nor oxazepam significantly reduced withdrawal severity
relative to their respective placebo control conditions, and likewise self-administration
of the active medications had no effect on withdrawal severity.
Carbamazepine
Carbamazepine, an anticonvulsant, can be used to treat alcohol or benzodiazepine with-
drawal (Schweizer et al., 1991) and has been studied in cocaine dependence (though not
found to be effective; Lima Reisser et al., 2002) as well as being used for a variety of
neuropsychiatric conditions. Therefore, the rationale of using it as an adjunct in opioid
detoxification is to ascertain whether carbamazepine improved outcome in polydrug
users. Two studies have given carbamazepine to all patients when comparing
methadone and buprenorphine detoxification (SEIFERT2002) and when comparing
oxazepam and clonidine as adjuncts in methadone detoxification (SCHNEIDER2000).
However, in neither study was there a group not given carbamazepine, thus it is not
possible to deduce if it does improve outcome in polydrug users.
6.2.9 Dosages and durations of detoxification
Information about databases searched and the inclusion/exclusion criteria used for this
guideline can be found in Table 14. The efficacy of substitute (for example, methadone
or buprenorphine) and adjunctive (for example, alpha2 adrenergic agonists) medications
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Electronic databases MEDLINE, EMBASE, PsycINFO, Cochrane Library, HMIC
Date searched Database inception to November 2006; table of contents
November 2005 to January 2007
Study design RCT
Patient population Opioid dependent
Interventions Pharmacological medication: methadone, buprenorphine,
other opioid agonists, alpha2 adrenergic agonists, opioid
antagonists, sedatives (including benzodiazepines and 
Z-drugs)
Dosage of medication: low, moderate, high starting dose
Duration of detoxification: short, moderate, long
Regulation of dosage schedule: linear schedule, exponen-
tial schedule; service user preference, provision of 
information to service user about schedule
Outcomes Abstinence, treatment completion, safety/adverse events,
severity of withdrawal
Table 14: Databases searched and inclusion/exclusion criteria for clinical
effectiveness of dosage, duration and regulation of detoxification
has been assessed above. This section examines whether the duration or rate of reduction
of substitute or dose of adjunctive medication contributes to the outcome of detoxifi-
cation (that is, abstinence/ completion of detoxification as assessed above).
Dosage of methadone
Table 15 summarises study information and evidence from studies comparing high
and moderate starting doses. The forest plots and full evidence profiles can be found
in Appendix 16 and Appendix 17, respectively.
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Methadone: high dose (80–100 mg) versus moderate
dose (40–50 mg)
Total no. of trials 2 RCTs 
(total no. of (N 135)
participants)
Study ID BANYS1994 
STRAIN1999
Diagnosis Opioid dependence
Mean opioid use No data (BANYS1994) 
25.3 times in last 30 days (STRAIN1999)
Treatment length 70 days: STRAIN1999 
78 days: BANYS1994
Length of follow-up None
Age 18–65
Evidence profile Table A17-11
table number 
(Appendix 17)
Overall quality of Moderate
evidence
Benefits
Abstinence Proportion opioid-positive urines during treatment: SMD
0.59 (0.97 to 0.21) 
K 1, N 111
Completion of 32% versus 22%, RR 1.45 (0.83 to 2.54) 
treatment K 2, N 142
Table 15: Study information and summary evidence table for trials of
methadone dosages in detoxification
RR  1 and negative SMD favours high dose.
In both studies participants were on methadone and on what may be considered 
as slow taper regimens, consisting of a 6-month stabilisation phase followed by a
detoxification phase of 70 days (STRAIN1999) or 78 days (BANYS1994). It appears
that for this type of detoxification regimen, beginning with a high dose of methadone
at the stabilisation phase is more effective than a moderate dose and that this contin-
ues to affect abstinence during treatment and completion of detoxification.
Duration of methadone taper
Three double-blind RCTs compared different durations of methadone detoxification.
Senay and colleagues (1981) randomised participants to an 84-day methadone
taper (n  37), or a 21-day taper followed by placebo for the remainder of the study
period (n  35). The two groups did not differ in completion rate or abstinence at the
end of the active medication period, or abstinence at 1-year follow-up. Sorensen and
colleagues (1982) similarly found no significant difference in completion rate for a
21-day methadone taper (n  15) versus a 42-day methadone taper (n  18).
Stitzer and colleagues (1984) randomised participants undergoing a 90-day detox-
ification programme to taper from 60 mg methadone over 70 days (n  13), or from
30 mg over 28 days (n  13). There was no significant difference between groups in
treatment retention.
In addition, one quasi-experimental study conducted by Gossop and colleagues
(1989) in two inpatient detoxification facilities in London compared a 10-day
methadone taper (n  50) against a 21-day methadone taper (n  82). The 10-day
group reported a significantly higher peak withdrawal score on the OWS than the 21-
day group (t  1.79, p 	 0.05), although there was no significant difference in the
total duration of withdrawal symptoms. The two groups also did not differ in comple-
tion rate for detoxification (70.5% for the 10-day group, and 78.8% for the 21-day
group; RR  0.88, 95% CI  0.71 to 1.09).
Regulation of methadone dosage schedules
There are a variety of ways to manage dosage schedules during methadone detoxifica-
tion. The effects of providing information to the service user about the dosage schedule,
the service user regulating the schedule, and schedules fixed by the clinician (for exam-
ple, linear and exponential reduction) will be assessed. Three RCTs were identified that
compared different ways of managing dosage schedules for methadone detoxification.
In a study lasting 42 days, Dawe and colleagues (1991) randomised participants to a
fixed schedule methadone taper (n  15), or were allowed to regulate their own dosage
schedule with the aim of completing detoxification (that is, reaching zero dose) within
the study period (n  24). The fixed group were significantly more likely to complete
detoxification (53% versus 17%, 2  4.49, p 	 0.05), and in a significantly shorter time
frame (35 days versus 47 days, t  1.97, p 	 0.05). However, urinalysis suggested no
significant difference between groups in illicit opioid use at 6-week follow-up.
Green and Gossop (1988) randomised participants undergoing a 21-day
methadone taper to the ‘informed group’ (n  15), who received detailed information
about aspects of the detoxification programme such as dosages and expected symp-
tomatology, and the ‘uninformed group’ (n  15), who received a routine clinical
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interview. The informed group were more likely to complete detoxification (46.7%
versus 80.0%, 2  32.12, p 	 0.01), and reported significantly lower withdrawal
scores on the final day of detoxification (t  2.48, p 	 0.05) as well as over the 25-day
post-detoxification period (F  3.93, p 	 0.05).
Strang and Gossop (1990) randomised participants undergoing a 10-day
methadone detoxification programme to a linear (n  43) or exponential (n  44)
taper schedule. Both groups were equally likely (84%) to complete detoxification but
the exponential group reported significantly higher withdrawal severity on the OWS
during the acute phase of withdrawal (F  4.34, p 	 0.05).
Dosage and duration of buprenorphine detoxification
The typical duration of detoxification using buprenorphine is between 4 and 8 days.
There is one RCT (Assadi et al., 2004) that compared regimens using a high dose of
buprenorphine in the first 24 hours only, with a more typical regimen reducing buprenor-
phine over 5 days. At high doses, buprenorphine may effectively act as an antagonist and
hence precipitate withdrawal. Buprenorphine was given intramuscularly; the high dose
(12 mg; 6  1.5 mg doses) was equivalent to 21.3 mg sublingual and the reducing regi-
men started at 1.5 mg of intramuscular buprenorphine twice a day. No significant differ-
ences in treatment retention, successful detoxification (negative naloxone challenge test)
or severity of withdrawal were reported. Adjunctive medications (trazodone and
indomethacin) were used more by the high-dose group than when buprenorphine was
reduced with equal amounts of the others (diazepam, chlorpromazine and hyoscine).
Dosage schedules for alpha2 adrenergic agonists
No studies were found comparing different dosage schedules of clonidine or lofexidine,
however a variety of regimens were reported in the included studies (see Table 12), with
some continuing substitute prescribing for a few days when starting the alpha2 adren-
ergic agonist, and in other studies it was stopped at that time. Doses of alpha2
adrenergic agonists were generally increased over 3 days depending on acceptability
and control of withdrawal symptoms, maintained for a period then tapered over
approximately 3 days at the end.
Clinical summary
For methadone, a high starting dose (80–100 mg/day) appeared to be superior to a
standard starting dose (40–50 mg/day) in abstinence (opioid-negative urinalyses
during treatment) and completion outcomes, although it may be argued whether absti-
nence during treatment is a meaningful outcome in this context, given that a higher
methadone dose would be expected to reduce the desire to use additional illicit
opioids. Improved completion rates could be the result of participants being better
stabilised at the outset on a higher dose.
Regarding the duration of detoxification, neither a long methadone taper (up to 
70 days) nor a fairly short programme (14 days) was any better than a standard 
21-day taper. Also, keeping service users fully informed about different aspects of
detoxification appears to have some effect in improving completion rates and
minimising reported withdrawal severity.
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There is a lack of data assessing dosage and duration for detoxification using
buprenorphine or alpha2 adrenergic agonists. Therefore it is not yet possible to draw
conclusions on these issues at present.
6.3 OVERALL CLINICAL SUMMARY OF PHARMACOLOGICAL
INTERVENTIONS IN DETOXIFICATION
For all sub-sections there were too few studies in each meta-analysis to check for
publication bias using funnel plots. However, publication bias is possible as the GDG
and review team had access to only very limited unpublished data.
Opioid agonists
Methadone and buprenorphine both appeared to be effective in comparison with 
other detoxification treatments such as alpha2 adrenergic agonists and other opioid
agonists. Dihydrocodeine did not appear to be effective in comparison with buprenor-
phine. However, it is not clear if there is any difference in efficacy between
methadone and buprenorphine for detoxification.
Alpha2 adrenergic agonists
There were no differences found in completion of detoxification between clonidine
and lofexidine. However, clonidine was associated with higher levels of hypotension.
It was also apparent that a wide range of adjunct medications was being used with
alpha2 adrenergic agonists in a majority of studies to ameliorate remaining withdrawal
symptoms, although this was not well reported.
Side effects and adverse events
Among the reviewed studies there was heterogeneity in how withdrawal symptoms,
side effects or adverse events were described and attributed. In addition, without a full
description of adjunctive medication taken, it was often not possible to delineate
further how to attribute a sign or symptom. Aside from hypotension, which was
recognised as a side effect or adverse event associated with clonidine (see above), the
majority of other signs or symptoms were consistent with those expected from opioid
withdrawal and often were non-specific.
6.4 CLINICAL PRACTICE RECOMMENDATIONS
6.4.1 The use of opioid agonists
6.4.1.1 Methadone or buprenorphine should be offered as the first-line treatment
in opioid detoxification. When deciding between these medications,
healthcare professionals should take into account:
● whether the service user is receiving maintenance treatment with
methadone or buprenorphine; if so, opioid detoxification should
normally be started with the same medication
● the preference of the service user.
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6.4.1.2 Dihydrocodeine should not be used routinely in opioid detoxification.
6.4.2 Use of adjunctive medications in opioid detoxification
6.4.2.1 Lofexidine may be considered for people:
● who have made an informed and clinically appropriate decision not to
use methadone or buprenorphine for detoxification
● who have made an informed and clinically appropriate decision to
detoxify within a short time period
● with mild or uncertain dependence (including young people).
6.4.2.2 Clonidine should not be used routinely in opioid detoxification.
6.4.2.3 When prescribing adjunctive medications during opioid detoxification,
healthcare professionals should:
● only use them when clinically indicated, such as when agitation, nausea,
insomnia, pain and/or diarrhoea are present
● use the minimum effective dosage and number of drugs needed to manage
symptoms
● be alert to the risks of adjunctive medications, as well as interactions
between them and with the opioid agonist.
6.4.3 Dosage and duration of detoxification
6.4.3.1 When determining the starting dose, duration and regimen (for example,
linear or stepped) of opioid detoxification, healthcare professionals, in
discussion with the service user, should take into account the:
● severity of dependence (particular caution should be exercised where
there is uncertainty about dependence)
● stability of the service user (including polydrug and alcohol use, and
comorbid mental health problems)
● pharmacology of the chosen detoxification medication and any adjunc-
tive medication
● setting in which detoxification is conducted.
6.4.3.2 The duration of opioid detoxification should normally be up to 4 weeks 
in an inpatient/residential setting and up to 12 weeks in a community
setting.
6.4.4 Research recommendation – adjunctive medication during
detoxification
6.4.4.1 If a person needs adjunctive medication during detoxification, in addition
to their opioid agonist reducing regimen or in addition to an adjunctive
alpha-2 adrenergic agonist (for example, lofexidine), what medications are
associated with greater safety and fewer withdrawal symptoms?
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Why this is important
A large variety of adjunctive medications are used for the management of withdrawal
symptoms during detoxification, particularly when alpha-2 adrenergic agonists are
used. Research is needed to guide decisions on how best to manage withdrawal symp-
toms with minimal risk of harm to the service user.
6.5 ULTRA-RAPID, RAPID AND ACCELERATED
DETOXIFICATION USING OPIOID ANTAGONISTS
6.5.1 Introduction
Ultra-rapid and rapid detoxification are approaches for detoxifying opioid-dependent
patients using opioid antagonists, such as naloxone, naltrexone or nalmefene, typi-
cally under general anaesthesia or heavy sedation. The aim is to flood the brain with
an opioid antagonist to remove all agonists very rapidly while the anaesthesia or seda-
tion minimises discomfort. The patient is then maintained on naltrexone, which has
led some to refer to this as ‘rapid antagonist induction’.
A variety of protocols have been used, with the essential distinctions between
ultra-rapid and rapid detoxification being the duration of detoxification and the level
of sedation. In ultra-rapid detoxification, patients are admitted to intensive care units
or high dependency units for 24 hours (therefore, not routine inpatient addiction facil-
ities) and receive naltrexone or naloxone to precipitate withdrawal; anaesthesia is
initiated as withdrawal symptoms emerge, and is maintained for 5–6 hours using vari-
ous medications in addition to those for controlling opioid withdrawal. In rapid detox-
ification, instead of anaesthesia, sedation with a benzodiazepine (most commonly
midazolam) is used, but otherwise the medications used are broadly similar. The typi-
cal duration is 1–5 days.
Others, however, have also referred to ultra-rapid detoxification more widely as
including the use of heavy sedation, and rapid detoxification when an opioid antago-
nist is used to precipitate withdrawal in awake patients (O’Connor & Kosten, 1998).
The reported advantage of using ultra-rapid or rapid detoxification with anaesthesia
or sedation is that the duration of withdrawal symptoms is shortened and discomfort is
minimised through the anaesthesia or sedation. Since it was reported in the late 1980s
(Loimer et al., 1989), the technique and medications used have evolved. It has also
courted controversy; the main issues with such an approach involve the high degree of
risk, including fatalities. This is particularly striking given that opioid withdrawal alone
rarely results in death. Furthermore, the associated costs required to give the appropriate
medical support are much greater than for other methods of detoxification. There has
been much debate over its effectiveness, with limited long-term outcome data available.
Alternatively, naltrexone and naloxone have been used in addition to clonidine,
lofexidine or buprenorphine to speed up or shorten detoxification without precipitating
full withdrawal; this is referred to here as accelerated detoxification. Note that such
use of naltrexone and naloxone has been considered distinct from the use of adjunc-
tive medications as defined here, since opioid antagonists do not actually ameliorate
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withdrawal symptoms. The service user is not sedated, or only minimally. This
approach may also help establish service users on naltrexone for preventing relapse.
Current practice
In the UK, ultra-rapid and rapid detoxification with anaesthesia or sedation are not
offered within the NHS but appear to occur in the private sector. They are also avail-
able in some parts of Europe (such as Spain, Switzerland and the Netherlands) and
Australia (Mattick et al., 2001).
The uses of naltrexone or naloxone to accelerate detoxification appear to be
uncommon in specialist drug services in the UK (Day et al., 2005).
6.5.2 Definitions of levels of sedation
Minimal or light sedation
Minimal or light sedation involves the administration of medication in order to deal
with anxiety, insomnia or agitation. The defining characteristic of this type of seda-
tion is that the person still appears relatively awake and is able to communicate
clearly at all times. Although cognitive function and coordination may be impaired,
ventilatory and cardiovascular functions are unaffected. This type of sedation is
usually not sufficient for a significant procedure or painful intervention to occur. Most
studies of ‘conventional’ detoxification in which adjunct sedative medications are
prescribed fall under this classification (see Section 6.2).
Moderate sedation
During moderate sedation, a higher level of sedation than minimal or light sedation,
the person appears obviously sedated, but importantly can maintain an open airway
independently and respond purposefully to stimuli (such as verbal questioning).
Deep sedation (or heavy sedation)
During deep sedation (or heavy sedation), an even higher level of sedation, the person
is clearly sedated, may not be easily aroused or respond purposefully to verbal
commands, and may only respond minimally to very significant stimuli (such as high
levels of pain). A person may experience partial or complete loss of protective reflexes,
including the ability to maintain an open airway independently and continuously. He or
she may therefore require assistance in maintaining an open airway, and spontaneous
ventilation may be inadequate. Cardiovascular function is usually maintained.
While deep sedation may not equate to general anaesthesia, there is a consensus
that its supervision requires the same level of training and skill (The Royal College
of Anaesthetists, 2001). If verbal responsiveness is lost, the person requires a level of
care identical to that needed for general anaesthesia.
General anaesthesia
Under general anaesthesia a person is unconscious and unresponsive, even in the face
of significant stimuli. The ability to maintain ventilatory function independently is
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often impaired. The person often requires assistance in maintaining an open airway,
and positive pressure ventilation may be required because of depressed spontaneous
ventilation or drug-induced depression of neuromuscular function. Cardiovascular
function may be impaired.
6.5.3 Databases searched and inclusion/exclusion criteria
Information about the databases searched and the inclusion/ exclusion criteria used
for this section of the guideline can be found in Table 16.
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6Here, and elsewhere in the guideline, each study considered for review is referred to by a study ID in capital
letters (primary author and date of study publication, except where a study is in press or only submitted for
publication, then a date is not used).
Electronic databases MEDLINE, EMBASE, PsycINFO, Cochrane Library,
HMIC
Date searched Database inception to November 2006; table of
contents November 2005–January 2007
Study design RCT
Patient population Adults and young people who are opioid dependent
Interventions Opioid antagonist-accelerated detoxification under
minimal or light sedation, rapid detoxification under
moderate sedation, ultra-rapid detoxification under
general anaesthesia or deep sedation
Outcomes Abstinence, treatment completion, safety/adverse
events, severity of withdrawal
Table 16: Databases searched and inclusion/exclusion criteria for clinical
effectiveness of rapid and ultra-rapid detoxification under sedation and/or
general anaesthesia
6.5.4 Studies considered6
The review team conducted a new systematic search for RCTs that assessed the effi-
cacy and safety of ultra-rapid and rapid detoxification under sedation and/or general
anaesthesia. In addition, a further search for observational studies was undertaken to
assess the safety of ultra-rapid and rapid detoxification under sedation and/or general
anaesthesia.
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Opioid antagonist-accelerated detoxification
versus detoxification without opioid agonists
Total no. of trials 5 RCTs 
(total no. of (N 399)
participants)
Study ID Naloxone with lofexidine: 
BESWICK2003A
Naltrexone with clonidine:
GERRA1995
GERRA2000
O’CONNOR1997
Naltrexone with buprenorphine:
UMBRICHT1999
Diagnosis Opioid dependence: all
Heroin: 100% (GERRA1995)
Injection drug use: 30% (UMBRICHT1999)
Mean years of Heroin: 2–4 (GERRA1995), 2– 6 (GERRA2000),
opioid use 6.5–8.3 (UMBRICHT1999), 7.7–8.9
(O’CONNOR1997)
Mean daily opioid Heroin: 0.5 g (GERRA1995), 0.55 g (BESWICK2003),
use 1.5–2.0 g (street heroin; GERRA2000)
Bags of heroin in past 30 days: 3.8–4.0 
(O’CONNOR1997)
Days of heroin use in past 30 days:
29 (UMBRICHT1999)
Methadone dose at entry (mg/day): 
41.9 (BESWICK2003A)
Table 17: Study information and summary evidence table for trials of opioid
antagonist-accelerated detoxification under minimal or light sedation
6.5.5 Opioid antagonist-accelerated detoxification under minimal 
or light sedation
For comparisons of naltrexone/naloxone versus placebo as an adjunct to buprenor-
phine, clonidine or lofexidine detoxification, five RCTs (GERRA1995; GERRA2000;
O’CONNOR1997; BESWICK2003A; UMBRICHT1999) met the eligibility criteria,
providing data on 399 participants (for further details on study information, evidence
from critical outcomes and overall quality of evidence see Table 17 and Table 18). The
forest plots and full evidence profiles can be found in Appendix 16 and Appendix 17,
respectively.
Continued
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Table 17: (Continued)
For abstinence, completion and starting naltrexone maintenance, RR  1 favours naltrexone/
naloxone. For drug use and leaving study early, RR 	 1 favours naltrexone/naloxone. For
withdrawal severity, negative SMD favours naltrexone/naloxone.
Opioid antagonist-accelerated detoxification
versus detoxification without opioid agonists
Treatment length 4 days: GERRA1995
6 days: BESWICK2003A
8 days: O’CONNOR1997, UMBRICHT1999
Length of follow-up Up to 6 months
Age 18–56 years
Evidence profile Table A17–12
table number 
(Appendix 17)
Overall quality of Moderate
evidence
Benefits
Abstinence Abstinent at 6-month follow-up: 44% versus 53%,
RR 0.82 (0.49 to 1.37) 
K 1, N 64
Maintained abstinence throughout at 9-month follow-
up: 20% versus 9%, RR 2.30 (0.76 to 6.94) 
K1, N 91
Abstinent in past month at 9-month follow-up: 36%
versus 26%, RR 1.36 (0.73 to 2.55) 
K 1, N 91
Completion of 78% versus 77%, RR 1.01 (0.86 to 1.17) 
treatment K 4, N 335
Concordance with 75% versus 53%, RR 1.41 (0.96 to 2.07)
naltrexone maintenance K 1, N 64
at 3-month follow-up
Self-rated withdrawal Peak: SMD 0.95 (1.20 to 3.10) 
severity K 2, N 184
Overall: SMD 0.51 (0.58 to 1.60) 
K 2, N 162
Left study early due to withdrawal: RR 1.75
(0.35 to 8.84) 
K 1, N 60
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In this approach, unlike ultra-rapid and rapid detoxification regimens using opioid
antagonists to precipitate full withdrawal (see Sections 6.5.6 and 6.5.7), detoxifica-
tion had already commenced (BESWICK2003A; GERRA1995) and/or a low dose of
the opioid antagonist was given (O’CONNOR1997; UMBRICHT1999). In addition,
in these protocols, other adjunct medication was used or available, such as clonidine
and benzodiazepines. Using a low dose of naltrexone (12.5 mg) is different from the 
so-called ‘Asturian method’, where 50 mg of naltrexone is given at the start with a
greater range and higher doses of medication to treat opioid withdrawal symptoms
(Carreno et al., 2002; see Section 6.5.6).
6.5.6 Rapid detoxification under moderate sedation
One RCT (ARNOLD-REED2005) comparing rapid detoxification under moderate
sedation against detoxification under minimal or light sedation met the eligibility
criteria, providing data on 80 participants. It was published in a peer-reviewed jour-
nal (for further details on study information, evidence from critical outcomes and
overall quality of evidence see Table 19).
The forest plots and full evidence profiles can be found in Appendix 16 and
Appendix 17, respectively.
Asturian method
One approach, the ‘Asturian method’, has been used at home without direct medical
or nursing supervision (Carreno et al., 2002). Service users were requested to take no
opioids for 12 hours before the procedure in order to reduce the severity of precipi-
tated withdrawal. They were then moderately sedated using the following medication:
0.45 mg clonidine, 40 mg famotidine, 4 mg loperamide, 22.5 mg midazolam, 12 mg
ondansetron and 50 mg clorazepate. After 45 minutes, they were then woken to
receive 10 mg metoclopramide and 50 mg naltrexone to precipitate withdrawal. After
1 hour 45 minutes, further symptomatic medication was provided (20 mg hyoscine
butylbromide, 0.3 mg clonidine and 10 mg metocopramide). After 24 hours, service
users were given a physical examination, medication to manage withdrawal symptoms
was provided if needed, and individuals were inducted onto naltrexone maintenance
treatment.
Carreno and colleagues (2002) reported a case series of 1,368 service users who
had received the Asturian method. This report was primarily descriptive, with limited
reporting of outcomes, and involved no comparison group; therefore conclusions
drawn on the efficacy of this procedure are limited.
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Rapid detoxification under moderate sedation versus
detoxification under minimal/light sedation
Total no. of trials 1 RCT 
(total no. of (N  80)
participants)
Study ID ARNOLD-REED2005
Diagnosis Opioid dependence
Years of opioid use Used heroin for more than 5 years: 66%
Daily opioid use Daily heroin use: 95%
Treatment length 1 day (rapid detoxification under moderate sedation)
versus 7–10 days (clonidine detoxification)
Length of follow-up 1 month
Mean age 30 years
Evidence profile  Table A17-14
table number 
(Appendix 17)
Overall quality of Moderate
evidence
Benefits
Abstinence 1-month follow-up: 39% versus 30%, RR 1.30 (0.59 to 2.84)
K 1, N 80
Completion of 88% versus 28%, RR  3.11 (1.86 to 5.20)
treatment K 1, N 80
Concordance with Started 50 mg maintenance dose: 86% versus 50%,
naltrexone RR 1.72 (1.09 to 2.72) 
maintenance K 1, N 80
Achieved 100% concordance over 4-week follow-up: 
56% versus 40%, RR 1.39 (0.75 to 2.56)
K 1, N 80
Self-rated  Mean change from baseline (completers analysis): 
withdrawal severity SMD 1.70 (2.56 to 0.84)
K 1, N 41
Table 19: Study information and summary evidence table for rapid
detoxification under moderate sedation
RR  1 and negative SMD favour ultra-rapid detoxification.
6.5.7 Ultra-rapid detoxification under general anaesthesia or deep 
(or heavy) sedation
For comparisons of ultra-rapid detoxification under general anaesthesia or deep (or
heavy) sedation against detoxification under minimal or no sedation, six RCTs
(COLLINS2005; DE JONG2005; FAVRAT2006; KRABBE2003; MCGREGOR2002;
SEOANE1997) met the eligibility criteria, providing data on 845 participants. In addi-
tion, one RCT (Hensel et al., 2000), one quasi-experimental study (Hoffman et al.,
1998), five case series (Armstrong et al., 2003; Cucchia et al., 1998; Elman et al.,
2001; Gold et al., 1999; Hamilton et al., 2002) and three case reports (Cook & Collins,
1998; Roozen et al., 2002; Shreeram et al., 2001) provided data on adverse events in
ultra-rapid detoxification. All studies were published in peer-reviewed journals (for
further details on study information, evidence from critical outcomes and overall quality
of evidence see Table 20 and Table 21). The forest plots and full evidence profiles can
be found in Appendix 16 and Appendix 17, respectively.
Ultra-rapid detoxification under general anaesthesia
versus detoxification under light or minimal sedation
Total no. of trials 6 RCTs 
(total no. (N  845)
of participants)
Study ID Propofol anaesthesia (versus clonidine without general
anaesthesia):
COLLINS2005
FAVRAT2006
MCGREGOR2002
Propofol anaesthesia (versus methadone without general
anaesthesia):
KRABBE2003
Propofol anaesthesia (versus naltrexone without general
anaesthesia):
DE JONG2005
Propofol with midazolam (versus light sedation with same
agents):
SEOANE1997
Diagnosis Opioid dependence
Table 20: Study information and summary evidence table for trials of 
ultra-rapid opioid detoxification
Continued
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Ultra-rapid detoxification under general anaesthesia
versus detoxification under light or minimal sedation
Mean years of Heroin: 6.3–11.1 (KRABBE2003), 
opioid use 9.9 (MCGREGOR2002), 12.0 (DEJONG2005)
Lifetime heroin use disorder: 7.5 (COLLINS2005)
Methadone: 3.5–9.4 (KRABBE2003)
Mean daily Heroin (mg): 741.3 (SEOANE1997)
opioid use Methadone (mg): 38.5–58.4 (KRABBE2003)
Times heroin used in past 30 days: 
87.1 (MCGREGOR2002)
Days heroin used in past 30 days: 18.4 (DE JONG2005),
30 (COLLINS2005)
Days methadone used in past 30 days: 
22.8 (DE JONG2005)
Treatment length 1 day: SEOANE1997
1 day (ultra-rapid group) versus 7 days (control group):
FAVRAT2006
3 days: COLLINS2005, MCGREGOR2002
7 days: DE JONG2005
Length of follow-up Up to 12 months
Mean age 30–36 years
Evidence profile Table A17-13
table number 
(Appendix 17)
Overall quality of Moderate
evidence
Benefits
Abstinence 1-month follow-up: 66% versus 58%, RR 1.54 
(0.66 to 3.59) 
K 2, N 302
3-month follow-up: 30% versus 14%, RR 2.08
(1.18 to 3.68) 
K 3, N169
6-month follow-up: 22% versus 8%, RR 2.70 (0.92 to 7.91)
K 1, N101
12-month follow-up: 20% versus 14%, RR 1.40
(0.58 to 3.39) 
K1, N101
Table 20: (Continued)
Continued
For benefits, RR  1 and negative SMD favour ultra-rapid detoxification. For adverse events,
RR 	 1 favours ultra-rapid.
Table 20: (Continued)
Ultra-rapid detoxification under general anaesthesia
versus detoxification under light or minimal sedation
Completion of 84% versus 54%, RR1.67 (0.88 to 3.18)
treatment K4, N270
Concordance with Started 50 mg maintenance dose 
naltrexone Versus clonidine control group: 61% versus 19%, 
maintenance RR 3.87 (1.03 to 14.54)
K3, N240 
Versus naltrexone control group: 90% versus 99%, 
RR 0.91 (0.86 to 0.97) 
K1, N272
Harms
Adverse events Serious adverse events: RR 3.62 (1.36, 9.61)
K3, N644
6.5.8 Clinical summary
There were too few studies in each meta-analysis to check for publication bias using
funnel plots. However, publication bias is possible as the review team and the GDG
did not have access to any unpublished data.
Accelerated detoxification under minimal or light sedation
Adding an opioid antagonist to clonidine, lofexidine or buprenorphine detoxification
had no effect on completion rates, but showed a trend for increased withdrawal sever-
ity, as might be expected from a process that accelerates withdrawal. Data for absti-
nence at follow-up were inconsistent, with one study showing a trend favouring an
opioid antagonist at 9-month follow-up while another study showed the opposite
trend at 6-month follow-up.
Rapid detoxification under moderate sedation
No firm conclusions could be drawn from the limited evidence base concerning the
safety and efficacy of this detoxification method. It was apparent however that precip-
itating withdrawal necessitated the polypharmacy of adjunct medications for manag-
ing symptoms; this is likely to carry inherent risks (for example, increased likelihood
of medication interactions), particularly if detoxification occurs within a setting with
minimal medical supervision (for example, at home).
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Ultra-rapid detoxification under general anaesthesia
This is associated with a substantially increased risk of serious adverse events, includ-
ing complications associated with the anaesthesia (such as aspiration pneumonia,
delirium and fever), above what would normally be expected in conventional opioid
detoxification under minimal sedation. In addition, the polypharmacy of adjunct
medications is likely to carry inherent risks. Although the evidence suggests 
that ultra-rapid detoxification is a very effective way of initiating individuals onto
naltrexone maintenance (compared with detoxification with clonidine) and that it
may have better abstinence outcomes at 3- to 6-month follow-up, these benefits are
outweighed by the considerable risks.
6.6 CLINICAL PRACTICE RECOMMENDATIONS
6.6.1 Accelerated detoxification
6.6.1.1 Ultra-rapid and rapid detoxification using precipitated withdrawal should
not be routinely offered. This is because of the complex adjunctive medica-
tion and the high level of nursing and medical supervision required.
6.6.1.2 Ultra-rapid detoxification under general anaesthesia or heavy sedation
(where the airway needs to be supported) must not be offered. This is
because of the risk of serious adverse events, including death.
6.6.1.3 Rapid detoxification should only be considered for people who specifically
request it, clearly understand the associated risks and are able to manage
the adjunctive medication. In these circumstances, healthcare professionals
should ensure during detoxification that:
● the service user is able to respond to verbal stimulation and maintain a
patent airway
● adequate medical and nursing support is available to regularly monitor
the service user’s level of sedation and vital signs
● staff have the competence to support airways.
6.2.1.4 Accelerated detoxification, using opioid antagonists at lower doses to
shorten detoxification, should not be routinely offered. This is because of
the increased severity of withdrawal symptoms and the risks associated
with the increased use of adjunctive medications.
6.7 PHYSICAL AND COMPLEMENTARY INTERVENTIONS
DURING DETOXIFICATION
It is acknowledged that many complementary interventions are offered to individuals
with opioid dependence as well as for alcohol or other drug misuse. In this review, the
focus was on their use specifically during or for detoxification; their role in other
stages of dependency or treatment, such as initiation or maintenance of substitute
medication, was not investigated.
A search for RCTs and observational studies for a number of physical and comple-
mentary interventions was conducted. Two RCTs, one of acupuncture alone versus
placebo (Washburn et al., 1993) and one of acupuncture as an adjunct to tapered
methadone (Zeng et al., 2005), met the eligibility criteria, providing data on 170 partic-
ipants. In addition, one systematic review (Jordan, 2006) covered reviews and clinical
trials of acupuncture published between 1973 and 2006. No other suitable/appropriate
studies for review were found on any other physical or complementary intervention.
6.7.1 Acupuncture
Acupuncture is a traditional form of Chinese medicine that has been practised for
over 3,000 years (Jordan, 2006). It involves inserting fine needles at selected points
on the skin to balance the body’s energy (chi), with the aim of treating and prevent-
ing disease. The review concluded that, despite there being some evidence potentially
supporting the use of acupuncture in opioid detoxification, this was mostly derived
from trials with poor methodological quality (that is, they were not randomised, not
controlled and/or had small sample sizes). In addition, it was not possible to detach
possible positive effects of acupuncture from those of other treatments being deliv-
ered concurrently. The review found no evidence to support acupuncture as a stand-
alone treatment option for opioid dependence (Jordan, 2006).
Further trials, in addition to Jordan’s review, were also identified. Zeng and
colleagues (2005) randomised participants undergoing a 10-day methadone taper into
an acupuncture group (n  35) and a methadone-only control group (n  35). The
acupuncture group reported significantly lower peak withdrawal severity
(SMD  0.75, 95% CI  1.29, 0.21) and were also more likely to complete
detoxification, with a trend towards significance (RR  1.19, 95% CI, 0.95 to 1.50),
in comparison with controls. However, the lack of an attentional control in the
methadone-only group may partly account for the apparent relative efficacy of
acupuncture.
Washburn and colleagues (1993) randomised participants to receive detoxification
by acupuncture alone (n  55) or sham acupuncture (n  45) over 21 days. Although
the acupuncture group spent longer time in treatment (acupuncture median  2 days,
sham acupuncture median  1 days), attrition was extremely high in both groups,
with very few completing the 21-day detoxification, suggesting little benefit for
acupuncture detoxification.
Clinical summary
In summary, there is a lack of trials assessing the efficacy of acupuncture during
detoxification either alone or as an adjunct to other treatments. Therefore there is no
established evidence base to support this as an effective method of detoxification.
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7. PSYCHOSOCIAL INTERVENTIONS
IN OPIOID DETOXIFICATION
7.1 INTRODUCTION
Although detoxification from opioids in NHS settings is generally focussed on 
pharmacological withdrawal, many detoxification programmes, particularly in
specialist units, also include an adjunctive psychosocial component (Day et al.,
2005). Recent consensus guidance in the UK (Specialist Clinical Addiction Network
[SCAN], 2006) and in the USA (Center for Substance Abuse Treatment [CSAT],
2006) suggests that attempts to treat opioid dependence by means of pharmacologi-
cal detoxification alone have been shown to have high rates of relapse to dependent
use. An obvious consequence of a ‘failed’ detoxification treatment is the possibility
of engendering pessimism in treatment staff and service users alike. The consequence
for some service users, particularly those more vulnerable to expectations of failure,
might be a further lowering in self-efficacy and the strengthening of beliefs about the
inevitability of continued drug dependence. If treatment outcomes can be enhanced
through the quality of the therapeutic environment, the availability of adjunctive
psychosocial interventions and consequently improved interactions with staff, this
pessimism can be effectively challenged.
It has also been argued that detoxification should only be encouraged as the first
step in a longer treatment process, and needs to be integrated with relapse prevention
or rehabilitation programmes (SCAN, 2006; CSAT, 2006). Detoxification may there-
fore present a real opportunity to intervene and encourage service users to make
changes in the direction of health and recovery. Hence, a primary goal of the detoxifi-
cation staff should be to build a therapeutic alliance and motivate the service user to
enter longer-term treatment for his or her drug misuse. This process should begin even
as the service user is being medically stabilised (Onken et al., 1997).
There is good evidence (Roth & Fonagy, 2004) that the quality of the therapeutic
alliance established between staff and service user can significantly affect the treat-
ment outcome in a diverse range of disorders. The therapeutic alliance refers to the
quality of the relationship between a service user and a care provider. In addition,
‘readiness to change’ may predict a positive therapeutic alliance (Connors et al.,
2000) and there is some evidence to suggest that a positive alliance is associated with
a positive outcome in those who are dependent on alcohol or involved in methadone
maintenance (Connors et al., 1997). Encouraging engagement with a social support
network is also important, as it may be a factor in determining whether the service
user stays in treatment (Perez de los Cobos et al., 1997).
It is often argued that psychosocial interventions are an important element of
detoxification programmes (Wanigaratne et al., 2005; NTA, 2005c; CSAT, 2006). The
aim of these interventions include: supporting retention in treatment for a period long
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enough to complete detoxification; providing an opportunity to learn about how to
reduce the risk of relapse; and addressing the psychological, social and relationship
problems that may have initiated or be maintaining drug use. This is supported by
recent cohort study evidence which suggests that service users who remain in contact
after detoxification have reduced overdose mortality rates (Davoli et al., in press).
The purpose of this chapter is to review the efficacy of adjunctive psychosocial
interventions. Specifically, the chapter aims to find out whether for people who are
opioid dependent, psychosocial interventions in combination with detoxification
compared with detoxification alone are associated with increased levels of abstinence,
completion of treatment and improvements in secondary outcomes. Evidence for the
efficacy of these interventions during detoxification is relatively sparse (see Section
7.6). There is more evidence for the efficacy of these psychosocial interventions alone
and in combination with opioid agonist maintenance treatment for the treatment of
drug misuse (NCCMH, 2008). The abstinence-oriented 12-steps and related self-help
approaches, which were assessed by NICE (2007), may have an important role in
supporting those undergoing opioid detoxification and pursuing abstinence.
7.1.1 Clinical practice recommendation
7.1.1.1 Service users considering opioid detoxification should be provided with
information about self-help groups (such as 12-step groups) and support
groups (such as the Alliance); staff should consider facilitating engagement
with such services.
7.2 CURRENT PRACTICE
Currently a range of formal psychosocial interventions are available in NHS
programmes and include motivational enhancement, CBT, coping skills training,
relapse prevention, counselling/supportive-expressive psychotherapy and 12-step
approaches (Wanigaratne et al., 2005). However, the relative extent or distribution of
these interventions is not well understood and the major provision of psychosocial
interventions in the UK consists of keyworking from staff in specialist drug services.
This typically includes: assessing need (and risk); establishing and sustaining a ther-
apeutic relationship; identifying treatment goals; implementing and evaluating a
treatment plan; liaising and collaborating with other care providers; and aiming to
engage and retain the client in treatment and to support the treatment plan (for exam-
ple, using drug diaries and motivational interviewing skills) in the absence of deliv-
ering a complete episode of formal psychological therapy. Contact with service users
varies but for those in maintenance treatment, typically this would be fortnightly. 
In contrast, standard care in the US, at least as described in most of the US studies 
on detoxification (where it is often referred to as ‘drug counselling’), will involve a
more frequent level of contact, with formal psychological treatments provided much
more often.
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7.3 DEFINITIONS
Psychosocial intervention
The term psychosocial intervention is defined here as any formal structured psycho-
logical or social intervention with a clearly defined treatment plan and goals, as
opposed to advice and information, drop-in support or informal keyworking (NTA,
2005c). Interventions that aim to address a person who misuses drugs and has comor-
bid mental health problems are outside the scope of the guideline and therefore will
not be reviewed in this chapter.
Contingency management
Contingency management provides a system of reinforcers or incentives designed to
make continual drug use less attractive and abstinence more attractive (Griffith et al.,
2000). There are four primary methods of providing incentives:
● Voucher-based reinforcement: people who misuse drugs receive vouchers with
various monetary values (usually increasing in value after successive periods of
abstinence) for performing the target behaviour, for example, providing biological
samples (usually urine) that are negative for the tested drugs or compliance with
particular interventions. These vouchers are withheld when the target behaviour is
not performed, for example, the biological sample indicates recent drug use. Once
earned, vouchers are exchanged for goods or services that are compatible with a
drug-free lifestyle.
● Cash: people who misuse drugs receive cash (usually of a relatively low value, for
example, £1.50–£10) for performing the target behaviour, such as submitting a
urine sample negative for drugs or compliance with particular interventions. Cash
incentives are withheld when the target behaviour is not performed.
● Clinic privileges: participants receive clinic privileges for performing the target
behaviour, for example, providing a negative biological sample. But these 
privileges are withheld when the target behaviour is not performed. An example
of a clinic privilege is a take-home methadone dose (for example, Stitzer et al.,
1992).
● Prize-based reinforcement: participants receive draws, often from a number of
slips of paper kept in a fishbowl, for performing the target behaviour, for exam-
ple, providing a negative biological specimen. Provision of a specimen indicating
recent drug use results in the withholding of draws. Each draw has a chance of
winning a ‘prize’, the value of which varies. Typically, about half of the draws say
‘Good job!’ The other half contain prizes, which may range in value from
£1–£100 (Prendergast et al., 2006).
Community reinforcement approach
In community reinforcement, emphasis is placed on environmental contingencies in
aspects of life such as work, recreation, family involvement, and so on, to promote a
lifestyle that is more rewarding than drug misuse (Roozen et al., 2004). In almost all
studies, the community reinforcement approach for people who misuse drugs is
conducted in combination with contingency management.
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Family interventions
Family interventions are psychological interventions derived from a model of the
interactional processes in families. Interventions are aimed to help participants under-
stand the effects of their interactions on each other as factors in the development
and/or maintenance of drug misuse. Additionally, the aim is to change the nature of
the interactions so that they may develop relationships that are more supportive and
have less conflict (NICE, 2004).
Social network interventions
Professionals seek to promote change by helping the person who misuses drugs to
engage with a close network of family members or friends who provide positive
social support for attempting or maintaining abstinence (Copello et al., 2005).
Individual drug counselling
This is the assessment of an individual’s needs, provision of information and referral to
services to meet these needs (including psychosocial interventions, methadone and resi-
dential rehabilitation). No attempt is made to engage in any specific formal psychologi-
cal intervention. Sessions are normally weekly and last 15–20 minutes (Rawson et al.,
1983). This to some extent resembles keyworking as used in the UK drug treatment field.
Interpersonal therapy
IPT is a discrete, time-limited, structured psychological intervention, originally
developed for the treatment of depression, which focuses on interpersonal issues and
where therapist and service user: a) work collaboratively to identify the effects of key
problematic areas related to interpersonal conflicts, role transitions, grief and loss,
and social skills, and their effects on current drug misuse, feelings states and/or prob-
lems; and b) seek to reduce drug misuse problems by learning to cope with or resolve
interpersonal problem areas (Weissman et al., 2000).
Standard cognitive behavioural therapy
Standard CBT is a discrete, time-limited, structured psychological intervention,
derived from a cognitive model of drug misuse (Beck et al., 1993). There is an
emphasis on identifying and modifying irrational thoughts, managing negative mood
and intervening after a lapse to prevent a full-blown relapse (Maude-Griffin, 1998).
Relapse-prevention cognitive behavioural therapy
This differs from standard CBT in the emphasis on training people who misuse drugs
to develop skills to identify situations or states where they are most vulnerable to drug
use, to avoid high-risk situations, and to use a range of cognitive and behavioural
strategies to cope effectively with these situations (Carroll & Onken, 2005).
Short-term psychodynamic interventions
Short-term psychodynamic interventions are derived from a psychodynamic/ psychoan-
alytic model in which: a) therapist and service user explore and gain insight into conflicts
and how these are represented in current situations and relationships, including the 
therapy relationship; b) service users are given an opportunity to explore feelings and
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conscious and unconscious conflicts originating in the past, with the technical focus on
interpreting and working through conflicts; c) therapy is non-directive and service users
are not taught specific skills such as thought monitoring, re-evaluation or problem solving.
Treatment typically consists of 16–30 sessions (Leichsenring et al., 2004).
7.4 OUTCOMES
The two main outcomes reported in studies of detoxification are abstinence and
completion. The most important outcome in a detoxification study is abstinence, as
that is the goal of the treatment. However, completion was also considered an impor-
tant measure of detoxification success.
Although studies were examined for follow-up, most studies only provided data
up to the end of treatment. Therefore it is difficult to assess the longer-term impact of
these interventions.
All studies were examined for reported harms, which included the severity of
withdrawal symptoms, side effects of the drugs used and other physical harms to the
services users. However, such data is rarely reported in any of the included trials.
Abstinence
Abstinence is here referred to as evidence (usually measured by urinalysis) of drug
use at a particular point in time, usually at the end of treatment, although it can also
be measured at a follow-up period after treatment.
Completion of treatment
Completion has typically been defined as being retained in treatment up to the final
day of its planned duration, ingestion of the final dose of study medication or reaching
the point of zero dose of study medication.
7.5 DATABASES SEARCHED AND INCLUSION/EXCLUSION
CRITERIA
Information about the databases searched and the inclusion/exclusion criteria used for
this section of the guideline can be found in Table 22.
7.6 STUDIES CONSIDERED7
The review team conducted a new systematic search for RCTs that assessed the effi-
cacy of psychosocial interventions in combination with detoxification. Only studies
where psychosocial interventions were part of a larger integrated programme of
detoxification were included.
7Here, and elsewhere in the guideline, each study considered for review is referred to by a study ID in capital
letters (primary author and date of study publication, except where a study is in press or only submitted for
publication, then a date is not used).
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In the review of contingency management in combination with detoxification, six
trials (BICKEL1997; HALL1979; HIGGINS1984; HIGGINS1986; KATZ2004;
MCCAUL1984) met the eligibility criteria set by the GDG, providing data on 417
participants. All trials were published in peer-reviewed journals.
In the review of family interventions, one trial (YANDOLI2002) met the eligibil-
ity criteria set by the GDG, providing data on 119 participants. This trial was
published in a peer-reviewed journal.
In the review of social network interventions, one trial (GALANTER2004) met
the eligibility criteria set by the GDG, providing data on 66 participants. This trial
was published in a peer-reviewed journal.
In the review of individual drug counselling, one trial (RAWSON1983) met the
eligibility criteria set by the GDG, providing data on 50 participants. This trial was
published in a peer-reviewed journal.
Six of the included trials were of methadone detoxification (HALL1979;
HIGGINS1984; HIGGINS1986; MCCAUL1984; RAWSON1983; YANDOLI2002)
and three trials were of buprenorphine detoxification (BICKEL1997; KATZ2004;
GALANTER2004).
In addition, two studies were excluded from the analysis. The most common
reason for exclusion was lack of adequate comparison groups (further information
about both included and excluded studies can be found in Appendix 15).
Evidence from critical outcomes and overall quality of evidence are presented in
Table 23. The forest plots and full evidence profiles can be found in Appendix 16 and
Appendix 17, respectively.
Electronic databases MEDLINE, EMBASE, PsycINFO, Cochrane Library,
HMIC
Date searched Database inception to November 2006; table of 
contents December 2005–January 2007
Study design RCT
Patient population Opioid dependent
Interventions Detoxification treatments: methadone, buprenorphine,
adrenergic agonists; psychosocial treatments: 
relapse-prevention CBT, standard CBT, contingency
management, community reinforcement approach, family
interventions, social network interventions, interpersonal
therapy, short-term psychodynamic interventions, 
individual drug counselling
Outcomes Abstinence, treatment completion, severity of withdrawal
Table 22: Databases searched and inclusion/exclusion criteria 
for clinical effectiveness of psychological interventions
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7.7 PSYCHOSOCIAL INTERVENTIONS IN COMBINATION WITH
DETOXIFICATION
7.7.1 Psychosocial interventions in combination with detoxification versus
detoxification in combination with standard care
Table 23 summarises the study information and evidence from the included studies.
7.8 CLINICAL SUMMARY
Most studies assessing the efficacy of adjunctive psychosocial interventions were
focused on contingency management during community detoxification. Provision of
contingency management in the included studies usually began after stabilisation had
occurred (for example, Higgins et al., 1984; Higgins et al., 1986) and continued through-
out the detoxification process up to completion of treatment. Katz and colleagues (2004)
only provided an incentive for the completion of treatment; this is mainly due to the short
duration of the detoxification (4 days). People receiving contingency management were
more likely to be abstinent at the end of treatment and to complete treatment. This effect
was found for short-term interventions (for example, 2 weeks) and those of longer 
duration (for example, 6 months). NICE (2007) has assessed the use of contingency
management to maintain abstinence, including for people who were opioid dependent,
finding similar benefits as those summarised above and suggesting the use of this inter-
vention after, as well as during, opioid detoxification. In addition, NICE (2007) reviewed
studies concerned with the implementation of contingency management in drug treat-
ment services and the frequency of testing. It was concluded that a tapering strategy of
biological testing beginning with three tests per week for the first 3 weeks, followed by
two tests per week for the next 3 weeks, followed by one test per week for the remain-
ing treatment period was best supported by the available evidence.
The trial of family interventions consisted of 16 sessions over an indefinite period
of time beginning once every 2 weeks and then when needed (Yandoli et al., 2002).
Abstinence outcomes were reported for 12-month follow-up; participants in the
family intervention group were more likely to be abstinent than the control group but
the percentage of abstinent participants in both groups was low (family interven-
tions  14.6%; control  7.5%), suggesting benefits were minimal.
The trial of social network interventions lasted 36 sessions over a period of 18
weeks (Galanter et al., 2004). People receiving social network interventions were
more likely to be abstinent at the end of treatment compared with the control group.
However, there were no differences found between the social network interventions
and control groups for completion of treatment. This is to some extent explained by
the difficulty found by some participants in the social network group establishing a
network. Many of these participants dropped out of treatment at an early stage.
Further research is required to establish the efficacy of this intervention.
Individual drug counselling was assessed in one study and lasted three sessions
during the 3-week detoxification; it was compared with the control condition, which
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made no attempt to engage participants in additional psychosocial interventions
(Rawson et al., 1983). The adjunctive provision of individual drug counselling was not
associated with improved abstinence or compliance when compared with control, there-
fore suggesting no additional benefit of this intervention to detoxification outcomes.
7.9 LITERATURE REVIEW OF HEALTH ECONOMICS EVIDENCE
The systematic literature review identified one study that examined the cost effective-
ness of contingency management in methadone detoxification (Hartz et al., 1999).
Full references, characteristics and results of the study included in the economic
review are presented in the form of evidence tables in Appendix 14.
Hartz and colleagues (1999) examined the cost effectiveness of contingency
management in a 180-day methadone detoxification study conducted in the US.
People dependent on opioids (N  102) received either detoxification enhanced with
contingency management or the same treatment without contingency management.
All participants were stabilised to a daily dose of 80 mg of methadone for the first 
4 months, followed by a 2-month taper. When methadone doses were fully stabilised,
and before initiation of methadone tapering, those in the enhanced treatment were
more likely to provide continuously drug-free samples than those in the control
group. The incremental cost-effectiveness ratio (ICER) indicated that an additional
1% of participants were continuously substance-free during month 4 for every $17.27
treatment expenditure increase. A cost-benefit analysis estimated that for every addi-
tional dollar spent on treatment, a $4.87 healthcare cost offset was realised. However,
both of these differences described in the study were not statistically significant owing
to small sample size and considerable variation in outcomes in each arm of the trial.
Another finding of the study was that participants receiving treatment enhanced
with contingency management incurred moderate healthcare costs compared with
control participants, who were more likely to utilise either minimum services or very
high-cost services. A possible explanation is that people treated with contingency
management tended to seek more regular medical care, whereas people in the control
group possibly neglected their health and avoided treatment unless urgent.
7.10 ECONOMIC MODELLING
A decision analytic model was developed to assess the cost effectiveness of contingency
management versus standard care for people who misuse opioids receiving detoxifica-
tion treatment in the UK. Contingency management involved regular contact with a 
case worker over 13 weeks, combined with reinforcement in the form of vouchers
exchangeable for retail goods and services awarded to the service user when weekly
abstinence from opioids was achieved. Standard care consisted of less regular contact
with a case-worker over the 13-week period. The time horizon of the analysis was 26
weeks. Detoxification lasted for 13 weeks and from that point until the 26th week people
misusing drugs in both arms of the model were assumed to receive standard care.
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7.10.1 Economic model structure
The economic model consisted of three health states:
● in treatment and abstinent
● in treatment and not abstinent
● not in treatment and not abstinent.
The model was run in weekly cycles. According to the model structure, hypothetical
cohorts of the study population received the interventions under assessment and were
followed for 26 weeks. People retained in treatment were either abstinent or not absti-
nent. People who dropped out or were lost at follow-up were assumed to misuse illicit
opioids and to remain non-abstinent thereafter. Once people were found not abstinent,
they could not move back to the abstinent state. A schematic diagram of the Markov
model is presented in Figure 3.
Figure 3: Schematic structure of the economic model
7.10.2 Costs and health benefits included in the analysis
The economic analysis adopted the perspective of the NHS and personal social serv-
ices (PSS). Costs included intervention costs and additional healthcare costs such as
those associated with A&E attendances, primary and secondary care for physical
health problems, as well as mental healthcare. A further non-reference case analysis
was undertaken. This analysis, besides NHS/PSS costs, included criminal justice system
and crime victim costs, because the economic impact of drug misuse on the criminal
justice system and victims of crime was judged to be significant. The measure of
health benefit used in the analysis was the quality adjusted life year (QALY).
7.10.3 Effectiveness data used in the model
Effectiveness data for the 13-week intervention period were derived from meta-analy-
ses of RCTs that compared the effectiveness of contingency management and standard
care in illicit opioid users receiving methadone detoxification treatment. Data from
studies that reported percentages of service users receiving methadone detoxification
remaining abstinent from opioids at certain points after initiation of treatment were
utilised. Follow-up data on abstinence rates after 13 weeks of contingency management
or standard care and up to 6 months were not available in the literature for people
having undergone detoxification. Nevertheless, data on abstinent rates at the end of
intervention and at 6-months were reported in RCTs comparing contingency manage-
ment versus standard care in people receiving methadone maintenance treatment
(Epstein et al., 2003, Petry et al., 2005, Rawson et al., 2002, Silverman et al., 1998).
Following meta-analysis of these data, weekly rates of failing to remain abstinent
between completion of the intervention (either contingency management or standard
care) and 6 months were estimated and subsequently utilised in the economic model in
order to estimate the levels of abstinence of opioid users under detoxification with or
without contingency management up to 6 months. Table 24 presents the effectiveness
data used in the economic analysis and the clinical studies from which these were
derived. Details of the clinical studies on contingency management in people receiving
detoxification treatment used in the economic analysis are provided in Appendix 15.
Data on retention in treatment used in the economic analysis for the 13-week
intervention period were derived from the meta-analysis of RCTs comparing the
effectiveness of contingency management and standard care in illicit opioid users
receiving methadone detoxification treatment.
Follow-up data on retention in treatment (that is, in regular contact with health
services) at completion of the intervention and at 6 months were taken from meta-
analyses of RCTs comparing contingency management versus standard care in illicit
opioid users receiving methadone maintenance treatment (Epstein et al., 2003; 
Petry et al., 2005; Petry & Martin, 2002). These data were used to estimate weekly
drop-out rates between completion of the intervention and at 6 months. Table 25
provides the data on the retention rates used in the economic analysis and the clinical
studies from which these were derived.
Table 24: Data on abstinence rates utilised in the economic model and 
weekly rates of failing to remain abstinent at follow-up
Data derived from meta-analysis Studies included
A. Percentage of users abstinent at 1 week of treatment 
(guideline meta-analysis)
Intervention Mean 95% CI KATZ2004
CM 31.19% 22.85 to 40.88
Standard care 17.65% 11.07 to 26.73
RR 1.77 1.07 to 2.92 
(fixed effects model)
Continued
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Table 24: (Continued)
B. Percentage of users abstinent at 2 weeks of treatment 
(guideline meta-analysis)
Intervention Mean 95% CI HALL1979
CM 62.50% 45.81 to 76.83
Standard care 51.22% 35.37 to 66.85
RR 1.22 0.83 to 1.79 
(fixed effects model)
C. Percentage of users abstinent at 13 weeks of treatment 
(guideline meta-analysis)
Intervention Mean 95% CI MCCAUL1984
CM 39.13% 20.47 to 61.22
HIGGINS1986
Standard care 17.39% 5.72 to 39.55
RR 2.25 1.55 to 3.58 
(fixed effects model)
D. Percentage of users abstinent at completion of intervention 
(studies on methadone maintenance treatment)
Intervention Mean 95% CI Epstein et al., 2003
CM 40.88% 32.66 to 49.62
Petry et al., 2005 
Standard care 14.07% 8.90 to 21.35
Rawson et al., 2002 
RR 2.90 1.84 to 4.58 
Silverman et al., 1998
(fixed-effects model)
E. Percentage of users abstinent at 6 months (studies on methadone 
maintenance treatment)
Intervention Mean 95% CI Epstein et al., 2003
CM 25.55% 18.66 to 33.84
Petry et al., 2005
Standard care 13.33% 8.30 to 20.51
Rawson et al., 2002 
RR 1.88 1.15 to 3.05 
Silverman et al., 1998
(fixed-effects model)
7.10.4 Cost data
Owing to lack of patient-level cost data, deterministic costing of relevant resources
was undertaken (that is, costs were analysed as point estimates). Resource utilisation
with respect to the interventions assessed (contingency management and standard
care) was estimated by the GDG to reflect UK clinical practice. The estimate was
subsequently combined with unit prices to provide the total intervention cost. For
each intervention, the GDG estimated the frequency and duration of contacts with
case workers and the frequency of urinalysis tests (dipsticks) undertaken for the
detection of opioids. The GDG also estimated the average daily dose of methadone
administered to the service users over the detoxification period. People in the contin-
gency management arm were assumed to receive a £3 voucher for each week they
remained abstinent from opioids during the first 6 weeks of the intervention, and a £5
voucher for each week of abstinence during the next 7 weeks of the intervention.
Table 25: Data on retention in treatment utilised in the economic model
Data derived from meta-analysis Studies included
A. Percentage of users remaining in the study at 13 weeks 
(guideline meta-analysis)
Intervention Mean 95% CI HIGGINS1984
CM 65.63% 46.78 to 80.83
HIGGINS1986 
Standard care 33.33% 18.55 to 51.89
MCCAUL1984
RR 1.95 1.95 to 3.34 
(fixed effects model)
B. Retention rates at completion of intervention (studies on methadone 
maintenance treatment)
Intervention Mean 95% CI Epstein et al., 2003
CM 85.85% 77.42 to 91.60
Petry et al., 2005 
Standard care 81.65% 72.84 to 88.17
Petry & Martin, 2002
RR 1.05 0.94 to 1.18
C. Retention rates at 6-month follow-up (studies on methadone 
maintenance treatment)
Intervention Mean 95% CI Epstein et al., 2003
CM 75.47% 65.98 to 83.08
Petry et al., 2005 
Standard care 73.39% 63.92 to 81.19
Petry & Martin, 2002
RR 1.03 0.88 to 1.20
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Table 26: Resource utilisation estimates and unit costs associated 
with contingency management and standard care
Resource utilisation (GDG opinion)
CM
Weeks 1–3: three contacts per week with a case worker, lasting 30 minutes each
Weeks 4–6: two contacts per week with a case worker, lasting 30 minutes each
Weeks 7–13: one contact per week with a case worker, lasting 30 minutes each
Weeks 14–26: one contact per fortnight with a case worker, lasting 20 minutes each
Plus urinalysis (dipstick)
Weeks 1–13: once per week
Weeks 14–26: once per fortnight
Plus reinforcers:
£3 voucher per week of abstinence during the first 6 weeks in treatment
£5 voucher per week of abstinence during the following 7 weeks in treatment
Standard care
Weeks 1–13: one contact per week with a case worker, lasting 20 minutes
Weeks 13–26: one contact per fortnight with a case worker, lasting 20 minutes each
Plus: urinalysis (dipstick)
Weeks 1–13: once per week
Weeks 14–26: once per fortnight
Methadone detoxification
Weeks 1–3: 30 mg daily
Weeks 4–10: 5 mg reduction in dosage per day (week 10: 0 mg)
Weeks 10–13: placebo
Weeks 14–26: none
Unit costs Source
Case worker per hour of clinic Curtis & Netten (2006); cost of 
contact: £53 community nurse (Band 6); 
qualification costs excluded 
Urinalysis (dipstick): £1.50 Personal communication with a 
pharmacist 
Methadone oral solution 1 mg/ml: BNF 53
£0.0135/mg
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Case-worker unit costs (assumed to be equivalent to those of community nurses
paid according to Band 6) were taken from Curtis and Netten (2006). The price of
urine dipsticks was determined by personal communication with a pharmacist.
Methadone unit costs were taken from BNF 53 (March 2007). Resource utilisation
estimates and unit costs associated with contingency management and standard care
are presented in Table 26.
Further healthcare costs, including costs associated with A&E attendances, GP
visits and inpatient care for physical health problems, as well as inpatient and outpa-
tient mental healthcare, were based on resource use data derived from the NTORS
study (Gossop et al., 1998). Using these data, Godfrey and colleagues (2002) esti-
mated the annual healthcare costs incurred by Class A problem drug users in England
and Wales, excluding treatment for dependence. Costs were reported separately for
drug users not in treatment for dependence, for those in treatment for less than a year,
and for those in treatment for more than a year. Costs relating to the first two cate-
gories of users were utilised in the economic analysis. Table 27 provides healthcare
resource use estimates and respective costs incurred by drug users in England and
Wales as reported in Godfrey and colleagues (2002).
From Table 27 it can be seen that healthcare costs are higher for users in treatment
than for those not in treatment. This finding suggests that increasing the number of
users in treatment may result in an increase in healthcare costs in the short term. In
addition, healthcare costs estimated by Godfrey and colleagues (2002) were not
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Table 27: Annual healthcare resource use and costs incurred by Class A
problem drug users in England and Wales (Godfrey et al., 2002; 2000 prices;
costs in brackets refer to lowest and highest estimates)
A. Drug users not in treatment
Type of healthcare Annual resource use per user Annual cost per user
Primary care 3.6 GP visits £65
A&E 0.7 episodes £197
Inpatient care 1.75 days £390
Community mental health 1.3 visits £65
Inpatient mental health 1.5 days £216
Total £933 (£780–£1,400)
B. Drug users in treatment for less than a year
Type of health care Annual resource use per user Annual cost per user
Primary care 5.6 GP visits £101
A&E 0.8 episodes £226
Inpatient care 2.8 days £624
Community mental health 0.8 visits £40
Inpatient mental health 0.4 days £58
Total £1,049 (£873–£1,572)
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Table 28: Annual criminal justice system and crime victim costs incurred by
Class A problem drug users in England and Wales (Godfrey et al., 2002; 2000
prices; costs in brackets refer to lowest and highest estimates)
A. Drug users not in treatment
Criminal justice system cost £7,037 (£5,864–£10,556)
Victim costs of crime £30,827 (£25,691–£46,242)
TOTAL £37,864 (£31,555–£56,798)
B. Drug users in treatment for less than a year
Criminal justice system cost £8,397 (£6,997–£12,582)
Victim costs of crime £8,893 (£7,417–£13,357)
Total £17,290 (£14,414–£25,939)
adjusted to take into account the impact of current drug use on future healthcare
demands. As a consequence, potential future costs from infectious disease risks
among drug users have not been included in the above estimates of healthcare costs
and, hence, in the economic analysis undertaken for this guideline.
Godfrey and colleagues (2002) did not report data on PSS costs associated with drug
misuse; for this reason, such costs have been assumed to be negligible in the economic
analysis. Criminal justice system and crime victim costs, which were included in the
non-reference case analysis, were available in Godfrey and colleagues (2002). Criminal
justice system costs included costs associated with drug arrests, arrests for acquisitive
crimes, stays in police custody, appearances in court, and stays in prison. Crime victim
costs referred to material or physical damage and loss, expenditures taken in anticipa-
tion of crime, and the wider fear of criminal elements. Table 28 provides estimates of
crime-related costs for people who misuse drugs not in treatment and for those in treat-
ment for less than a year, as reported in Godfrey and colleagues (2002).
It should be noted that the amount of healthcare costs and crime-related costs
incurred by people who misuse drug as reported in Godfrey and colleagues (2002)
exclusively depended on whether they were engaged in treatment or not; the impact
of effectiveness of treatment (in terms of achieving abstinence from drug misuse) on
these costs was not discussed in the study; therefore, the economic analysis under-
taken for this guideline has not differentiated between abstinent users and non-
abstinent users in treatment at estimation of costs.
Healthcare costs were adjusted to 2006 prices using the hospital and community
health services (HCHS) pay and price inflation rates (Curtis & Netten, 2006). The
inflation rate for 2005/2006 was estimated using the average value of the HCHS pay
and price inflation rates of the previous 3 years. Crime-related costs were adjusted to
2006 prices using the Retail Prices Index (Office for National Statistics, 2007).
7.10.5 Utility data
Utility values required for the estimation of QALYs were derived from data reported
in two recent NHS Health Technology Assessments of methadone and buprenorphine,
and of oral naltrexone for the management of opioid-dependent drug users (Connock
et al., 2007, Adi et al., 2007). Utility data in these studies were obtained by a panel
of members of the public, co-ordinated by the Peninsula Technology Assessment
Group (PenTAG). The panel made valuations of given health states via the Value of
Health Panel website using the standard gamble technique. The utility values result-
ing from this exercise, which were used in the economic analysis performed in this
guideline, are presented in Table 29.
Table 29: Utility values used in the economic analysis 
(Connock et al., 2007, Adi et al., 2007)
Health state Utility value (range)
In treatment–drugs free 0.8673 (0.525–1)
In treatment–drugs reduction Injectors: 0.6332 (0.275–0.935)
Not in treatment–drug misusers Injectors: 0.5880 (0.125–0.960)
Psychosocial interventions in opioid detoxification
165
7.10.6 Sensitivity analysis
In addition to the base-case analysis, which utilised the most accurate data available,
a sensitivity analysis was undertaken to investigate the robustness of the results under
the uncertainty characterising the model input parameters. Selected parameters were
varied over a range of values and the impact of these variations on the results was
explored. The following scenarios were tested in sensitivity analysis:
● Change in the RRs of the percentage abstinence during treatment or at follow-up
of service users receiving contingency management versus standard care. The
95% CIs of RRs calculated in the guideline meta-analyses, as shown in Table 24,
were used. Two scenarios examined the simultaneous use of the lower 95% CIs
and the upper 95% CIs of all estimated RRs, respectively.
● Changes in the total value of vouchers received by abstinent service users undergo-
ing contingency management. A 100% increase and a 50% decrease were examined.
● Changes in the additional (that is, besides intervention costs) healthcare and
crime-related costs. Lowest and highest estimates reported in Godfrey and
colleagues (2002), as shown in Table 27 and Table 28, were used.
● Exclusion of crime victim costs from the non-reference case analysis, as crime
victim costs differed greatly between users in treatment (£8,893) and users not in
treatment (£30,827) in Godfrey and colleagues (2002).
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7.10.7 Results
Base-case analysis
Contingency management was cost effective over 26 weeks. The ICER of contin-
gency management versus standard care was £15,753/QALY from an NHS/PSS
perspective. From a wider perspective including criminal justice system and crime
victim costs, detoxification with contingency management dominated standard detox-
ification; it was more effective and cheaper at the same time. Full results of the analy-
sis are provided in Table 30.
Table 30: Results of the economic analysis: total average costs and 
QALYs per user under contingency management or 
standard care, over a year of follow-up
Intervention Average Average total Average ICER of 
total cost cost (NHS/PSS number  contingency 
(NHS/PSS) plus crime- of QALYs management versus
related) standard care
Contingency £1,216 £14,910 0.34 
management
Standard care £807 £17,654 0.32 
Difference £4088 £2,744 0.03
8The figures in the model were calculated using many decimal places and some figures are rounded.
£15,700/QALY
(NHS/PSS)
Contingency
management 
dominates
(NHS/PSS plus
crime-related)
Sensitivity analysis
From a NHS/PSS perspective, results were sensitive to changes in the RRs of the
percentage abstinence achieved by users receiving contingency management versus
standard care. When the lower 95% CIs of all estimated RRs were used, the ICER of
contingency management versus standard care became £22,225/QALY. It must be
noted, though, that the base-case results were less sensitive under changes in the RRs
of abstinence rates referring to the 13-week intervention period only (that is, when RRs
of abstinence rates achieved at follow-up remained intact). In this case, the ICER of
contingency management versus standard care was £20,732/QALY, which is very
close to the cost-effectiveness threshold of £20,000/QALY set by NICE (NICE, 2005).
The ICER was robust in changes in the value of reinforcing vouchers, as well as
in the use of lowest and highest estimates of healthcare costs reported in Godfrey and
colleagues (2002).
When a wider perspective that included crime-related costs was considered (non-
reference case analysis), contingency management was the dominant option under all
scenarios explored.
Full results of the one-way sensitivity analysis are provided in Table 31.
In addition to one-way sensitivity analyses, a threshold analysis was undertaken in
order to explore the impact of using follow-up data on abstinence and retention rates from
RCTs assessing contingency management in users receiving methadone maintenance
treatment rather than detoxification treatment, owing to a lack of more relevant data. For
this purpose, the estimated relative risk of failing to remain abstinent of contingency
management versus standard care at follow-up was varied. This RR equalled 8.46 in the
base-case analysis; threshold analysis showed that it had to reach 37.17 in order for the
ICER of contingency management versus standard care to exceed the £20,000/QALY set
threshold. Likewise, the estimated relative risk of dropping out at follow-up of contin-
gency management versus standard care was 1.21; threshold analysis revealed that this
figure had to rise to 12.19 in order for the ICER of contingency management versus stan-
dard care to exceed the £20,000/QALY threshold. It is unlikely that both RRs (either of
failing to remain abstinent or of dropping out of treatment at follow-up), are substantially
different between service users receiving detoxification treatment and those receiving
methadone maintenance treatment, and it is highly unlikely that they approximate to the
cut-off points identified in threshold analyses; therefore, use of follow-up data from the
methadone maintenance treatment population seemed to be a safe assumption.
Limitations of the economic analysis and overall conclusions
The results of the analysis are subject to various limitations. Since follow-up data 
on abstinence and retention rates were not available for service users undergoing
Table 31: Results of sensitivity analysis
Input parameter varied Results – NHS/PSS Results – non-reference 
analysis case analysis
RRs of abstinence
Lower 95% CIs £26,623/QALY Contingency management
dominates standard care
Upper 95% CIs £9,347/QALY Contingency management
dominates standard care
Costs of vouchers
100% increase £16,465/QALY Contingency management 
dominates standard care
50% decrease £15,317/QALY Contingency management
dominates standard care
Additional healthcare 
and crime-related costs
Lowest estimates £15,557/QALY Contingency management 
dominates standard care
Highest estimates £16,070/QALY Contingency management
dominates standard care
Exclusion of crime N/A Contingency management 
victim costs dominates standard care
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detoxification receiving contingency management or standard care, we used data 
from service users receiving methadone maintenance treatment, contingency manage-
ment or standard care. Threshold analysis showed that it was safe to make such an
assumption because the estimated relative risks of contingency management versus
standard care in service users receiving methadone maintenance treatment regarding
failure to remain abstinent and dropping out of treatment should be substantially
increased before contingency management ceased to be a cost-effective option. It is
unlikely that these relative risks are so much higher in service users undergoing
detoxification compared with those receiving methadone maintenance treatment. It
has to be acknowledged, though, that methadone maintenance treatment and detoxi-
fication are two interventions with different approaches and aims so the study popu-
lations may present differences in terms of abstinence levels and rates of retention in
treatment at follow-up. In addition, in order to construct the economic model it was
assumed that once service users were found to misuse opioids, they continued misus-
ing opioids and did not achieve abstinence thereafter. This assumption is rather
conservative and may not accurately reflect abstinence trends among users over time.
The time horizon of the analysis is very limited (only 6 months) owing to lack of
data allowing further extrapolation. Retention and abstinence rates at the end of
detoxification and at 6-month follow-up were higher for the contingency management
group. So, limiting the time horizon at 6 months may be a conservative approach that
underestimates the cost effectiveness of detoxification with contingency management
in the long term.
Intervention costs were based on GDG estimates of relevant resource use, owing
to lack of research-based data. Other healthcare costs, as well as crime-related costs
that were included in the non-reference case analysis, were derived from Godfrey and
colleagues (2002), who estimated such costs based on UK resource use data.
According to the study, these costs depended exclusively on retention of people who
misuse drugs in treatment, and were not affected by levels of abstinence achieved 
by treatment. This is a rather conservative assumption, at least in the longer term. 
If remaining in abstinence for longer periods reduces healthcare resource use and costs
related to crime, then the cost effectiveness of contingency management is greater than
that estimated in this analysis, since contingency management is more effective than
standard care in achieving higher rates and longer periods of abstinence.
Long-term healthcare costs incurred by drug misuse, such as costs associated with
infectious disease risks among injecting drug misusers, were not considered in the
economic analysis, as no data were available in the literature. However, some of these
costs have already been taken into account in the estimation of healthcare costs of
drug misusers reported by Godfrey and colleagues (2002). Voluntary sector costs,
social service costs and productivity losses were not included in the analysis. If all
these cost elements are expected to be lower when higher rates of abstinence are
achieved, then contingency management is likely to be more cost effective than the
findings of the analysis suggest.
Contingency management was shown to be a cost-effective option under most
scenarios explored from an NHS/PSS perspective. Results were only sensitive to the
uncertainty characterising the effectiveness data on people who misuse drugs under
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maintenance methadone treatment at 6-month follow-up. On the other hand, when a
wider perspective including criminal justice and crime victim costs was considered,
contingency management was cost-effective (dominant option) under all scenarios tested
in sensitivity analysis. In conclusion, despite the limitations of the analysis, the results
indicate that contingency management is likely to be a cost effective option for users of
illicit opioids undergoing methadone detoxification treatment, especially when the wider
economic, social and public health consequences of drug misuse are considered.
7.11 CLINICAL PRACTICE RECOMMENDATIONS
7.11.1.1 Contingency management aimed at reducing illicit drug use should be
considered both during detoxification and for up to 3–6 months after
completion of detoxification.
7.11.1.2 Contingency management during and after detoxification should be based
on the following principles.
● The programme should offer incentives (usually vouchers that can be
exchanged for goods or services of the service user’s choice, or privi-
leges such as take-home methadone doses) contingent on each presen-
tation of a drug-negative test (for example, free from cocaine or
non-prescribed opioids).
● If vouchers are used, they should have monetary values that start in the
region of £2 and increase with each additional, continuous period of
abstinence.
● The frequency of screening should be set at three tests per week for the
first 3 weeks, two tests per week for the next 3 weeks, and one per week
thereafter until stability is achieved.
● Urinalysis should be the preferred method of testing but oral fluid tests
may be considered as an alternative.
7.11.1.3 Staff delivering contingency management programmes should ensure that:
● the target is agreed in collaboration with the service user
● the incentives are provided in a timely and consistent manner
● the service user fully understands the relationship between the treatment
goal and the incentive schedule
● the incentive is perceived to be reinforcing and supports a healthy/drug-
free lifestyle.
7.11.1.4 Drug services should ensure that as part of the introduction of contingency
management, staff are trained and competent in appropriate near-patient
testing methods and in the delivery of contingency management.
7.11.1.5 Contingency management should be introduced to drug services in the
phased implementation programme led by the National Treatment Agency
for Substance Misuse (NTA), in which staff training and the development
of service delivery systems are carefully evaluated. The outcome of this
evaluation should be used to inform the full-scale implementation of
contingency management.
Settings for opioid detoxification 
170
8. SETTINGS FOR OPIOID DETOXIFICATION
8.1 INTRODUCTION
Detoxification from opioids takes place in a variety of settings, including the com-
munity, inpatient units, residential units and prisons. Although there are no precise
data, it has been estimated that if those taking place in prison are excluded, at least
90% of opioid detoxifications take place in the community, with only a very small
number being treated as inpatients. The NDTMS (2003–2004) reports that 3% of all
drug service users receive inpatient or residential detoxification, but there is no
specific data on community-based detoxification or what proportion were opioid
cases (NTA, 2005a). In addition, approximately 56,000 service users currently
undergo detoxification in prison every year (DH, 2006). In the past few years, there
has been an increasing emphasis on legally sanctioned treatment, which may include
detoxification, both under coerced conditions as Drug Rehabilitation Requirements
(formerly DTTOs) and under voluntary conditions as the Drug Interventions
Programme (DIP).
Inpatient detoxification is expensive to provide and this has led to a reduction in
its availability—in some areas of England and Wales provision is almost non-existent
despite recommendations that it should be available (NTA, 2002, 2005c). Community-
based detoxification is available both through specialist drug services and some
primary care services.
Currently, the evidence for the importance of setting in affecting the outcome for
detoxification is very sparse, with little research being available to guide clinicians
about the service and setting in which users are likely to do well. In addition, for
some, such as those in prison, it is helpful to know whether detoxification treatments
are likely to be clinically useful, as goals for this group of service users may differ
from their counterparts in the community.
Treatment settings in England and Wales
Detoxification in community settings has traditionally divided into specialist and
primary-care-based services. Specialist services, often known as community drug
teams, are multidisciplinary and are led by an addiction psychiatrist or another addic-
tion specialist and are staffed by professionals from a range of disciplines, including
medicine, nursing, psychology and social work, and drug workers (usually graduates
with experience and qualifications in treating drug users). Primary care encompasses a
range of treatment models, from the GP providing the treatment with no support, to drug
workers or nurses working with a GP in a surgery, to services that resemble a commu-
nity drug team with a doctor from a primary care background providing the leadership.
Another important community setting is the criminal justice treatment service.
Service users treated in the DIP will in most cases receive the same treatment in the
community drug team or primary care drug services as non-DIP service users, there-
fore any differences in outcome would not be attributed to the setting.
Detoxification can take place in inpatient or residential settings. As noted above,
inpatient detoxification has a limited availability but involves a medically led multi-
disciplinary team with a full nursing team. In some areas, the inpatient beds are
located on a psychiatric ward with no specialist provision for detoxification. In addi-
tion, some voluntary and private residential units also provide medically managed
care with high staff levels, including 24-hour nursing and medical cover (SCAN,
2006). Other settings may offer medically monitored detoxification but often lack
both 24-hour nursing and medical cover. Although some units in England run by the
non-statutory sector provide only detoxification, most are usually rehabilitation
centres, where opioid-dependent service users may go for an extended period of
psychosocial rehabilitation and are offered detoxification as part of the programme.
The whole situation is complicated by the fact that some service users are detoxified
on general psychiatric or medical and surgical wards as they are being treated there
for other conditions (SCAN, 2006).
With very large numbers of people who misuse opioids receiving treatment in
prison each year (DH, 2006), prisons are now recommended to structure their care
into an early high-intensity phase similar to the inpatient settings already described,
with 24-hour supervision by trained healthcare staff, a second stage of continued
enhanced support and, finally, ‘outpatient’-type care back in the main prison commu-
nity. A menu of psychosocial treatment options accompanies the provision of phar-
macological treatments for 28 days after reception into prison (Home Office Drug
Strategy Directorate, 2006). Prisoners who are opioid dependent can undergo detox-
ification in any of these stages (DH, 2006). However, caution should be exercised
where the necessary stabilisation period and support required for people undergoing
detoxification in prison settings may not be possible, in situations such as short 
prison sentences, a short period of remand and for those in police custody. In such
situations, the level of assessment and monitoring for detoxification treatment may 
be limited due to time constraints and the potential for short notice of release or 
transfer.
In understanding the evidence for the effectiveness of various detoxification regi-
mens, attention should be given to the content of the intervention and the nature of
support that is provided within a community setting, for example, how much individ-
ual contact service users have with a worker, whether they are seen in their home, how
often they are seen and what services are provided.
Current practice
Service users may wish to become abstinent at any time in a period of treatment,
from initial contact with services to many years into their opioid dependence follow-
ing a long period of maintenance treatment. Accident and emergency departments
are often the first point of contact with health services for many people who misuse
drugs, who primarily attend for treatment of accidental overdose (Gossop et al.,
1995). Although this encounter presents an opportunity to refer drug users to drug
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treatment services, or to encourage them to consider addressing their drug misuse,
detoxification treatment should not normally be immediately initiated within this
setting. The majority of opioid users who want to become abstinent are offered
community detoxification as the first-line treatment. In some areas of the country,
opioid users currently have a choice between treatments offered by the local commu-
nity drug service or by their GP, although that option is not always available. There
may be considerable variation in the level of support provided during a period of
community detoxification.
Inpatient detoxification is usually only offered after community treatment has
repeatedly failed (SCAN, 2006). It is often offered before a period of residential reha-
bilitation, as many programmes require service users to be drug free before entry. It
is common practice to offer inpatient detoxification to the service users with the most
complex needs (SCAN, 2006). These are usually those with multiple dependencies
(for example, benzodiazepines and alcohol), those with dual physical and mental
health diagnoses and those who are particularly socially chaotic.
Day and colleagues (2005) conducted a survey on provision of inpatient and resi-
dential detoxification. There were an estimated 532 beds available for people detoxi-
fying from drugs in residential rehabilitation units in the UK, with a total of 1,085
admissions per year. There were estimated to be 356 specialist inpatient beds avail-
able for drug detoxification, with an estimated 6,829 annual admissions. In addition,
there were an estimated 103 beds available in non-specialist psychiatric or medical
wards, with a total of 2,077 admissions per year for drug detoxification. This resulted
in a combined estimate of 10,711 annual admissions for people who misuse drugs in
inpatient and residential treatment (Day et al., 2005).
8.1.1 Clinical practice recommendation
8.1.1.1 Opioid detoxification should not be routinely offered to people:
● with a medical condition needing urgent treatment
● in police custody, or serving a short prison sentence or a short period of
remand; consideration should be given to treating opioid withdrawal
symptoms with opioid agonist medication
● who have presented to an acute or emergency setting; the primary
emergency problem should be addressed and opioid withdrawal symp-
toms treated, with referral to further drug services as appropriate.
8.2 INPATIENT AND COMMUNITY-BASED SETTINGS
8.2.1 Databases searched and inclusion/exclusion criteria
Information about the databases searched and inclusion/exclusion criteria can be
found in Table 32.
8.2.2 Studies considered9
The review team conducted a new systematic search for RCTs and observational 
studies that assessed the efficacy of detoxification in inpatient, residential and
community-based settings.
In the review comparing inpatient/residential detoxification with community-
based detoxification, three trials (DAY2006; GOSSOP1986; WILSON1975) met the
eligibility criteria set by the GDG, providing data on 171 participants. Two trials
(GOSSOP1986; WILSON1975) were published in peer-reviewed journals and one
trial (DAY2006) was unpublished.
In the review comparing specialist inpatient detoxification and generic inpatient
detoxification, one trial (Strang et al., 1997b) met the eligibility criteria set by the
GDG, providing data on 99 participants. This trial was published in a peer-review
journal.
In the review comparing detoxification in a specialist community-based drug
clinic and detoxification in a community-based primary care clinic, one trial met the
criteria set by the GDG (Gibson et al., 2003), providing data on 115 participants. This
trial was published in a peer-reviewed journal.
Evidence from critical outcomes and overall quality of evidence are presented in
Table 33. The forest plots and full evidence profiles can be found in Appendix 16 and
Appendix 17, respectively.
In addition, two studies were excluded from the analysis. The most common
reason for exclusion was lack of adequate comparison groups (further information
about both included and excluded studies can be found in Appendix 15).
Electronic databases MEDLINE, EMBASE, PsycINFO, Cochrane Library,
HMIC
Date searched Database inception to November 2006; table of
contents November 2005–January 2007
Study design RCT
Observational studies
Patient population Opioid dependent
Interventions Detoxification in the following settings: inpatient,
community, residential
Outcomes Abstinence, treatment completion
Table 32: Databases searched and inclusion/exclusion criteria for clinical
effectiveness of inpatient, residential and community detoxification
Settings for opioid detoxification
173
9Here, and elsewhere in the guideline, each study considered for review is referred to by a study ID in 
capital letters (primary author and date of study publication, except where a study is in press or only
submitted for publication, then a date is not used).
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8.2.3 Inpatient detoxification versus community-based detoxification
Three trials were identified that compared inpatient and community-based detoxifica-
tion. The two RCTs (DAY2006; WILSON1975) were meta-analysed and summarised
below (see Table 33). The third trial, which did not provide separate data for patient
preference and randomised samples, was reported separately.
Table 33 shows that participants receiving inpatient detoxification were more
likely to complete their detoxification than those receiving this treatment in the
community (RR  1.60; 95% CI, 1.05 to 2.42). However, this should be interpreted
with caution as results are more modest (RR  1.38; 95% CI, 0.79 to 2.42) for the
recent UK trial (DAY2006) in comparison with Wilson and colleagues’ (1975) earlier
US trial (RR  1.91; 95% CI, 1.03 to 3.55). A number of additional problems with
the data from Wilson and colleagues (1975) limit the strength of the conclusions that
can be drawn. There is evidence that data from the urine samples were not reliable: a
small number of urines were tested in the hospital group, and 42.9% were reported to
be contaminated. Therefore comparisons between the two groups on continuing drug
use are problematic. Furthermore, the restricted starting dose of methadone (40 mg in
the first 24 hours) limits the applicability of this study to current practice, where much
higher doses are now recommended (DH, 1999) and may further suggest the lack of
applicability of this trial to current UK clinical practice.
A third trial considered in this review (Gossop et al., 1986) was not included in
the meta-analysis because randomised and non-randomised data were combined. 
This trial also compared people receiving inpatient detoxification with those who
received community-based detoxification and, consistent with the data above, 
found statistically significant differences between inpatient and community-based
Inpatient detoxification versus community-
based detoxification
Total no. of trials 2 RCTs 
(total no. of participants) (N  111)
Study ID DAY2006 WILSON1975
Length of follow-up End of treatment
Evidence profile table Table A17-19
number (Appendix 17)
Overall quality of evidence Low
Completion of detoxification 53% versus 36%, RR 1.60 (1.05 to 2.42)
K  2, N  111
Table 33: Summary evidence table for inpatient detoxification 
compared with community-based detoxification
RR  1 favours inpatient detoxification.
detoxification. Sixty participants, who were opioid dependent, elected to receive
either inpatient or community-based detoxification. Participants were assigned to one
of four groups: preferred inpatient, preferred community-based, randomised inpatient
and randomised community-based. Forty participants expressed strong preferences
and were assigned to the appropriate groups. The remaining 20 subjects were
randomly assigned to one of the randomised groups. Differences between inpatient
and community-based settings were much more pronounced in this trial compared
with the other RCTs (DAY2006; WILSON1975). In total, 81% of the inpatient group
were successfully detoxified from opioids compared with 17% in the community-
based group (RR  4.68; 95% CI 2.07 to 10.58).
The main finding of the study was that supervised inpatient detoxification was
more successful than the community-based comparison group. However, there are two
main problems with this study. Firstly, data comparing outcomes in the community-
based and inpatient settings were combined from participants who were assigned by
preference and participants who were randomly assigned. There was a strong trend
favouring participants in the preferred group (RR  1.64; 95% CI 0.85 to 3.16). In
addition, the level of support and therapy within the inpatient group was significantly
higher, although of a shorter duration (21 days), whereas the community-based detox-
ification programme was for 8 weeks and no support was provided outside the clinic.
The evidence base comparing detoxification in inpatient and community-based
settings is limited. There is some evidence suggesting inpatient detoxification is more
effective than community-based detoxification. But two of the three trials
(WILSON1975; Gossop et al., 1986) had significant methodological limitations that
make these findings difficult to interpret.
8.2.4 Specialist inpatient versus generic inpatient
One RCT was identified that compared detoxification in specialist and generalist
settings. Strang and colleagues (1997b) compared outcomes from people with opioid
dependence receiving detoxification in a specialist drug dependency unit with those on
a general psychiatric ward. A total of 186 participants were randomised to the waiting
list for treatment in either a drug dependency unit (n  115) or a general psychiatric
ward (n  71). However, only 69 in the drug dependency unit group and 30 in the
general psychiatric ward group remained after the waiting list period to enter inpatient
treatment. A total of 75% completed detoxification in the drug dependency unit,
compared with 43% in the general psychiatric ward (RR  1.74; 95% CI 1.13 to 2.68).
Follow-up at 7 months found a trend favouring greater abstinence (27.5%) in the
drug dependency unit group compared with the general psychiatric ward group
(13.3%) (RR  2.07; 95% CI 0.77 to 5.55).
A number of significant limitations to this study raise questions as to whether
differences in outcome were due to the setting or some other confounding factor and
therefore preclude any specific recommendations arising from this study. Firstly,
different medication was used for detoxification in the drug dependency unit
(methadone) and general psychiatric ward (clonidine) groups; therefore there is some
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uncertainty over whether the reported differences in outcome were due to the setting
or the medication. In addition, all participants had previously been referred to a
specialist service, thus allocation to a general psychiatric ward may have contributed
towards resistance, a higher dropout rate and poorer outcomes.
8.2.5 Specialist community-based versus generic community-based
Only one study (Gibson et al., 2003) from Australia compared community-based
buprenorphine detoxification in a specialist clinic setting with a similar regimen in a
primary care setting (5-day detoxification with assessment on day 8). Participants
attended daily to receive a supervised dose of buprenorphine. The primary care group
received their doses from the GP’s surgery on weekdays and from the specialist clinic
at weekends. The specialist clinic group received all their doses from this setting. At
each visit, practitioners were encouraged to review side effects, dose adequacy,
participants’ goals and post-detoxification treatment options. They found that the
settings had similar efficacy and cost effectiveness: with 71% completing detoxifica-
tion in the primary care setting and 78% in the specialist clinic setting (RR  1.09;
95% CI, 0.88 to 1.35). Additionally, 23% reported no opioid use during detoxification
treatment in the primary care group compared with 22% in the specialist clinic group
(RR  0.95; 95% CI, 0.48 to 1.87).
There are no published UK studies comparing detoxification in primary and
secondary care, although the above study would suggest there are no differences in
outcome or cost effectiveness between primary and secondary care settings.
8.2.6 Predictors of outcome in inpatient settings
Information about the databases searched and inclusion/exclusion criteria can be
found in Table 34.
Electronic databases MEDLINE, EMBASE, PsycINFO, Cochrane Library, HMIC
Date searched Database inception to November 2006; table of contents
November 2005–January 2007
Study design RCT
Observational studies
Patient population Opioid dependent
Interventions Detoxification in the following settings: inpatient,
residential
Outcomes Abstinence, treatment completion
Table 34: Databases searched and inclusion/exclusion criteria for 
predictors of outcome in inpatient detoxification
In the review of predictors of outcome for inpatient settings, five studies met the
criteria set by the GDG (Araujo et al., 1996; Backmund et al., 2001; Franken &
Hendriks, 1999; Hattenschwiler et al., 2000; Perez de los Cobos et al., 1997). All
studies were published in peer-reviewed journals.
Several studies have looked at both service user and programme factors that may
predict outcome in service users presenting for inpatient detoxification. Franken and
Hendriks (1999) in a study of 175 service users found that greater severity of drug use
was associated with lower completion rates for inpatient detoxification (OR  9.0;
95% CI, 4.50 to 17.75). Similarly, in a study of 275 service users entering inpatient
detoxification, Perez de los Cobos and colleagues (1997) found more frequent
cocaine use was associated with discharge against medical advice from a detoxifica-
tion programme (OR  3.81; 95% CI, 1.30 to 11.04). Franken and Hendriks also
found that severe physical health problems predicted poor completion outcomes
(OR  9.3; 95% CI, 4.72 to 18.63). Backmund and colleagues (2001) reviewed the
records of 1,070 patients admitted for inpatient detoxification and found that
outcomes were better in service users already on methadone maintenance treatment
(50.4% completed) compared with those (35.9%) who primarily injected heroin
(RR  1.40, 95% CI, 1.11 to 1.77). Measures of social stability, such as lack of social
integration (r  0.26) (Hattenschwiler et al., 2000) and being single (2  4.32, 
p 	 .05) (Perez de los Cobos et al., 1997), were also associated with poor completion
outcomes.
Process factors such as the perceived suitability (F  16.63, p 	 0.001) of a treat-
ment programme (Franken & Hendriks, 1999) were found to predict positive comple-
tion outcomes. Backmund and colleagues (2001) found a positive dose–response
relationship between the amount of psychosocial or psychotherapeutic support and
completion of detoxification.
Regarding psychopathology as a possible predictor, Araujo and colleagues 
(1996) failed to show any relationship between anxiety (SMD  0.16; 95% 
CI, 0.18 to 0.50) or depression (SMD  0.07; 95% CI, 0.27 to 0.41) in comple-
tion of detoxification. Franken and Hendriks (1999) found that psychopathology,
coping styles and sociodemographic variables failed to predict the outcome of 
detoxification.
The studies considered above are process studies only, with no formal clinical
trials available. It would seem that using fewer combinations of drugs in lower quan-
tities and being more socially stable at admission predicts a better outcome from inpa-
tient detoxification. There seems to be an uncertain relationship between
psychopathology and outcome. However, it should be noted that, although the stud-
ies suggest that service users with better prognostic factors do well, there is no
research to address whether people with poorer prognostic factors would benefit
greater from alternative treatment settings or additional input in those settings. Some
participants may have had poor prognostic factors, compared with other participant
groups, but still benefited more from inpatient treatment than they would have done
in the community.
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8.2.7 Literature review of health economics evidence
The systematic literature review identified two studies that assessed the cost effective-
ness of detoxification treatment in different settings (Gossop & Strang, 2000 and
Shanahan et al., 2006). Full references, characteristics and results of all studies included
in the economic review are presented in the form of evidence tables in Appendix 14.
Gossop and Strang (2000) performed a reanalysis of data from two randomised
trials assessing opioid detoxification treatments in different settings. A crude economic
analysis was done, using completion rates as the outcome measure against which costs
were examined. In the first analysis, the cost of the inpatient detoxification was 24
times more than that of the outpatient treatment, but when adjusted for successful
achievement for abstinence costs were almost identical.
In the second analysis, completion rates were 45% and 18% of the original
cohort for the specialist inpatient unit and the general psychiatric ward respectively.
Costs in the specialist unit were three times more than the general ward, but after
accounting for completion rates the ratio was 1.9:1. Even though the analysis was
based on crude estimates and may have not expanded to other settings, the authors
concluded that provision of 10-day inpatient detoxification was as cost effective as
the outpatient detoxification programme. In addition, they suggested that inpatient
detoxification was easier and cheaper to run in a general psychiatric ward rather than
in a specialist unit.
A cost-effectiveness analysis of heroin detoxification methods in Australia was
performed by Shanahan and colleagues (2006). Five inpatient and outpatient detoxi-
fication methods were compared using data from four trials involving 365 people
using heroin. The study assessed the achievement of an initial 7-day period of absti-
nence as well as entry into ongoing post-detoxification treatment. The base compara-
tor for the analysis was conventional outpatient detoxification; other comparators
included: conventional inpatient, rapid detoxification under sedation, rapid detoxifi-
cation under anaesthesia and buprenorphine. Mean costs for all methods analysed
were calculated. Buprenorphine outpatient detoxification was the least expensive
method per episode ($491), the most expensive being rapid detoxification under
anaesthesia ($2,689). In terms of abstinence, rapid detoxification under anaesthesia
and rapid detoxification under sedation were equivalent (59%) with levels of absti-
nence significantly higher than conventional inpatient (24%), buprenorphine (12%)
and conventional outpatient (4%). The incremental cost-effectiveness analysis found
that buprenorphine-based outpatient detoxification was the most cost effective over-
all. Indeed, buprenorphine was the only treatment that at the same time was more
effective and less costly than the base comparator, conventional outpatient. Rapid
opioid detoxification under sedation was the most cost-effective inpatient method.
The choice of setting for opioid detoxification has major resource implications.
Effectiveness data comparing inpatient versus community detoxification are poor and do
not indicate significant differences between them in terms of abstinence. Inpatient treat-
ment is substantially more expensive compared with community detoxification, due to
hospitalisation costs and more intensive pharmacological regimes. As a consequence,
and in light of the very poor evidence for increased cost effectiveness for inpatient 
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services and the lack of information on particular patient sub-groups, the current data
would suggest that community detoxification should be provided as first-line treatment.
8.2.8 Clinical practice recommendations
The choice of setting for detoxification
8.2.8.1 Staff should routinely offer a community-based programme to all service
users considering opioid detoxification. Exceptions to this may include
service users who:
● have not benefited from previous formal community-based detoxification
● need medical and/or nursing care because of significant comorbid
physical or mental health problems
● require complex polydrug detoxification, for example concurrent
detoxification from alcohol or benzodiazepines
● are experiencing significant social problems that will limit the benefit of
community-based detoxification.
8.2.8.2 Residential detoxification should normally only be considered for people
who have significant comorbid physical or mental health problems, or who
require concurrent detoxification from opioids and benzodiazepines or
sequential detoxification from opioids and alcohol.
8.2.8.3 Residential detoxification may also be considered for people who have less
severe levels of opioid dependence, for example those early in their drug-
using career, or for people who would benefit significantly from a residen-
tial rehabilitation programme during and after detoxification.
8.2.8.4 Inpatient, rather than residential, detoxification should normally only be
considered for people who need a high level of medical and/or nursing
support because of significant and severe comorbid physical or mental
health problems, or who need concurrent detoxification from alcohol or
other drugs that requires a high level of medical and nursing expertise.
8.2.8.5 Following successful opioid detoxification, and irrespective of the setting
in which it was delivered, all service users should be offered continued
treatment, support and monitoring designed to maintain abstinence. This
should normally be for a period of at least 6 months.
Delivering detoxification
8.2.8.6 Community detoxification should normally include:
● prior stabilisation of opioid use through pharmacological treatment
● effective coordination of care by specialist or competent primary 
practitioners
● the provision of psychosocial interventions, where appropriate, during
the stabilisation and maintenance phases.
8.2.8.7 Inpatient and residential detoxification should be conducted with 24-hour
medical and nursing support commensurate with the complexity of the serv-
ice user’s drug misuse and comorbid physical and mental health problems.
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Both pharmacological and psychosocial interventions should be available
to support treatment of the drug misuse as well as other significant comor-
bid physical or mental health problems.
8.2.9 Research recommendation – comparing inpatient or residential and
community detoxification
8.2.9.1 Is inpatient or residential detoxification associated with greater probability
of abstinence, better rates of completion of treatment, lower levels of
relapse and increased cost effectiveness than community detoxification?
Why this is important
There have been some studies comparing inpatient or residential detoxification with
community detoxification. However, these studies are often based on small sample
sizes, have considerable methodological problems and have produced inconsistent
results. Inpatient or residential detoxification requires significantly more resources than
community detoxification, so it is important to assess whether treatment in such settings
is more clinically and cost effective. If so, it is also important to understand if there are
particular subgroups that are more likely to benefit from treatment in these settings.
8.3 UNASSISTED/SELF-DETOXIFICATION
Unassisted or self-detoxification, defined as ‘the deliberate attempt to achieve absti-
nence from drugs which is sustained for longer than 24 hours in the absence of clin-
ical assistance’ (Gossop et al., 1991; Noble et al., 2002), has been a subject of
concern for some time, not least because it is clear from epidemiological studies that
a significant number of people stop misusing opioids without formal treatment.
However, it is not clear if these people who attempt to self-detoxify are likely to expe-
rience more harm or to be less successful than those undergoing professional detoxi-
fication procedures. In addition, the study of unassisted detoxification may provide
some understanding of what contributes to successful detoxification and thereby
potentially improve the outcomes for assisted detoxifications.
8.3.1 Databases searched and inclusion/exclusion criteria
Information about the databases searched and the inclusion/exclusion criteria used
can be found in Table 35.
8.3.2 Studies considered
The review team conducted a new systematic search for observational and non-
comparative studies that assessed the efficacy of unassisted detoxification.
Four interview-based studies (Gossop et al., 1991; Ison et al., 2006; Noble et al.,
2006; Scherbaum et al., 2005) documented service users’ experiences of previous
attempts at unassisted detoxification.
In addition, five studies were excluded from the analysis. The most common
reason for exclusion was that they were not directly related to detoxification.
8.3.3 Experiences of unassisted detoxification
While it is common practice for individuals wishing to terminate drug use to self-
detoxify, there is little documentation of the methods by which they do this and their
respective success rates (Gossop et al., 1991). Several authors have retrospectively
investigated dependent drug users’ previous unassisted detoxification attempts
(Gossop et al., 1991; Ison et al., 2006; Noble et al., 2002; Scherbaum et al., 2005).
The main limitation of this approach is selection bias in that participants selected for
the study represent those who are currently engaged with services and therefore have
not benefited from unassisted detoxification. Thus it is difficult to discern the true
numbers of those who have successfully self-detoxified from this sample.
Gossop and colleagues (1991) examined the frequency of and circumstances asso-
ciated with unassisted detoxification attempts, the methods employed and subsequent
rates of abstinence. Within a sample of 50 dependent opioid users, attempts to 
self-detoxify involved either abrupt cessation of drugs or detoxification with self-
administered drugs including benzodiazepines and opioids. Of the 212 documented
unassisted detoxification attempts, 24% resulted in abstinence lasting one week or
more, 14% lasting 4 weeks or more and 3% lasting 1 year or more. There were no
differences in outcomes for abrupt cessation versus detoxification with the aid of
drugs; these were comparable with results for outpatient detoxification.
Employing a larger data-set, Noble and colleagues (2002) extended Gossop 
and colleagues’ (1991) findings. A total of 114 participants completed structured
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Electronic databases MEDLINE, EMBASE, PsycINFO, Cochrane Library,
HMIC
Date searched Database inception to November 2006; table of
contents November 2005–January 2007
Study design Observational studies
Non-comparative studies
Patient population Opioid dependent
Interventions Unassisted detoxification
Outcomes Abstinence, treatment completion
Table 35: Databases searched and inclusion/exclusion criteria for 
clinical effectiveness of psychological interventions
interviews regarding their personal experiences of unassisted detoxification. Of these,
58% had previously attempted unassisted detoxification with a mean of 3.6 attempts
per individual. There were no significant demographic or gender differences between
this group and those who had never attempted unassisted detoxification. Of the 66
who had attempted unassisted detoxification, 38% had never succeeded in achieving
24 hours of abstinence.
The majority (76%) of unassisted detoxification attempts were made at home,
often with the aid of drugs such as diazepam (43%), methadone (22%), cannabis
(22%), or alcohol (25%). The most common motives for initiating unassisted detoxi-
fication were frustration with the current drug-taking lifestyle and family pressure.
Around 25% of participants felt that they did not need formal help with detoxifica-
tion and often perceived waiting times for formal treatment to be too long.
When comparing length of time abstinent after the most recent detoxification
attempt between less than 1 week (n  35) and more than 1 week (n  31), the
groups did not differ in terms of age, age at first injection or number of attempts at
unassisted detoxification. However, those who achieved more than 1 week of absti-
nence after the last unassisted detoxification attempt had initiated heroin use at a
significantly younger age (mean 17.7 years) than those who achieved less than 1
week’s abstinence (mean 21.1 years). Individuals with a longer drug use history may
be better equipped to self-detoxify.
Scherbaum and colleagues (2005) investigated the unassisted detoxification expe-
riences of 142 dependent opioid users. In total, 23% of participants reported use of
illicitly acquired methadone to self-detoxify or to bridge the waiting period for formal
treatment. Similar findings were reported by Ison and colleagues (2006). Among a
sample of 98 opioid-dependent users, the most common reason for not accessing
medically assisted detoxification was the length of the waiting list for formal treat-
ment. Furthermore, relapse into drug use often occurred as a result of the severity of
withdrawal symptoms. Thus, preventing relapse may be achieved by directing atten-
tion to ways in which to overcome persistent withdrawal symptoms.
Overall, the findings suggest that greater emphasis should be placed on making
formal detoxification treatment more readily available for individuals wishing to
detoxify, which could potentially reduce both demand for illicit methadone and unas-
sisted detoxification attempts.
It must be noted that all of the detoxification attempts reported in the previous
studies eventually failed, as participants were drawn from a population currently drug
dependent or seeking treatment. Therefore it is difficult to assess if there are any posi-
tive outcomes associated with unassisted detoxification. Further research into the
methods and circumstances of these detoxifications could be very informative.
8.3.4 Clinical practice recommendation
8.3.4.1 People who are opioid dependent and considering self-detoxification
should be encouraged to seek detoxification in a structured treatment
programme or, at a minimum, to maintain contact with a drug service.
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8.4 PRISON-BASED DETOXIFICATION
As was noted in the introduction to this chapter, an increasingly active role is being
taken by the prison services in the treatment of individuals with opioid misuse prob-
lems. For the majority of drug users, this may involve assessment, stabilisation, the
provision of appropriate maintenance treatment and referral onto community-based
services following release from prison. However, as the prison drug service develops
its drug treatment capacity so there is an increasing opportunity to offer detoxifica-
tion programmes to people who misuse opioids.
8.4.1 Databases searched and inclusion/exclusion criteria
Information about the databases searched and the inclusion/exclusion criteria used for
this section of the guideline can be found in Table 36.
Electronic databases MEDLINE, EMBASE, PsycINFO, Cochrane Library,
HMIC
Date searched Database inception to November 2006; table of
contents November 2005–January 2007
Study design RCT 
Observational studies
Patient population Opioid dependent
Interventions Prison-based detoxification
Outcomes Abstinence, treatment completion
Table 36: Databases searched and inclusion/exclusion criteria 
for clinical effectiveness of psychological interventions
8.4.2 Studies considered
The review team conducted a new systematic search for RCTs and observational stud-
ies that assessed the efficacy of prison-based detoxification. No studies met the eligi-
bility criteria set by the GDG. One study was excluded because it primarily assessed
pharmacological efficacy rather than the specific issues associated with prison-based
detoxification.
8.4.3 Clinical management of prison-based detoxification
No studies were identified that specifically assessed prison-based detoxification.
However, a recent consensus-based document by the Prison Service (DH, 2006)
provided guidance on the clinical management of drug misuse in prisons. It points out
that detoxification within a prison setting requires particular consideration with
regard to the risks involved when providing clinical management to prisoners upon
reception. Within the prison setting there is limited ability to adequately assess and
confirm previous drug use, due to the late arrival of prisoners being received from the
courts on a daily basis. In addition, prisoners in withdrawal are unlikely to provide
reliable self-reports of their drug use, and formal confirmation of their level of use is
often impossible to verify. The risk of opioid toxicity at the outset of treatment is
therefore ever present.
Detoxification resulting in abstinence from opioids can place prisoners at
increased risk of post-release overdose (WHO, 2001). Again, this is a particular risk
where prisoners have not made a positive decision to abstain from drugs, but have
accepted the detoxification offered upon arrival in prison. These risks can be further
exacerbated by the sudden unplanned release of a prisoner during treatment. There is
also an acknowledged vulnerability of drug users to self-harm and die by suicide in
prison, particularly during the first 28 days of custody. This risk could be increased
by starting a detoxification programme at this stage.
8.4.4 Summary
The particular constraints of prison life require some modification of the programmes
used in community and inpatient settings. However, apart from a greater degree of
uncertainty surrounding the assessment of recent drug use, most centre on the limita-
tions imposed by the uncertainty about many prisoners’ duration of stay in a particular
prison, especially those on remand. This suggests the need for considerable caution
in the use of detoxification programmes, particularly for those who are recently
admitted to prison or who are nearing release.
8.4.5 Clinical practice recommendation
8.4.5.1 People in prison should have the same treatment options for opioid detoxifi-
cation as people in the community. Healthcare professionals should take into
account additional considerations specific to the prison setting, including:
● practical difficulties in assessing dependence and the associated risk of
opioid toxicity early in treatment
● length of sentence or remand period, and the possibility of unplanned
release
● risks of self-harm, death or post-release overdose.
Settings for opioid detoxification 
184
9. APPENDICES
Appendix 1: Scope for the development of the clinical guideline 186
Appendix 2: Declarations of interest by Guideline Development 
Group members 192
Appendix 3: Special advisors to the Guideline Development Group 205
Appendix 4: Stakeholders who responded to early requests for evidence 206
Appendix 5: Stakeholders and experts who submitted comments in 
response to the consultation draft of the guideline 207
Appendix 6: Researchers contacted to request information about 
unpublished or soon-to-be published studies 208
Appendix 7: Clinical questions 209
Appendix 8: Search strategies for the identification of clinical studies 211
Appendix 9: Clinical study data extraction form 215
Appendix 10: Quality checklists for clinical studies and reviews 217
Appendix 11: Search strategies for the identification of health 
economics evidence 230
Appendix 12: Quality checklists for economic studies 233
Appendix 13: Data extraction form for economic studies 237
Appendix 14: Evidence tables for economic studies 240
Appendix 15: Characteristics of reviewed studies On CD
Appendix 16: Clinical evidence forest plots On CD
Appendix 17: Evidence profile tables On CD
Appendices
185
APPENDIX 1:
SCOPE FOR THE DEVELOPMENT OF THE 
CLINICAL GUIDELINE
Final version
28 September 2005
GUIDELINE TITLE
Drug misuse: opiate detoxification of drug misusers in the community, hospital and
prison.12
Short title
Drug misuse – detoxification.
BACKGROUND
The National Institute for Health and Clinical Excellence (‘NICE’ or ‘the Institute’)
has commissioned the National Collaborating Centre for Mental Health to develop a
clinical guideline on opiate13 detoxification of drug misusers14 in the community,
hospital and prison settings for use in the NHS in England and Wales. This follows
referral of the topic by the Department of Health and Welsh Assembly Government
(see Appendix [to the scope] below). The guideline will provide recommendations 
for good practice that are based on the best available evidence of clinical and cost
effectiveness.
The Institute has simultaneously commissioned the National Collaborating Centre
for Mental Health to develop a clinical guideline on psychosocial interventions for
people who misuse drugs in the community and in prison settings for use in the NHS
in England and Wales.
The Institute’s clinical guidelines will support the implementation of National Service
Frameworks (NSFs) in those aspects of care where a Framework has been published.
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12The guideline title changed during the development process to Drug Misuse: Opioid Detoxification.
13The term opiates has been replaced with the generic term opioids throughout the guideline, with the
exception of the scope (where it originally appeared) and where the term relates specifically to the subset
of opioids that are naturally occurring or semi-synthetic derivatives of the opium poppy, including heroin.
14The term drug misusers has been replaced with people who misuse drugs throughout the guideline, with
the exception of the scope, where it originally appeared.
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The statements in each NSF reflect the evidence that was used at the time the
Framework was prepared. The clinical guidelines and technology appraisals published
by the Institute after an NSF has been issued will have the effect of updating the
Framework.
NICE clinical guidelines support the role of healthcare professionals in providing
care in partnership with patients, taking account of their individual needs and prefer-
ences, and ensuring that patients (and their carers and families, where appropriate)
can make informed decisions about their care and treatment.
CLINICAL NEED FOR THE GUIDELINE
The term opiate is used throughout this scope. Although this term normally implies
substances containing natural opium, in this scope the term is used more broadly to
include opioids (synthetic substances with similar properties).
It is estimated that there are between 250,000 and 500,000 problem drug users in
the United Kingdom, of whom about 125,500 are in treatment in any year. There is a
government target of ensuring 200,000 are in effective treatment in 2008. The major-
ity of those requiring treatment are opiate dependent (and currently or previously
using illicit heroin), although the use of other drugs such as stimulants (for example,
cocaine) is known to be increasing.
Severe opiate dependence is a disorder of multi-factorial aetiology, with multiple
and varied perpetuating factors. It has a central feature of psychological reinforce-
ment of repeated drug-taking behaviour and it also has a marked withdrawal
syndrome. Disturbances of the brain reward pathways may be important underlying
pathological mechanisms. For this reason, it is usually considered that a range of
interventions may be required in addition to pharmacological treatments.
There may be associated problems of family, social, criminal justice difficulties,
health problems including blood borne viruses and other drug and alcohol problems.
Families themselves may be affected by the drug misuse and are often a major
resource in resolving problems and supporting the family member through treatment.
For people with severe drug dependency and others with long-standing depend-
ency, the disorder has characteristics as a long-term chronic relapsing disorder with
periods of remission and relapse, so while abstinence may be one of a range of long-
term goals of treatment this is not always achieved. Even when abstinence is achieved,
the benefits are not always maintained, and periods of relapse may still occur.
The evidence for detoxification programmes including the use of a range of phar-
macological treatments (including methadone, buprenorphine and lofexidine) and the
appropriate settings in which to best provide these interventions is not as strong as the
evidence for maintenance and harm-reduction programmes.
The societal costs of drug misuse have been estimated at many billions of pounds,
with opiate dependence and use of Class A drugs constituting the main cause of 
these costs.
Opiate substitution therapies (methadone and buprenorphine are most commonly
used) allow the patient to replace street heroin with a longer-acting, less euphoriant
and safer drug while avoiding the withdrawal syndrome. Once stabilised, many
patients remain on maintenance treatment, which brings improvements in illicit drug
use, physical health, well-being, social stabilisation and reduced criminality and costs
to society.
People who misuse drugs in prison sometimes receive assistance with withdrawal
symptoms and some receive a treatment programme in prison. Access to regular high
levels of illicit drugs in prisons is limited, so most people with drug dependency lose
tolerance and are at risk of overdose if – as commonly happens – they begin using
again on release.
Determining when to offer detoxification and where to provide it is often a diffi-
cult clinical decision. Clarity about the purpose of any treatment strategy is crucial
because confusion between detoxification and maintenance programmes can lead to
a lack of clear treatment aims and a poorer quality of care.
THE GUIDELINE
The guideline development process is described in detail in two publications which
are available from the NICE website (see ‘Further information’). The Guideline
Development Process – An Overview for Stakeholders, the Public and the NHS
(Second Edition) (NICE, 2006b) describes how organisations can become involved in
the development of a guideline. The Guidelines Manual (NICE, 2006a) provides
advice on the technical aspects of guideline development.
This document is the scope. It defines exactly what this guideline will (and will
not) examine, and what the guideline developers will consider. The scope is based on
the referral from the Department of Health (see Appendix [to the scope] below). The
areas that will be addressed by the guideline are described in the following sections.
POPULATION
Groups that will be covered
● adults and young people who are dependent on opiates and have been identified
as suitable for a detoxification programme.
Groups that will not be covered
● adults and young people whose primary drug of misuse is a non-opiate
● adults and young people who misuse alcohol, where the primary diagnosis and
focus of intervention is alcohol misuse
● adults and young people who misuse other prescription drugs – for example,
benzodiazepines
● adults and young people who misuse solvents (for example, aerosols and glue) or
other street drugs (for example, LSD [lysergic acid diethylamide])
● adults and young people prescribed opiates and related drugs for therapeutic
purposes unrelated to substance misuse.
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HEALTHCARE SETTING
The guideline will be of relevance to the NHS and related organisations, including:
● prison services
● inpatient and specialist residential and community-based treatment settings.
This is an NHS guideline. Although it will comment on the interface with other 
services such as those provided by social services, educational services and the volun-
tary sector, it will not provide specific recommendations directed solely to non-NHS
services, except insofar as they are provided under contract to the NHS.
CLINICAL MANAGEMENT – AREAS THAT WILL BE COVERED
The guideline will cover the following areas of clinical practice and will do so in a
way that is sensitive to the cultural, ethnic and religious backgrounds of people who
misuse drugs/are drug dependent and their families and carers.
● The guideline will cover detoxification programmes for people who misuse
opiates in community, residential, prison and inpatient settings including the type
and duration of the programme.
● The guideline will identify the most appropriate programmes for specific popula-
tions of people who misuse opiates.
● The guideline will make recommendations on the use of methadone, buprenor-
phine, lofexidine and other related products in opiate detoxification programmes,
and the dose and duration of use.
● The guideline will include the treatment and management of non-opiate drug and
alcohol misuse in the context of an opiate detoxification programme.
● When referring to pharmacological treatments, the guideline will, wherever possi-
ble, recommend use within their licensed indications. However, where the evidence
clearly supports it, recommendations for use outside the licensed indications may
be made in exceptional circumstances.
● The guideline will include the appropriate use of psychosocial interventions to
support detoxification programmes.
● The safety, side effects and other disbenefits of the interventions reviewed will be
considered.
● The guideline will address the integration of the interventions reviewed with a
broad approach to the care and treatment of people who misuse drugs/are drug
dependent and their families and carers.
● The guideline will consider the separate needs of families and carers as well as
addressing the potential positive contribution of family and carers in the treatment
and support of people who misuse drugs/are drug dependent.
● The guideline will address the various needs for information of patients, families
and carers, at different stages of their treatment and in different settings, includ-
ing the role of self-help interventions and of support and self-help groups, and the
importance of agreeing objectives with patients before they agree to treatment.
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CLINICAL MANAGEMENT – AREAS THAT WILL NOT BE COVERED
● The guideline will not consider diagnosis or primary prevention.
● The guideline will not consider pharmacological maintenance programmes.
STATUS
Scope
This is the final draft of the scope following consultation, which will be reviewed by
the Guidelines Review Panel and the Institute’s Guidance Executive.
The guideline will incorporate the following NICE guidance, which is published
or in development:
Methadone and Buprenorphine for the Treatment of Opiate Drug Misuse. NICE
Technology Appraisal. (Publication expected March 2007.)15
Naltrexone to Prevent Relapse in Drug Misuse. NICE Technology Appraisal.
(Publication expected March 2007.)16
Drug Misuse: Psychosocial Management of Drug Misuse. NICE Clinical
Guideline. (Publication expected July 2007.)17
Schizophrenia: Core Interventions in the Treatment and Management of
Schizophrenia in Primary and Secondary Care. NICE Clinical Guideline No. 1.
(2002).
Anxiety: Management of Anxiety (Panic Disorder, with or without Agoraphobia,
and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community
Care. NICE Clinical Guideline No. 22. (2004).
Depression: Management of Depression in Primary and Secondary Care. NICE
Clinical Guideline No. 23. (2004).
Self-Harm: the Short-Term Physical and Psychological Management and
Secondary Prevention of Self-Harm in Primary and Secondary Care. NICE Clinical
Guideline No. 16. (2004).
GUIDELINE
The development of the guideline recommendations will begin in October 2005.
Appendix 1
190
15This technology appraisal has now been published with a different title: NICE (2006c) Methadone and
Buprenorphine for the Management of Opioid Dependence. Evaluation Report. London: NICE.
16This technology appraisal has now been published with a different title: NICE (2006a) Naltrexone for the
Management of Opioid Dependence. Evaluation Report. London: NICE.
17This guideline has now been published with a different title: NICE (2007) Drug Misuse: Psychosocial
Interventions. NICE Clinical Guideline no. 51. London: NICE.
FURTHER INFORMATION
Information on the guideline development process is provided in:
● The Guideline Development Process – An Overview for Stakeholders, the Public
and the NHS (Second Edition)
● The Guidelines Manual.
These booklets are available as PDF files from the NICE website (www.nice.org.uk).
Information on the progress of the guideline will also be available from the website.
Appendix – Referral from the Department of Health and Welsh Assembly Government
The Department of Health and Welsh Assembly Government asked the Institute to
prepare a guideline for the NHS in England and Wales on opiate detoxification of
drug misusers in the community, hospital and prison settings.
The guidance will:
● by using the evidence base examine the effectiveness and cost effectiveness of
detoxification regimes for the management of opiate misusers
● identify those groups of drug misusers who are most likely to benefit from detox-
ification regimes, and
● identify the key components of the effectiveness of detoxification within a wider
package of pharmacological interventions, and the overall care provided for the
drug misuser.
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APPENDIX 2:
DECLARATIONS OF INTEREST BY GUIDELINE
DEVELOPMENT GROUP MEMBERS
With a range of practical experience relevant to drug misuse in the GDG, members
were appointed because of their understanding and expertise in healthcare for people
who misuse drugs and support for their families and carers, including: scientific
issues; health research; the delivery and receipt of healthcare, along with the work of
the healthcare industry; and the role of professional organisations and organisations
for people who misuse drugs and their families and carers.
To minimise and manage any potential conflicts of interest, and to avoid any
public concern that commercial or other financial interests have affected the work of
the GDG and influenced guidance, members of the GDG must declare as a matter of
public record any interests held by themselves or their families that fall under speci-
fied categories (see below). These categories include any relationships they have with
the healthcare industries, professional organisations and organisations for people who
misuse drugs and their families and carers.
Individuals invited to join the GDG were asked to declare their interests before
being appointed. To allow the management of any potential conflicts of interest that
might arise during the development of the guideline, GDG members were also asked
to declare their interests at each GDG meeting throughout the guideline development
process. The interests of all the members of the GDG are listed below, including inter-
ests declared prior to appointment and during the guideline development process.
CATEGORIES OF INTEREST
● Paid employment
● Personal interests related to drug misuse: payment in cash or kind and/or fund-
ing from the drug misuse-related healthcare industry, including consultancies,
grants, fee-paid work and shareholdings or other beneficial interests.
● Personal interests not specifically related to drug misuse: any other payment
and/or funding from the healthcare industry, including consultancies, grants and
shareholdings or other beneficial interests.
● Non-personal interests: funding from the healthcare industry received by the
GDG member’s organisation or department, but where the GDG member has not
personally received payment, including fellowships and other support provided by
the healthcare industry.
● Personal non-monetary interests: these include, but are not limited to, clear
opinions or public statements you have made about drug misuse, holding office in
a professional organisation or advocacy group with a direct interest in drug
misuse, other reputational risks relevant to drug misuse.
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● Personal family interests: payments in cash or kind that were received by a
member of your family.
● Other interests relating to drug misuse: funding from governmental or non-
governmental organisations, charities, and so on, and/or ownership in a company
that provides therapy or treatments likely to be covered in the guideline.
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Trust, London Practice; Primary Care Lead
for Drug Misuse and Chair at the Royal
College of General Practitioners
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received payment of £1000); member of
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attending only)
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Non-personal interests Royal College of General Practitioners
received funding from Schering-Plough 
for educational material
Personal non-monetary interests Spoken publicly about heroin treatment:
against heroin treatment until methadone
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Personal family interests None
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substance misuse; Advisor to Royal College
of General Practitioners on all matters relating
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Non-personal interests None
Personal non-monetary interests None
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Mr Neil Connelly
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APPENDIX 6:
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APPENDIX 7:
CLINICAL QUESTIONS
TOPIC GROUP 1: PHARMACOLOGICAL AND PHYSICAL
INTERVENTIONS
1) For people who are opioid dependent, what detoxification treatments are
associated with abstinence, completion of treatment and improvements on
secondary outcomes (entry rate for naltrexone maintenance, use of other
drugs, severity of withdrawal)?
1.1) For people who are opioid dependent, what durations of detoxifica-
tion treatment are associated with abstinence, completion of treat-
ment and improvements on secondary outcomes (same as above)?
TOPIC GROUP 2: PSYCHOSOCIAL ADJUNCTS/PREDICTORS 
OF BENEFIT
2) For people who are opioid dependent, are there particular groups that are
more likely to benefit from detoxification?
3) For people who are opioid dependent, are psychosocial interventions in
combination with detoxification compared with detoxification with stan-
dard care associated with increased levels of abstinence, completion of
treatment and improvements on secondary outcomes?
TOPIC GROUP 3: TREATMENT SETTING
4) For people who are opioid dependent, is inpatient detoxification in
comparison with community-based detoxification associated with
increased levels of abstinence, completion of treatment and improvements
of secondary outcomes?
4.1) For people who are opioid dependent, are there particular groups
that respond better/worse to particular treatment settings?
5) For people who are opioid dependent and who are in prison, what detoxi-
fication treatment settings are associated with safety, abstinence, comple-
tion of treatment and improvements on secondary outcomes?
5.1) For people who are opioid dependent and who are in contact with the
community criminal justice system, what detoxification treatment
settings are associated with abstinence, completion of treatment and
improvements on secondary outcomes?
Appendix 7
209
TOPIC GROUP 4: TESTING
6) For people in whom opioid dependence is suspected, are oral fluid and urine
testing reliable methods, for example in terms of sensitivity and specificity,
for identifying, confirming, quantifying and monitoring drug use?
7) In the context of opioid detoxification, what is good clinical practice in the
assessment of dependence and monitoring of withdrawal?
7.1) In the context of opioid detoxification, are there reliable and valid
rating scales for the assessment of dependence and monitoring of
withdrawal?
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APPENDIX 8:
SEARCH STRATEGIES FOR THE IDENTIFICATION
OF CLINICAL STUDIES
1. GENERAL SEARCH FILTERS
Drug misuse
a. CINAHL, HMIC, EMBASE, MEDLINE, PsycINFO – OVID interface
1 exp narcotic dependence/ or exp opioid-related disorders/
2 (addiction or analgesic agent abuse or drug abuse or drug abuse pattern or
drug dependenc$ or drug misuse or intravenous drug abuse or psychoses,
substance-induced or substance abuse, intravenous or substance abuse,
perinatal or substance abuse or substance dependence or substance with-
drawal syndrome or substance-related disorders).sh.
3 “substance use disorders”/
4 ((drug$1 or substance$) adj3 (abstain$ or abstinen$ or abus$ or addict$ or
dependen$ or disorder$ or intoxicat$ or misus$ or over dos$ or overdos$
or use$2 or using or withdraw$)).tw.
5 or/1-4
6 diamorphine/ or exp heroin/ or morphine/
7 exp narcotic agent/ or exp narcotics/ or exp narcotic drugs/
8 (acetomorphine or diacephine or diacetylmorphine or diamorphine or
diaphorin or heroin$ or morphacetin or morphine).mp. or 1502-95-0, 
561-27-3.rn.
9 (anpec or duromorph or epimorph or morfin$ or morphia or morphin$ or
morphinium or morphium or opso$1 or skenan).mp. or 57-27-2.rn.
10 opiate$.mp. or 8008-60-4.rn.
11 (opioid$ or opium or narcotic$).tw.
12 (abstain$ or abstinen$ or abus$ or addict$ or (excessive adj use$) or depen-
den$ or (inject$ adj2 drug$) or intoxicat$ or misus$ or over dos$ or over-
dos$ or (use$ adj (disorder$ or illicit)) or withdraw$).mp.
13 (or/6-11) and 12
14 or/5,13
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b. Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of
Reviews of Effects (DARE), Cochrane Central Register of Controlled Trials
(CENTRAL) – Wiley Interscience interface
#1 MeSH descriptor Opioid-Related Disorders explode all trees
#2 MeSH descriptor Substance-Related Disorders, this term only
#3 MeSH descriptor Substance Abuse, Intravenous, this term only
#4 MeSH descriptor Substance Withdrawal Syndrome, this term only
#5 MeSH descriptor Psychoses, Substance-Induced, this term only
#6 (drug* or substance*) near (abstain* or abstinen* or abus* or addict* or
dependen* or disorder* or intoxicat* or misuse* or over dos* or overdos*
or use or user* or using or withdraw*): ti or (drug* or substance*) near
(abstain* or abstinen* or abus* or addict* or dependen* or disorder* or
intoxicat* or misuse* or over dos* or overdos* or use or user* or using or
withdraw*): ab or (drug* or substance*) near (abstain* or abstinen* or abus*
or addict* or dependen* or disorder* or intoxicat* or misuse* or over dos*
or overdos* or use or user* or using or withdraw*): kw
#7 (#1 OR #2 OR #3 OR #4 OR #5 OR #6)
#8 MeSH descriptor Heroin, this term only
#9 MeSH descriptor Morphine explode all trees
#10 MeSH descriptor Narcotics explode all trees
#11 (acetomorphine or diacephine or diacetylmorphine or diamorphine or
diaphorin or heroin* or morphacetin or morphin*):ti or (acetomorphine or
diacephine or diacetylmorphine or diamorphine or diaphorin or heroin* or
morphacetin or morphin*):ab or (acetomorphine or diacephine or diacetylmor-
phine or diamorphine or diaphorin or heroin* or morphacetin or morphin*):kw
#12 (anpec or duromorph or epimorph or morfin* or morphia or morphin* or
morphinium or morphium or opso* or skenan):ti or (anpec or duromorph or
epimorph or morfin* or morphia or morphin* or morphinium or morphium
or opso* or skenan):ab or (anpec or duromorph or epimorph or morfin* or
morphia or morphin* or morphinium or morphium or opso* or skenan):kw
#13 (opiate*):ti or (opiate*):ab or (opiate*):kw
#14 (opioid* or opium or narcotic*):ti or (opioid* or opium or narcotic*):ab or
(opioid* or opium or narcotic*):kw
#15 (abstain* or abstinen* or abus* or addict* or (drug near use*) or (exces-
sive* near use*) or dependen* or (inject* near drug*) or intoxicat* or
misus* or over dos* or overdos* or (use* near (disorder* or illicit)) or
withdraw*):ti or (abstain* or abstinen* or abus* or addict* or (drug near
use*) or (excessive* near use*) or dependen* or (inject* near drug*) or
intoxicat* or misus* or over dos* or overdos* or (use* near (disorder* or
illicit)) or withdraw*):ab or (abstain* or abstinen* or abus* or addict* or
(drug near use*) or (excessive* near use*) or dependen* or (inject* near
drug*) or intoxicat* or misus* or over dos* or overdos* or (use* near
(disorder* or illicit)) or withdraw*):kw
#16 ((#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14) AND #15)
#17 (#7 OR #16)
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2. SYSTEMATIC REVIEW SEARCH FILTERS
a. MEDLINE, EMBASE, PsycINFO, CINAHL – OVID interface
1 exp meta analysis/ or exp systematic review/ or exp literature review/ or
exp literature searching/ or exp cochrane library/ or exp review literature/
2 ((systematic or quantitative or methodologic$) adj5 (overview$ or
review$)).mp.
3 (metaanaly$ or meta analy$).mp.
4 (research adj (review$ or integration)).mp.
5 reference list$.ab.
6 bibliograph$.ab.
7 published studies.ab.
8 relevant journals.ab.
9 selection criteria.ab.
10 (data adj (extraction or synthesis)).ab.
11 ((handsearch$3 or (hand or manual)) adj search$).tw.
12 ((mantel adj haenszel) or peto or dersimonian or der simonian).tw.
13 (fixed effect$ or random effect$).tw.
14 review$.pt,mp. and (bids or cochrane or index medicus or isi citation or
medlars or psyclit or psychlit or scisearch or science citation or web adj1
science).mp.
15 (systematic$ or meta$).pt.
16 or/1-15
3. RCT SEARCH FILTERS
a. MEDLINE, EMBASE, PsycINFO, CINAHL – OVID interface
1 exp clinical trials/ or exp clinical trial/ or exp controlled clinical trials/
2 exp crossover procedure/ or exp cross over studies/ or exp crossover design/
3 exp double blind procedure/ or exp double blind method/ or exp double
blind studies/ or exp single blind procedure/ or exp single blind method/ or
exp single blind studies/
4 exp random allocation/ or exp randomization/ or exp random assignment/
or exp random sample/ or exp random sampling/
5 exp randomized controlled trials/ or exp randomized controlled trial/
6 (clinical adj2 trial$).tw.
7 (crossover or cross over).tw.
8 (((single$ or doubl$ or trebl$ or tripl$) adj5 (blind$ or mask$ or dummy))
or (singleblind$ or doubleblind$ or trebleblind$)).tw.
9 (placebo$ or random$).mp.
10 (clinical trial$ or clinical control trial or random$).pt.
11 animals/ not (animals/ and human$.mp.)
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12 animal$/ not (animal$/ and human$/)
13 (animal not (animal and human)).po.
14 (or/1-10) not (or/11-13)
Details of additional searches undertaken to support the development of this guide-
line are available on request.
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APPENDIX 9:
CLINICAL STUDY DATA EXTRACTION FORM
Information about each study was entered into an Access database using specially
designed forms (see below for an example).
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APPENDIX 10:
QUALITY CHECKLISTS FOR CLINICAL STUDIES
AND REVIEWS
The methodological quality of each study was evaluated using dimensions adapted
from SIGN (SIGN, 2002). SIGN originally adapted its quality criteria from checklists
developed in Australia (Liddel et al., 1996). Both groups reportedly undertook exten-
sive development and validation procedures when creating their quality criteria.
NOTES ON THE USE OF THE METHODOLOGY CHECKLIST:
SYSTEMATIC REVIEWS AND META-ANALYSES
Section 1 identifies the study and asks a series of questions aimed at establishing the
internal validity of the study under review – that is, making sure that it has been
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carried out carefully and that the outcomes are likely to be attributable to the interven-
tion being investigated. Each question covers an aspect of methodology that research
has shown makes a significant difference to the conclusions of a study.
For each question in this section, one of the following should be used to indicate
how well it has been addressed in the review:
● well covered
● adequately addressed
● poorly addressed
● not addressed (that is, not mentioned or indicates that this aspect of study design
was ignored)
● not reported (that is, mentioned but insufficient detail to allow assessment to be
made)
● not applicable.
1.1 THE STUDY ADDRESSES AN APPROPRIATE AND CLEARLY
FOCUSED QUESTION
Unless a clear and well-defined question is specified in the report of the review, it will
be difficult to assess how well it has met its objectives or how relevant it is to the
question to be answered on the basis of the conclusions.
1.2 A DESCRIPTION OF THE METHODOLOGY USED IS
INCLUDED
One of the key distinctions between a systematic review and a general review is the
systematic methodology used. A systematic review should include a detailed descrip-
tion of the methods used to identify and evaluate individual studies. If this descrip-
tion is not present, it is not possible to make a thorough evaluation of the quality of
the review, and it should be rejected as a source of level-1 evidence (though it may be
useable as level-4 evidence, if no better evidence can be found).
1.3 THE LITERATURE SEARCH IS SUFFICIENTLY RIGOROUS 
TO IDENTIFY ALL THE RELEVANT STUDIES
A systematic review based on a limited literature search – for example, one limited 
to MEDLINE only – is likely to be heavily biased. A well-conducted review should
at a minimum look at EMBASE and MEDLINE and, from the late 1990s onward, 
the Cochrane Library. Any indication that hand searching of key journals, or 
follow-up of reference lists of included studies, were carried out in addition to 
electronic database searches can normally be taken as evidence of a well-conducted
review.
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1.4 STUDY QUALITY IS ASSESSED AND TAKEN INTO ACCOUNT
A well-conducted systematic review should have used clear criteria to assess whether
individual studies had been well conducted before deciding whether to include or
exclude them. If there is no indication of such an assessment, the review should be
rejected as a source of level-1 evidence. If details of the assessment are poor, or the
methods are considered to be inadequate, the quality of the review should be down-
graded. In either case, it may be worthwhile obtaining and evaluating the individual
studies as part of the review being conducted for this guideline.
1.5 THERE ARE ENOUGH SIMILARITIES BETWEEN 
THE STUDIES SELECTED TO MAKE COMBINING 
THEM REASONABLE
Studies covered by a systematic review should be selected using clear inclusion crite-
ria (see question 1.4 above). These criteria should include, either implicitly or explic-
itly, the question of whether the selected studies can legitimately be compared. It
should be clearly ascertained, for example, that the populations covered by the stud-
ies are comparable, that the methods used in the investigations are the same, that the
outcome measures are comparable and the variability in effect sizes between studies
is not greater than would be expected by chance alone.
Section 2 relates to the overall assessment of the paper. It starts by rating the
methodological quality of the study, based on the responses in Section 1 and using the
following coding system:
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 All or most of the criteria have been fulfilled. 
Where they have not been fulfilled, the conclusions of the study or
review are thought very unlikely to alter.
 Some of the criteria have been fulfilled. 
Those criteria that have not been fulfilled or not adequately described
are thought unlikely to alter the conclusions.
– Few or no criteria fulfilled.
The conclusions of the study are thought likely or very likely to alter.
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NOTES ON THE USE OF THE METHODOLOGY CHECKLIST: RCTS
Section 1 identifies the study and asks a series of questions aimed at establishing the
internal validity of the study under review – that is, making sure that it has been
carried out carefully and that the outcomes are likely to be attributable to the inter-
vention being investigated. Each question covers an aspect of methodology that
research has shown makes a significant difference to the conclusions of a study.
For each question in this section, one of the following should be used to indicate
how well it has been addressed in the review:
● well covered
● adequately addressed
● poorly addressed
● not addressed (that is, not mentioned or indicates that this aspect of study design
was ignored)
● not reported (that is, mentioned but insufficient detail to allow assessment to be
made)
● not applicable.
1.1 THE STUDY ADDRESSES AN APPROPRIATE AND CLEARLY
FOCUSED QUESTION
Unless a clear and well-defined question is specified, it will be difficult to assess how
well the study has met its objectives or how relevant it is to the question to be
answered on the basis of its conclusions.
1.2 THE ASSIGNMENT OF SUBJECTS TO TREATMENT GROUPS
IS RANDOMISED
Random allocation of patients to receive one or other of the treatments under investi-
gation, or to receive either treatment or placebo, is fundamental to this type of study.
If there is no indication of randomisation, the study should be rejected. If the descrip-
tion of randomisation is poor, or the process used is not truly random (for example,
allocation by date or alternating between one group and another) or can otherwise be
seen as flawed, the study should be given a lower quality rating.
1.3 AN ADEQUATE CONCEALMENT METHOD IS USED
Research has shown that where allocation concealment is inadequate, investigators
can overestimate the effect of interventions by up to 40%. Centralised allocation,
computerised allocation systems or the use of coded identical containers would all be
regarded as adequate methods of concealment and may be taken as indicators of 
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a well-conducted study. If the method of concealment used is regarded as poor, or
relatively easy to subvert, the study must be given a lower quality rating, and can be
rejected if the concealment method is seen as inadequate.
1.4 SUBJECTS AND INVESTIGATORS ARE KEPT ‘BLIND’ 
ABOUT TREATMENT ALLOCATION
Blinding can be carried out up to three levels. In single-blind studies, patients are
unaware of which treatment they are receiving; in double-blind studies, the doctor and
the patient are unaware of which treatment the patient is receiving; in triple-blind
studies, patients, healthcare providers and those conducting the analysis are unaware
of which patients received which treatment. The higher the level of blinding, the
lower the risk of bias in the study.
1.5 THE TREATMENT AND CONTROL GROUPS ARE SIMILAR 
AT THE START OF THE TRIAL
Patients selected for inclusion in a trial should be as similar as possible, in order to
eliminate any possible bias. The study should report any significant differences in the
composition of the study groups in relation to gender mix, age, stage of disease (if
appropriate), social background, ethnic origin or comorbid conditions. These factors
may be covered by inclusion and exclusion criteria, rather than being reported
directly. Failure to address this question, or the use of inappropriate groups, should
lead to the study being downgraded.
1.6 THE ONLY DIFFERENCE BETWEEN GROUPS IS THE
TREATMENT UNDER INVESTIGATION
If some patients received additional treatment, even if of a minor nature or consisting
of advice and counselling rather than a physical intervention, this treatment is a
potential confounding factor that may invalidate the results. If groups were not treated
equally, the study should be rejected unless no other evidence is available. If the 
study is used as evidence, it should be treated with caution and given a low quality
rating.
1.7 ALL RELEVANT OUTCOMES ARE MEASURED IN A
STANDARD, VALID AND RELIABLE WAY
If some significant clinical outcomes have been ignored, or not adequately taken into
account, the study should be downgraded. It should also be downgraded if the meas-
ures used are regarded as being doubtful in any way or applied inconsistently.
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1.8 WHAT PERCENTAGE OF THE INDIVIDUALS OR CLUSTERS
RECRUITED INTO EACH TREATMENT ARM OF THE STUDY
DROPPED OUT BEFORE THE STUDY WAS COMPLETED?
The number of patients that drop out of a study should give concern if the number is
very high. Conventionally, a 20% drop-out rate is regarded as acceptable, but this may
vary. Some regard should be paid to why patients dropped out, as well as how many.
It should be noted that the drop-out rate may be expected to be higher in studies
conducted over a long period of time. A higher drop-out rate will normally lead to
downgrading, rather than rejection of a study.
1.9 ALL THE SUBJECTS ARE ANALYSED IN THE GROUPS TO
WHICH THEY WERE RANDOMLY ALLOCATED (OFTEN
REFERRED TO AS INTENTION-TO-TREAT ANALYSIS)
In practice, it is rarely the case that all patients allocated to the intervention group receive
the intervention throughout the trial, or that all those in the comparison group do not.
Patients may refuse treatment, or contra-indications arise that lead them to be switched to
the other group. If the comparability of groups through randomisation is to be maintained,
however, patient outcomes must be analysed according to the group to which they were
originally allocated, irrespective of the treatment they actually received. (This is known as
intention-to-treat analysis.) If it is clear that analysis was not on an intention-to-treat basis,
the study may be rejected. If there is little other evidence available, the study may be
included but should be evaluated as if it were a non-randomised cohort study.
1.10 WHERE THE STUDY IS CARRIED OUT AT MORE THAN ONE
SITE, RESULTS ARE COMPARABLE FOR ALL SITES
In multi-site studies, confidence in the results should be increased if it can be shown
that similar results were obtained at the different participating centres.
Section 2 relates to the overall assessment of the paper. It starts by rating the
methodological quality of the study, based on the responses in Section 1 and using the
following coding system:
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 All or most of the criteria have been fulfilled.
Where they have not been fulfilled, the conclusions of the study or
review are thought very unlikely to alter.
 Some of the criteria have been fulfilled. 
Those criteria that have not been fulfilled or not adequately described
are thought unlikely to alter the conclusions.
– Few or no criteria fulfilled.
The conclusions of the study are thought likely or very likely to alter.
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NOTES ON THE USE OF THE METHODOLOGY 
CHECKLIST: COHORT STUDIES
The studies covered by this checklist are designed to answer questions of the type
‘What are the effects of this exposure?’ It relates to studies that compare a group of
people with a particular exposure with another group who either have not had the
exposure or have a different level of exposure. Cohort studies may be prospective
(where the exposure is defined and subjects selected before outcomes occur) or retro-
spective (where exposure is assessed after the outcome is known, usually by the
examination of medical records). Retrospective studies are generally regarded as a
weaker design, and should not receive a 2 rating.
Section 1 identifies the study and asks a series of questions aimed at establishing
the internal validity of the study under review – that is, making sure that it has been
carried out carefully, and that the outcomes are likely to be attributable to the inter-
vention being investigated. Each question covers an aspect of methodology that has
been shown to make a significant difference to the conclusions of a study.
Because of the potential complexity and subtleties of the design of this type of
study, there are comparatively few criteria that automatically rule out use of a study
as evidence. It is more a matter of increasing confidence in the likelihood of a causal
relationship existing between exposure and outcome by identifying how many aspects
of good study design are present and how well they have been tackled. A study that
fails to address or report on more than one or two of the questions considered below
should almost certainly be rejected.
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For each question in this section, one of the following should be used to indicate
how well it has been addressed in the review:
● well covered
● adequately addressed
● poorly addressed
● not addressed (that is, not mentioned or indicates that this aspect of study design
was ignored)
● not reported (that is, mentioned but insufficient detail to allow assessment to be made)
● not applicable.
1.1 THE STUDY ADDRESSES AN APPROPRIATE AND CLEARLY
FOCUSED QUESTION
Unless a clear and well-defined question is specified, it will be difficult to assess how
well the study has met its objectives or how relevant it is to the question to be
answered on the basis of its conclusions.
1.2 THE TWO GROUPS BEING STUDIED ARE SELECTED FROM
SOURCE POPULATIONS THAT ARE COMPARABLE IN ALL
RESPECTS OTHER THAN THE FACTOR UNDER
INVESTIGATION
Study participants may be selected from the target population (all individuals to
which the results of the study could be applied), the source population (a defined
subset of the target population from which participants are selected) or from a pool
of eligible subjects (a clearly defined and counted group selected from the source
population). It is important that the two groups selected for comparison are as simi-
lar as possible in all characteristics except for their exposure status or the presence of
specific prognostic factors or prognostic markers relevant to the study in question. If
the study does not include clear definitions of the source populations and eligibility
criteria for participants, it should be rejected.
1.3 THE STUDY INDICATES HOW MANY OF THE PEOPLE 
ASKED TO TAKE PART DID SO IN EACH OF THE GROUPS
BEING STUDIED
This question relates to what is known as the participation rate, defined as the number
of study participants divided by the number of eligible subjects. This should be calcu-
lated separately for each branch of the study. A large difference in participation rate
between the two arms of the study indicates that a significant degree of selection bias
may be present, and the study results should be treated with considerable caution.
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1.4 THE LIKELIHOOD THAT SOME ELIGIBLE SUBJECTS MIGHT
HAVE THE OUTCOME AT THE TIME OF ENROLMENT IS
ASSESSED AND TAKEN INTO ACCOUNT IN THE ANALYSIS
If some of the eligible subjects, particularly those in the unexposed group, already
have the outcome at the start of the trial, the final result will be biased. A well-
conducted study will attempt to estimate the likelihood of this occurring and take it
into account in the analysis through the use of sensitivity studies or other methods.
1.5 WHAT PERCENTAGE OF INDIVIDUALS OR CLUSTERS
RECRUITED INTO EACH ARM OF THE STUDY DROPPED OUT
BEFORE THE STUDY WAS COMPLETED?
The number of patients that drop out of a study should give concern if the number is
very high. Conventionally, a 20% drop-out rate is regarded as acceptable, but in
observational studies conducted over a lengthy period of time a higher drop-out rate
is to be expected. A decision on whether to downgrade or reject a study because of a
high drop-out rate is a matter of judgement based on the reasons why people dropped
out and whether drop-out rates were comparable in the exposed and unexposed
groups. Reporting of efforts to follow up participants that dropped out may be
regarded as an indicator of a well-conducted study.
1.6 COMPARISON IS MADE BETWEEN FULL PARTICIPANTS AND
THOSE LOST TO FOLLOW-UP BY EXPOSURE STATUS
For valid study results, it is essential that the study participants are truly representa-
tive of the source population. It is always possible that participants who dropped out
of the study will differ in some significant way from those who remained part of the
study throughout. A well-conducted study will attempt to identify any such differ-
ences between full and partial participants in both the exposed and unexposed groups.
Any indication that differences exist should lead to the study results being treated
with caution.
1.7 THE OUTCOMES ARE CLEARLY DEFINED
Once enrolled in the study, participants should be followed until specified end points
or outcomes are reached. In a study of the effect of exercise on the death rates from
heart disease in middle-aged men, for example, participants might be followed up
until death, reaching a predefined age or until completion of the study. If outcomes
and the criteria used for measuring them are not clearly defined, the study should be
rejected.
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1.8 THE ASSESSMENT OF OUTCOME IS MADE BLIND TO
EXPOSURE STATUS
If the assessor is blinded to which participants received the exposure, and which did not,
the prospects of unbiased results are significantly increased. Studies in which this is
done should be rated more highly than those where it is not done or not done adequately.
1.9 WHERE BLINDING WAS NOT POSSIBLE, THERE IS SOME
RECOGNITION THAT KNOWLEDGE OF EXPOSURE STATUS
COULD HAVE INFLUENCED THE ASSESSMENT OF
OUTCOME
Blinding is not possible in many cohort studies. In order to assess the extent of any bias
that may be present, it may be helpful to compare process measures used on the partic-
ipant groups – for example, frequency of observations, who carried out the observa-
tions, the degree of detail and completeness of observations. If these process measures
are comparable between the groups, the results may be regarded with more confidence.
1.10 THE MEASURE OF ASSESSMENT OF EXPOSURE IS RELIABLE
A well-conducted study should indicate how the degree of exposure or presence of
prognostic factors or markers was assessed. Whatever measures are used must be
sufficient to establish clearly that participants have or have not received the exposure
under investigation and the extent of such exposure, or that they do or do not possess
a particular prognostic marker or factor. Clearly described, reliable measures should
increase the confidence in the quality of the study.
1.11 EVIDENCE FROM OTHER SOURCES IS USED TO
DEMONSTRATE THAT THE METHOD OF OUTCOME
ASSESSMENT IS VALID AND RELIABLE
The inclusion of evidence from other sources or previous studies that demonstrate the
validity and reliability of the assessment methods used should further increase the
confidence in the quality of the study.
1.12 EXPOSURE LEVEL OR PROGNOSTIC FACTOR IS ASSESSED
MORE THAN ONCE
Confidence in data quality should be increased if exposure level or the presence of
prognostic factors is measured more than once. Independent assessment by more than
one investigator is preferable.
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1.13 THE MAIN POTENTIAL CONFOUNDERS ARE IDENTIFIED
AND TAKEN INTO ACCOUNT IN THE DESIGN AND ANALYSIS
Confounding is the distortion of a link between exposure and outcome by another
factor that is associated with both exposure and outcome. The possible presence of
confounding factors is one of the principal reasons why observational studies are not
more highly rated as a source of evidence. The report of the study should indicate
which potential confounders have been considered and how they have been assessed
or allowed for in the analysis. Clinical judgement should be applied to consider
whether all likely confounders have been considered. If the measures used to address
confounding are considered inadequate, the study should be downgraded or rejected,
depending on how serious the risk of confounding is considered to be. A study that
does not address the possibility of confounding should be rejected.
1.14 HAVE CONFIDENCE INTERVALS BEEN PROVIDED?
Confidence limits are the preferred method for indicating the precision of statistical
results and can be used to differentiate between an inconclusive study and a study that
shows no effect. Studies that report a single value with no assessment of precision
should be treated with caution.
Section 2 relates to the overall assessment of the paper. It starts by rating the
methodological quality of the study, based on the responses in Section 1 and using the
following coding system:
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 All or most of the criteria have been fulfilled. 
Where they have not been fulfilled, the conclusions of the study or
review are thought very unlikely to alter.
 Some of the criteria have been fulfilled. 
Those criteria that have not been fulfilled or not adequately described
are thought unlikely to alter the conclusions.
– Few or no criteria fulfilled.
The conclusions of the study are thought likely or very likely to alter.
APPENDIX 11:
SEARCH STRATEGIES FOR THE IDENTIFICATION
OF HEALTH ECONOMICS EVIDENCE
1. GENERAL SEARCH FILTERS
Drug misuse
a. CINAHL, HMIC, EMBASE, MEDLINE, PsycINFO – OVID interface
1 exp narcotic dependence/ or exp opioid-related disorders/
2 (addiction or analgesic agent abuse or drug abuse or drug abuse pattern or
drug dependenc$ or drug misuse or intravenous drug abuse or psychoses,
substance-induced or substance abuse, intravenous or substance abuse,
perinatal or substance abuse or substance dependence or substance with-
drawal syndrome or substance-related disorders).sh.
3 “substance use disorders”/
4 ((drug$1 or substance$) adj3 (abstain$ or abstinen$ or abus$ or addict$ or
dependen$ or disorder$ or intoxicat$ or misus$ or over dos$ or overdos$
or use$2 or using or withdraw$)).tw.
5 or/1-4
6 diamorphine/ or exp heroin/ or morphine/
7 exp narcotic agent/ or exp narcotics/ or exp narcotic drugs/
8 (acetomorphine or diacephine or diacetylmorphine or diamorphine or diaphorin
or heroin$ or morphacetin or morphine).mp. or 1502-95-0, 561-27-3.rn.
9 (anpec or duromorph or epimorph or morfin$ or morphia or morphin$ or
morphinium or morphium or opso$1 or skenan).mp. or 57-27-2.rn.
10 opiate$.mp. or 8008-60-4.rn.
11 (opioid$ or opium or narcotic$).tw.
12 (abstain$ or abstinen$ or abus$ or addict$ or (excessive adj use$) or depen-
den$ or (inject$ adj2 drug$) or intoxicat$ or misus$ or over dos$ or overdos$
or (use$ adj (disorder$ or illicit)) or withdraw$).mp.
13 (or/6-11) and 12
14 or/5,13
b. NHS Economic Evaluation Database (NHS EED), Health Technology Assessment
Database (HTA) – Wiley Interscience interface
1 MeSH descriptor Opioid-Related Disorders explode all trees
2 MeSH descriptor Substance-Related Disorders, this term only
3 MeSH descriptor Substance Abuse, Intravenous, this term only
4 MeSH descriptor Substance Withdrawal Syndrome, this term only
5 MeSH descriptor Psychoses, Substance-Induced, this term only
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6 (drug* or substance*) near (abstain* or abstinen* or abus* or addict* or
dependen* or disorder* or intoxicat* or misuse* or over dos* or overdos*
or use or user* or using or withdraw*):ti or (drug* or substance*) near
(abstain* or abstinen* or abus* or addict* or dependen* or disorder* or
intoxicat* or misuse* or over dos* or overdos* or use or user* or using 
or withdraw*):ab or (drug* or substance*) near (abstain* or abstinen* or
abus* or addict* or dependen* or disorder* or intoxicat* or misuse* or over
dos* or overdos* or use or user* or using or withdraw*):kw
7 (#1 OR #2 OR #3 OR #4 OR #5 OR #6)
8 MeSH descriptor Heroin, this term only
9 MeSH descriptor Morphine explode all trees
10 MeSH descriptor Narcotics explode all trees
11 (acetomorphine or diacephine or diacetylmorphine or diamorphine or
diaphorin or heroin* or morphacetin or morphin*):ti or (acetomorphine 
or diacephine or diacetylmorphine or diamorphine or diaphorin or heroin*
or morphacetin or morphin*):ab or (acetomorphine or diacephine or
diacetylmorphine or diamorphine or diaphorin or heroin* or morphacetin
or morphin*):kw
12 (anpec or duromorph or epimorph or morfin* or morphia or morphin* or
morphinium or morphium or opso* or skenan):ti or (anpec or duromorph
or epimorph or morfin* or morphia or morphin* or morphinium or
morphium or opso* or skenan):ab or (anpec or duromorph or epimorph 
or morfin* or morphia or morphin* or morphinium or morphium or opso*
or skenan):kw
13 (opiate*):ti or (opiate*):ab or (opiate*):kw
14 (opioid* or opium or narcotic*):ti or (opioid* or opium or narcotic*):ab or
(opioid* or opium or narcotic*):kw
15 (abstain* or abstinen* or abus* or addict* or (drug near use*) or (exces-
sive* near use*) or dependen* or (inject* near drug*) or intoxicat* or
misus* or over dos* or overdos* or (use* near (disorder* or illicit)) or
withdraw*):ti or (abstain* or abstinen* or abus* or addict* or (drug near
use*) or (excessive* near use*) or dependen* or (inject* near drug*) or
intoxicat* or misus* or over dos* or overdos* or (use* near (disorder* 
or illicit)) or withdraw*):ab or (abstain* or abstinen* or abus* or addict*
or (drug near use*) or (excessive* near use*) or dependen* or (inject* near
drug*) or intoxicat* or misus* or over dos* or overdos* or (use* near
(disorder* or illicit)) or withdraw*):kw
16 ((#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14) AND #15)
17 (#7 OR #16)
c. Health Economic Evaluations Database (OHE HEED) – Wiley interface
1 AX  (stimulant* or drug* or substance) and (abstain* or abstinen* or
abus* or addict* or dependen* or detox* or disorder* or intoxicat* or
misuse* or overdos* or use* or using* or withdraw*)
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2 AX  acetomorphine or diacephine or diacetylmorphine or diamorphine
or diaphorin or heroin or morphacetin or morphine
3 AX  anpec or duromorph or epimorph or morfin* or morphia or morphin
or morphinium or morphium or opso* or skenan
4 AX  opioid* or opium or narcotic* or opiate*
5 AX  abstain* or abstinen* or abus* or addict* or dependen* or intoxi-
cat* or misus* or overdos* or withdraw* or ‘disorder within 1 use’ or
‘disorder within 1 user’ or ‘disorder within 1 using’ or ‘disorders within 1
use’ or ‘disorders within 1 user’ or ‘disorders within 1 using’ or ‘drug
within 2 use’ or ‘drug within 2 user’ or ‘excessive within 2 use’ or ‘exces-
sive within 2 user’ or ‘excessively within 2 use’ or ‘excessively within 2
user’ or ‘illicit within 1 use’ or ‘illicit within 1 user’ or ‘illicit within 1
using’ or ‘illicitly within 1 use’ ‘illicitly within 1 user’ or ‘illicitly within
1 using’ or ‘inject drug’ or ‘inject drugs’ or ‘injecting drug’ or ‘injecting
drugs’
6 CS  2 OR 3 OR 4
7 CS  5 AND 6
8 CS  1 OR 7
2. HEALTH ECONOMIC AND QUALITY OF LIFE FILTERS
a. MEDLINE, EMBASE, PsycINFO, CINAHL – OVID interface
1 exp “costs and cost analysis”/ or “health care costs”/
2 exp health resource allocation/ or exp health resource utilization/
3 exp economics/ or exp economic aspect/ or exp health economics/
4 exp value of life/
5 (burden adj5 (disease or illness)).tw.
6 (cost or costs or costly or costing or price or prices or pricing or pharma-
coeconomic$ or expenditure$ or economic$).tw.
7 (fiscal or funding or financial or finance or budget).tw.
8 (resource adj5 (allocation$ or utility$)).tw.
9 or/1-8
10 (value adj5 money).tw.
11 exp quality of life/
12 (qualit$3 adj5 (life or survival)).tw.
13 (wellbeing or health status or QOL).tw.
14 or/9-13
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APPENDIX 12:
QUALITY CHECKLISTS FOR ECONOMIC STUDIES
1.1 FULL ECONOMIC EVALUATIONS
Author: Date:
Title:
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1.2 PARTIAL ECONOMIC EVALUATIONS
Author: Date:
Title:
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APPENDIX 13:
DATA EXTRACTION FORM FOR ECONOMIC
STUDIES
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APPENDIX 14:
EVIDENCE TABLES FOR ECONOMIC STUDIES
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10. GLOSSARY
12-step group: A non-profit fellowship of people who meet regularly to help each other
remain abstinent. The core of the 12-step programme is a series of 12 stages that include
admitting to a drug problem, seeking help, self-appraisal, confidential self-disclosure,
making amends (when possible) where harm has been done, achieving a spiritual awak-
ening and supporting other people who misuse drugs who want to recover.
Abstinence: Abstinence-oriented treatments aim to reduce an individual’s level of
drug use, with the ultimate goal of refraining from use altogether.
Agonist: An agonist is a substance that mimics the actions of a neurotransmitter or
hormone to produce a response when it binds to a specific receptor in the brain.
Opioid drugs, for example heroin and methadone, are agonists that produce
responses such as ‘liking’, analgesia and respiratory depression.
Alpha2 adrenergic agonist: An adrenergic agonist has an adrenaline-like action
upon adrenergic receptors in the brain. Stimulation of the alpha adrenergic receptors
leads to constriction of the bronchi and blood vessels, and dilation of the pupils of the
eyes. Consequently, alpha2 adrenergic agonists are useful in improving opioid with-
drawal symptoms associated with the noradrenaline system, including sweating,
shivering, and runny nose and eyes. Clonidine and lofexidine are examples of adren-
ergic agonists used as adjunctive medication in opioid detoxification.
Antagonist: In contrast to the action of an agonist, an antagonist, such as naltrex-
one, binds to a specific receptor in the brain but does not activate it. Therefore, if an
agonist, for example heroin or methadone, is present and activating the receptor,
taking naltrexone will counteract the activation, resulting in withdrawal.
Buprenorphine: An analgesic opioid substitute used in maintenance-oriented treat-
ment, buprenorphine has both agonist and antagonist properties.
Cannabis: Cannabis is a generic term denoting the various psychoactive preparations
of the hemp plant, including marijuana leaves, hashish resin and oil (WHO, 2006). It
is the most commonly used illicit drug in the UK.
Cognitive behavioural therapy (CBT): Cognitive behavioural therapy encompasses
a range of behavioural and cognitive behavioural therapies, in part derived from the
cognitive behavioural model of affective disorders, in which the patient works collab-
oratively with a therapist using a shared formulation to achieve specific treatment
goals. Such goals may include recognising the impact of behavioural and/or thinking
patterns on feeling states and encouraging alternative cognitive and/or behavioural
coping skills to reduce the severity of target symptoms and problems. Therapies rele-
vant to the field of drug misuse include standard cognitive behavioural therapy and
relapse-prevention cognitive behavioural therapy.
Community reinforcement approach: In community reinforcement, emphasis is
placed on environmental contingencies in aspects of life such as work, recreation,
family involvement, and so on, to promote a lifestyle that is more rewarding than drug
misuse (Roozen et al., 2004).
Confidence interval (CI): The range within which the ‘true’ values (for example,
size of effect of an intervention) are expected to lie with a given degree of certainty
(for example, 95% or 99%). (Note: confidence intervals represent the probability of
random errors, but not systematic errors or bias.)
Contingency management (CM): Contingency management provides a system of
incentives and disincentives designed to make continual drug use less attractive and absti-
nence more attractive (Griffith et al., 2000). The three main methods of providing incen-
tives are voucher-based, whereby vouchers representing monetary values are provided
upon receipt of biological samples (usually urine) that are negative for the tested drugs,
prize-based (whereby participants receive prize-draw entries upon presentation of a nega-
tive biological sample) and privilege-based (whereby participants receive privileges such
as take home methadone doses upon presentation of a negative biological sample).
Deep/heavy sedation: A high level of sedation, where the subject may not be easily
aroused or purposefully respond to verbal commands and may only respond mini-
mally to very significant stimuli (such as high levels of pain). He or she may experi-
ence partial or complete loss of protective reflexes, including the ability to
independently and continuously maintain an open airway. The individual may there-
fore require assistance in maintaining an open airway, and spontaneous ventilation
may be inadequate. Cardiovascular function is usually maintained.
Dependence: Dependence is defined by the WHO as a strong desire or sense of
compulsion to take a substance, a difficulty in controlling its use, the presence of a
physiological withdrawal state, tolerance of the use of the drug, neglect of alternative
pleasures and interests and persistent use of the drug, despite harm to oneself and
others (WHO, 2006).
Detoxification: Detoxification is the process by which an individual is withdrawn
from the effects of a psychoactive substance. As a clinical procedure, the withdrawal
process should be supervised and carried out in a safe and effective manner, such that
withdrawal symptoms are minimised. Typically, the individual is clinically intoxi-
cated or already in withdrawal at the outset of detoxification. Detoxification may
involve the administration of medication, the dose of which is calculated to relieve
withdrawal symptoms without inducing intoxication, and is gradually tapered off as
the individual recovers.
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Drug misuse/problem drug use: Drug misuse is the use of a substance for a purpose
not consistent with legal or medical guidelines (WHO, 2006). The ACMD defines
problem drug use as a condition that may cause an individual to experience social,
psychological, physical or legal problems related to intoxication and/or regular exces-
sive consumption, and/or dependence; any injection drug use also constitutes misuse
(ACMD, 1998).
False negative: A test result that fails to detect an effect, condition or drug when it is
in fact present.
False positive: A test result that incorrectly shows an effect, condition or drug to be
present when it is not.
Family intervention: A psychological intervention derived from a model of 
the interactional processes in families. Interventions are aimed to help participants
understand the effects of their interactions on each other as factors in the development
and/or maintenance of drug misuse. Additionally, the aim is to change the nature of
the interactions so that they may develop relationships that are more supportive and
have less conflict (NICE, 2004).
General anaesthesia: Under general anaesthesia, an individual is unconscious and
unresponsive, even in the face of significant stimuli. The ability to independently
maintain ventilatory function is often impaired and assistance is frequently required
in maintaining an open airway. Cardiovascular function may be impaired.
Harm reduction: Measures aiming to prevent or reduce negative health or other
consequences associated with drug misuse, whether to the drug-using individual or to
society. Attempts are not necessarily made to reduce the drug use itself.
Incremental cost-effectiveness ratio (ICER): The difference in the mean costs in
the population of interest divided by the differences in the main outcomes in the
population of interest.
Individual drug counselling: The assessment of an individual’s needs, provision of
information and referral to services to meet these needs (including psychosocial inter-
ventions, methadone and residential rehabilitation). No attempt is made to engage in
any specific formal psychological intervention. Sessions are normally weekly and last
15–20 minutes (Rawson et al., 1983). This to some extent resembles keyworking as
used in the UK drug treatment field.
Interpersonal therapy (IPT): A discrete, time-limited, structured psychological
intervention that focuses on interpersonal issues and where therapist and service user:
a) work collaboratively to identify the effects of key problematic areas related to
interpersonal conflicts, role transitions, grief and loss, and social skills, and their
effects on current drug misuse, feelings states and/or problems; and b) seek to reduce
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drug misuse problems by learning to cope with or resolve interpersonal problem areas
(Weissman et al., 2000).
Legally coerced (drug) treatment: This requires that the person who misuses drugs
enter into treatment as an alternative or adjunct to criminal sanctions (Wild et al.,
2002). Such treatment can either be legally ordered by the court or through diversion
away from the judicial process, usually following arrest and charge for drug-related
and other offences.
Lofexidine: An alpha2 adrenergic agonist currently licensed and used widely in the
UK to ameliorate a cluster of opioid withdrawal symptoms (those associated with the
noradrenaline system, including sweating, shivering, and runny nose and eyes).
Maintenance: In the UK context this refers primarily to the pharmacological main-
tenance of people who are opioid dependent; that is, prescription of opioid substitutes
(methadone or buprenorphine). This aims to reduce illicit drug use and its conse-
quent harms.
Meta-analysis: The use of statistical techniques to integrate the results of several
independent studies.
Metabolite: A chemical product derived from breakdown (metabolism) of another
chemical.
Methadone: A synthetic, psychoactive opioid substitute used in maintenance-
oriented treatment, particularly heroin dependence. Methadone has agonist properties.
Minimal/light sedation: This involves the administration of medication in 
order to deal with anxiety, insomnia or agitation. The defining characteristic of this
type of sedation is that the individual still appears relatively awake and is able to
communicate clearly at all times. Although cognitive function and coordination may
be impaired, ventilatory and cardiovascular functions are unaffected.
Moderate sedation: This occurs where the individual appears obviously sedated but,
importantly, is able to independently maintain an open airway and respond to stimuli
purposefully (such as verbal questioning).
Naloxone: A short-acting antagonist that blocks the effects of opioid drugs on recep-
tors in the brain, naloxone is used to detect the presence of opioid effects (in what is
known as a naloxone challenge test) and also in emergency situations to reverse
opioid overdose.
Naltrexone: An antagonist that blocks the effects of opioid drugs on receptors in the
brain, naltrexone is used in maintenance treatment to prevent detoxified service users
from relapsing to opioid use.
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National Collaborating Centre for Mental Health (NCCMH): One of seven centres
established by the National Institute for Health and Clinical Excellence (NICE) to
develop guidance on the appropriate treatment and care of people with specific
diseases and conditions within the NHS in England and Wales. Established in 2001,
the NCCMH is responsible for developing mental health guidelines, and is a partner-
ship between the Royal College of Psychiatrists and the British Psychological Society.
National Institute for Health and Clinical Excellence (NICE): An independent
organisation responsible for providing national guidance on the promotion of good
health and the prevention and treatment of ill health. It provides guidance on three
areas of health: clinical practice, public health and health technologies.
National Treatment Agency for Substance Misuse (NTA): The NTA is a special
health authority, which was established by the government in 2001. It is tasked with
increasing the availability, capacity and effectiveness of treatment for drug misuse in
England and embraces user involvement as a core component of its strategy.
Near-patient testing: This refers to the process of obtaining a biological sample from
a service user and using a drug-testing kit to immediately detect the presence of any
of a variety of substances (for example, opioids, amphetamines, cocaine metabolite,
benzodiazepines, methadone and cannabis) on site. This process eliminates the need
for external laboratory support and provides rapid results.
Needle and syringe exchange: A service aiming to reduce transmission of blood-
borne viruses through the promotion of safer drug injection behaviour, primarily via
the distribution of sterile needles, but often also by offering education and other
psychosocial interventions.
Neurotransmitter: A chemical messenger (for example, dopamine or noradrena-
line) used by nerve cells to transmit nerve impulses from one nerve cell (neuron) to
another, or between neurons and other tissues, such as muscles or glands.
Noradrenaline system: A neuronal system that is responsible for the synthesis, stor-
age and release of the neurotransmitter noradrenaline, which exists in both the central
and peripheral nervous systems. It is the primary neurotransmitter released by the
sympathetic nervous system, which mediates the ‘fight or flight’ reaction, preparing
the body for action by affecting cardiovascular function, gastrointestinal motility and
secretion, bronchiole dilation, glucose metabolism, and so on.
Odds ratio (OR): A measure of the relative benefit of the experimental treatment that
can be obtained by dividing the experimental odds by the control odds.
Opioid: A class of psychoactive substances derived from the poppy plant, including
opium, morphine and codeine, as well as their semi-synthetic counterparts, including
heroin (WHO, 2004). In this guideline, the term ‘opioid’ is used more broadly to
incorporate synthetic compounds (including methadone) with similar properties,
also commonly known as opioids.
Psychosocial intervention: Any formal, structured psychological or social interven-
tion with assessment, clearly defined treatment plans and treatment goals, and regu-
lar reviews (NTA, 2006), as opposed to advice and information, drop-in support or
informal keyworking.
Quality adjusted life years (QALY): A form of utility measure calculated by esti-
mating the total life years gained from a treatment and weighting each year with a
quality-of-life score in that year.
Randomised controlled trial (RCT): An experiment in which investigators
randomly allocate eligible people into groups to receive or not to receive one or more
interventions that are being compared. The results are assessed by comparing
outcomes in the different groups. Through randomisation, the groups should be simi-
lar in all aspects, apart from the treatment they receive during the study.
Rapid/ultra-rapid detoxification: Approaches for detoxifying those dependent upon
opioids whereby opioid antagonists, such as naloxone, naltrexone or nalmefene, are
used under general anaesthesia or deep sedation. The aim is to flood the brain with
an opioid antagonist to remove all agonists while the sedation (for rapid detoxifica-
tion) or anaesthesia (ultra-rapid detoxification) minimises discomfort. The individual
is then maintained on naltrexone.
Relapse-prevention cognitive behavioural therapy: This differs from standard
cognitive behavioural therapy in the emphasis on training drug users to develop
skills to identify situations or states where they are most vulnerable to drug use, to
avoid high-risk situations, and to use a range of cognitive and behavioural strategies
to cope effectively with these situations (Carroll & Onken, 2005).
Relative risk (RR): The ratio of risk in the intervention group to the risk in the
control group. The risk (proportion, probability or rate) is the ratio of people with an
event in a group to the total in the group. An RR of 1 indicates no difference between
comparison groups. For undesirable outcomes, an RR that is less than 1 indicates that
the intervention was effective in reducing the risk of that outcome.
Residential rehabilitation programme: Residential rehabilitation centres provide
accommodation in a drug-free environment and a range of structured interventions 
to address drug misuse, including, but not limited to, abstinence-oriented interven-
tions (NTA, 2006). Services vary and are based on a number of different treatment
philosophies.
Screening: The systematic application of a test or enquiry to identify individuals at
high risk of developing a specific disorder who may benefit from further investigation
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or preventative action (Peckham & Dezateux, 1998). Routine screening for drug
misuse in the UK is largely restricted to criminal justice settings, including police
custody and prisons (Matrix Research and Consultancy & NACRO, 2004).
Self-help group: A group of people who misuse drugs meet regularly to provide help
and support for one another. The group is typically community-based, peer-led and
non-professional.
Sensitivity: A term used to assess screening tools, sensitivity refers to the proportion
of people with disease who test positive for that disease.
Short-term psychodynamic intervention: A psychological intervention, derived
from a psychodynamic/psychoanalytic model in which: a) therapist and service user
explore and gain insight into conflicts and how these are represented in current situ-
ations and relationships, including the therapy relationship; b) service users are given
an opportunity to explore feelings and conscious and unconscious conflicts originat-
ing in the past, with the technical focus on interpreting and working through conflicts;
c) therapy is non-directive and service users are not taught specific skills such as
thought monitoring, re-evaluation or problem solving. Treatment typically consists of
16–30 sessions (Leichsenring et al., 2004).
Social network interventions: Professionals seek to promote change by helping the
person who misuses drugs to engage with a close network of family members or
friends who provide positive social support for attempting or maintaining abstinence
(Copello et al., 2005).
Specificity: A term used to assess screening tools, specificity refers to the proportion
of people without disease who test negative for that disease.
Standard cognitive behavioural therapy: A discrete, time-limited, structured
psychological intervention, derived from a cognitive model of drug misuse (Beck
et al., 1993). There is an emphasis on identifying and modifying irrational thoughts,
managing negative mood and intervening after a lapse to prevent a full-blown relapse
(Maude-Griffin et al., 1998).
Standard deviation (SD): A statistical measure of variability in a population of indi-
viduals or in a set of data. While the average measures the expected middle position
of a group of numbers, the standard deviation is a way of expressing how different the
numbers are from the average. The standard deviation is (approximately) the amount
by which the average person’s score differs from the average of all scores.
Standardised mean difference (SMD): In a meta-analysis, a way of combining the
results of studies that may have measured the same outcome in different ways, using
different scales. Statistically, it is calculated by dividing the weighted average effect
size by the pooled standard deviation. The SMD is expressed as a standard value with
no units.
Stimulant: Broadly any substances that activate, enhance or increase neural activity
(WHO, 2006). Illicit stimulants include cocaine, crack cocaine and methampheta-
mine. Cocaine is one of the most commonly misused stimulants in the UK; crack
cocaine refers to the cocaine alkaloid that has been purified from the other compo-
nents of cocaine powder, and methamphetamine is one of a group of synthetic
substances (amphetamines) with broadly similar properties to cocaine.
Systematic review: Research that summarises the evidence on a clearly formulated
question according to a predefined protocol using systematic and explicit methods to
identify, select and appraise relevant studies, and to extract, collate and report their
findings. It may or may not use statistical meta-analysis.
Tramadol: A synthetic opioid, tramadol is a weak agonist which may also have
partial antagonist properties. More commonly used in the context of pain relief, it is
neither licensed nor routinely used in the UK for the treatment of opioid dependence.
Weighted mean difference (WMD): A method of meta-analysis used to combine
measures on continuous scales, where the mean, standard deviation and sample size
in each group are known. The weight given to each study (for example, how much
influence each study has on the overall results of the meta-analysis) is determined by
the precision of its estimate of effect and, in the statistical software used by the
NCCMH, is equal to the inverse of the variance. This method assumes that all of the
trials have measured the outcome on the same scale.
Withdrawal symptoms: Withdrawal symptoms ensue when a person who has
become tolerant to the effects of a drug stops taking it. Such symptoms typically
emerge within 6–12 hours for short-acting opioids such as heroin and about 24–36
hours after the last dose of methadone or buprenorphine, depending on the dose.
Withdrawal can also ensue when an opioid antagonist, such as naloxone or naltrex-
one is taken; this is called precipitated or abrupt withdrawal. Opioid withdrawal
symptoms can include pupil dilation, diarrhoea, low mood, irritability, anxiety,
insomnia, muscular and abdominal pains, restlessness and ‘craving’. In addition,
tachycardia, sweating, runny nose, hair standing on end and shivering are generally
experienced.
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12. ABBREVIATIONS
ACMD Advisory Council on the Misuse of Drugs
AE adverse event
AGREE Appraisal of Guidelines for Research and Evaluation Instrument
AIDS autoimmune deficiency syndrome
AMED A bibliographic database produced by the Health Care
Information Service of the British Library
APA American Psychiatric Association
ASI Addiction Severity Index
CA Cost analysis
CBA Cost-benefit analysis
CBT cognitive behavioural therapy
CCA Cost-consequences analysis
CEA Cost-effectiveness analysis
CI confidence interval
CINAHL Cumulative Index to Nursing and Allied Health Literature
CMA Cost-minimisation analysis
COWS Clinical Opiate Withdrawal Scale
CSAT Center for Substance Abuse Treatment
CUA Cost-utility analysis
DD drug dependence
DDU drug-dependence unit
DH Department of Health
DIP Drug Interventions Programme
DSM Diagnostic and Statistical Manual of Mental Disorders 
(versions III-R and IV-TR)
DTTO Drug Treatment and Testing Order
EMBASE Excerpta Medica database
EEG electroencephalogram
F the statistic calculated by analysis of variance (F ratio)
GDG Guideline Development Group
GFN guanfacine
GP general practitioner
GRADE Grading of Recommendations: Assessment, Development and
Evaluation (Working Group)
GRP Guideline Review Panel
HIV human immunodeficiency virus
HMIC Health management and policy database from the Healthcare
Management Information Consortium
HTA Health Technology Assessment
ICER incremental cost-effectiveness ratio
K number of studies
LAAM levo-alpha acetyl methadol
LDQ Leeds Dependence Questionnaire
LSD lysergic acid diethylamide
MAP Maudsley Addiction Profile
MEDLINE Compiled by the US National Library of Medicine and
published on the web by Community of Science, MEDLINE 
is a source of life sciences and biomedical bibliographic 
information
MMT methadone maintenance treatment
n number of participants in a group
N total number of participants
NACB National Academy of Clinical Biochemistry
NACRO National Association for the Care and Rehabilitation of
Offenders
NCCMH National Collaborating Centre for Mental Health
NDTMS National Drug Treatment Monitoring System
NHS National Health Service
NHS EED National Health Service Economic Evaluation Database
NICE National Institute for Health and Clinical Excellence
NIDA National Institute on Drug Abuse
NSF National Service Framework
NTA National Treatment Agency for Substance Misuse
NTORS National Treatment Outcomes Research Study
OHE HEED Office of Health Economics, Health Economics Evaluation
Database
OR odds ratio
OTI Opiate Treatment Index
OWS Opiate Withdrawal Scale
p probability
PICO patient, intervention, comparison and outcome
PILOTS An electronic index to the worldwide literature on 
post-traumatic stress disorder and other mental-health 
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consequences of exposure to traumatic events, produced 
by the US National Center for PTSD
PSS Personal Social Services
PsycINFO An abstract (not full text) database of psychological literature
from the 1800s to the present
QALY quality adjusted life year
qid four times a day
r correlation
RCT randomised controlled trial
RD rapid detoxification (-GA, with general anaesthesia)
RODA rapid opioid detoxification under anaesthetic
RODS rapid opioid detoxification under sedation
RR relative risk
SCAN Specialist Clinical Addiction Network
SDS Severity of Dependence Scale
SIGLE System for Information on Grey Literature in Europe database
SIGN Scottish Intercollegiate Guidelines Network
SMD standardised mean difference
SODQ Severity of Opiate Dependence Questionnaire
t t-statistic
tid three times a day
WHO World Health Organization
WMD weighted mean difference
 chi
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The guideline on Drug misuse: opioid detoxification, commissioned by NICE and
developed by the National Collaborating Centre for Mental Health, sets out clear,
evidence-based recommendations for healthcare staff on how to work with people
who misuse opioids to significantly improve their treatment and care, and to deliver
detoxification safely and effectively. Of the estimated 4 million people in the UK
who use illicit drugs each year, approximately 50,000 misuse opioids (such as
heroin, opium, morphine, codeine and methadone). Opioid misuse presents a
considerable health risk and can lead to significant social problems. This NICE
guideline is an important tool in helping people to overcome their drug problem.
This publication brings together all of the evidence that led to the recommendations
in the NICE guideline. It provides an overview of drug misuse and opioid
detoxification and covers assessment and testing, pharmacological and physical
interventions used in detoxification, psychosocial interventions to support
detoxification, and the settings in which the treatment can take place. The book is
illustrated by the experiences of people who have been dependent on opioids, and
there is also advice for family members and carers of people with a drug problem.
An accompanying CD contains further information about the evidence, including
● included and excluded studies;
● profile tables that summarise both the quality of the evidence and the results of
the evidence synthesis;
● all meta-analytical data presented as forest plots; and
● detailed information about how to use and interpret forest plots. 
This book is accompanied by another guideline, 
Drug misuse: psychosocial interventions.
Cover photo: Ryan Li
9 7 8 1 8 5 4 3 3 4 6 9 5
